NCT Number,Study Title,Study Status,Conditions,Interventions,Sponsor,Collaborators,Study Type,Start Date,Primary Completion Date,Completion Date
NCT03658772,Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer,ACTIVE_NOT_RECRUITING,Microsatellite Stable Colorectal Cancer,DRUG: grapiprant|DRUG: grapiprant and pembrolizumab,Arrys Therapeutics,Merck Sharp & Dohme LLC,INTERVENTIONAL,"September 20, 2018","September 20, 2018","June 1, 2022"
NCT04606472,"A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors",RECRUITING,Solid Tumor,DRUG: SI-B003,"Sichuan Baili Pharmaceutical Co., Ltd.",SystImmune Inc.,INTERVENTIONAL,"November 19, 2020","November 19, 2020",September 2022
NCT03237572,Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer,TERMINATED,Breast Cancer,DRUG: Pembrolizumab|DEVICE: High-intensity focused ultrasound (HIFU),"Patrick Dillon, MD",,INTERVENTIONAL,"September 25, 2017","September 25, 2017","June 1, 2022"
NCT05478772,"Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects",COMPLETED,Health Volunteers,DRUG: CTP-543|DRUG: Fluconazole,Concert Pharmaceuticals,,INTERVENTIONAL,"July 11, 2022","July 11, 2022","August 6, 2022"
NCT04902131,A Study Comparing MENOPUR in a Pen Formulation With a Powder and Solvent Formulation in Healthy Women,COMPLETED,"Infertility, Female","DRUG: A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL|DRUG: A MENOPUR powder including solvent for solution for injection, 75 IU",Ferring Pharmaceuticals,,INTERVENTIONAL,"November 2, 2021","November 2, 2021","August 15, 2022"
NCT03592888,DC Vaccine in Pancreatic Cancer,RECRUITING,Pancreatic Ductal Adenocarcinoma,DRUG: mDC3/8-KRAS Vaccine,University of Pennsylvania,,INTERVENTIONAL,"November 20, 2018","November 20, 2018",September 2022
NCT04368988,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,COMPLETED,COVID-19,"BIOLOGICAL: SARS-CoV-2 rS - Phase 1|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1|OTHER: Normal saline solution (NSS), Placebo - Phase 1|OTHER: Normal saline solution (NSS), Placebo - Phase 2|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1|OTHER: Normal saline solution (NSS), Placebo, Day 21 - Phase 1|BIOLOGICAL: SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2",Novavax,Coalition for Epidemic Preparedness Innovations,INTERVENTIONAL,"May 25, 2020","May 25, 2020","June 1, 2022"
NCT05279872,A Study of Zanubrutinib in Patients With ITP,RECRUITING,Immune Thrombocytopenia|Bruton Tyrosine Kinase,DRUG: Zanubrutinib,Peking University People's Hospital,,INTERVENTIONAL,"January 1, 2022","January 1, 2022","July 1, 2022"
NCT04927572,"Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis",COMPLETED,Atopic Dermatitis,DRUG: FMX114|OTHER: Vehicle,Vyne Therapeutics Inc.,,INTERVENTIONAL,"October 13, 2021","October 13, 2021","August 9, 2022"
NCT04908462,"To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects",ACTIVE_NOT_RECRUITING,Autosomal Dominant Polycystic Kidney,DRUG: AL01211 or Placebo (Part A)|DRUG: AL01211 or Placebo (Part B),"AceLink Therapeutics, Inc.",Novotech (Australia) Pty Limited,INTERVENTIONAL,"June 8, 2021","June 8, 2021","June 1, 2022"
NCT03781362,Study of CPI-100 in Patients With Advanced Tumors,COMPLETED,Advanced Tumors,DRUG: CPI-100|DRUG: Capecitabine,"Coordination Pharmaceuticals, Inc.",,INTERVENTIONAL,"December 21, 2018","December 21, 2018","June 21, 2022"
NCT05219838,Binding and Effects of Lu AG06466 in the Brain of Healthy Men,COMPLETED,Healthy Participants,DRUG: Lu AG06466,H. Lundbeck A/S,,INTERVENTIONAL,"January 18, 2022","January 18, 2022","August 18, 2022"
NCT04798638,A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers,ACTIVE_NOT_RECRUITING,Healthy Volunteers,DRUG: TY-9591 Tablets under Fasted Condition - Arm1|DRUG: Osimertinib Mesylate Tablets under Fasted Condition - Arm1|DRUG: TY-9591 Tablets after a High-fat Meal - Arm1|DRUG: Osimertinib Mesylate Tablets under Fasted Condition - Arm2|DRUG: TY-9591 Tablets under Fasted Condition - Arm2|DRUG: TY-9591 Tablets after a High-fat Meal - Arm2,"TYK Medicines, Inc",,INTERVENTIONAL,"April 30, 2021","April 30, 2021","August 20, 2022"
NCT04082962,Dexamethasone Implant for Retinal Detachment in Uveal Melanoma,RECRUITING,Exudative Retinal Detachment and Uveal Melanoma,DRUG: Dexamethasone intravitreal implant,Ivana K. Kim,,INTERVENTIONAL,"April 16, 2018","April 16, 2018",June 2022
NCT01843738,Radiation Use During Vemurafenib Treatment,WITHDRAWN,BRAFV600 Mutation|Stage IV Melanoma,RADIATION: Radiation therapy|DRUG: Vemurafenib,University of Utah,,INTERVENTIONAL,June 2017,June 2017,August 2022
NCT02099825,Medication Enhanced Rapid Therapy,SUSPENDED,Anxiety Disorders,DRUG: d-cycloserine and mifepristone,Washington University School of Medicine,,INTERVENTIONAL,"January 13, 2014","January 13, 2014",August 2022
NCT03960125,Photodynamic Therapy and Microvesicles,WITHDRAWN,Photodynamic Therapy|Microvesicle Particle,DEVICE: Photodynamic Therapy|DRUG: 4% Imipramine|DRUG: Base Cream,Wright State University,,INTERVENTIONAL,"March 29, 2021","March 29, 2021",August 2022
NCT03600155,Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome,UNKNOWN,Allogeneic Hematopoietic Stem Cell Transplantation Recipient|Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia,BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"October 11, 2018","October 11, 2018","June 1, 2022"
NCT05079425,A First-in-Human Study to Assess Single and Multiple Doses of NXC736 in Healthy Participants,RECRUITING,Healthy,DRUG: NXC736|DRUG: Placebo,NEXTGEN Bioscience,,INTERVENTIONAL,"September 10, 2021","September 10, 2021",July 2022
NCT02852655,"A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",COMPLETED,Brain Cancer,DRUG: MK-3475,Dana-Farber Cancer Institute,Merck Sharp & Dohme LLC,INTERVENTIONAL,"September 21, 2016","September 21, 2016","June 2, 2022"
NCT04849429,Intra-discal Injection of Platelet-rich Plasma (PRP) Enriched With Exosomes in Chronic Low Back Pain,COMPLETED,Chronic Low Back Pain|Degenerative Disc Disease,BIOLOGICAL: Platelet rich plasma (PRP) with exosomes|DRUG: Normal Saline,Dr. Himanshu Bansal Foundation,,INTERVENTIONAL,"September 10, 2021","September 10, 2021","June 18, 2022"
NCT03735277,"Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke",NOT_YET_RECRUITING,Acute Ischemic Stroke,"BIOLOGICAL: HPC, Cord Blood",BHI Therapeutic Sciences,,INTERVENTIONAL,"March 6, 2021","March 6, 2021",July 2022
NCT04563377,Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially,COMPLETED,Healthy,BIOLOGICAL: ChAdOx1.HTI and MVA.HTI,University of Oxford,,INTERVENTIONAL,"November 1, 2021","November 1, 2021","August 16, 2022"
NCT04779177,"Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder",RECRUITING,Schizophrenia|Pediatric,DRUG: Lumateperone 42 mg|DRUG: Lumateperone 28 mg,"Intra-Cellular Therapies, Inc.",,INTERVENTIONAL,"March 12, 2021","March 12, 2021",July 2022
NCT05411146,"A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer",COMPLETED,Healthy Participants,DRUG: [14C]-etrumadenant,"Arcus Biosciences, Inc.",Gilead Sciences,INTERVENTIONAL,"May 25, 2022","May 25, 2022","July 7, 2022"
NCT05330273,Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz,NOT_YET_RECRUITING,Malaria,DRUG: Ganaplacide|COMBINATION_PRODUCT: Lumefantrine|DRUG: Efavirenz,Novartis Pharmaceuticals,Medicines for Malaria Venture,INTERVENTIONAL,"April 18, 2022","April 18, 2022","June 27, 2022"
NCT05429073,A Study of RGLS8429 in Healthy Volunteers,RECRUITING,Healthy Volunteers,DRUG: RGLS8429|DRUG: Placebo volume-matching RGLS8429 dose,Regulus Therapeutics Inc.,,INTERVENTIONAL,"June 10, 2022","June 10, 2022",September 2022
NCT02960646,Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies,ACTIVE_NOT_RECRUITING,"Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Aplastic Anemia|Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Chronic Myelomonocytic Leukemia|Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Lymphoblastic Lymphoma|Myelodysplastic Syndrome|Myeloproliferative Neoplasm|Plasma Cell Myeloma|Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Recurrent Hodgkin Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Plasma Cell Myeloma|Therapy-Related Myelodysplastic Syndrome",DRUG: Cyclophosphamide|BIOLOGICAL: Filgrastim|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Melphalan|PROCEDURE: Peripheral Blood Stem Cell Transplantation|BIOLOGICAL: Rituximab|DRUG: Tacrolimus|RADIATION: Total-Body Irradiation,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"January 18, 2017","January 18, 2017","June 30, 2022"
NCT04586673,A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines,COMPLETED,HIV,BIOLOGICAL: ChAdOx1.tHIVconsv1 (C1)|BIOLOGICAL: ChAdOx1.tHIVconsv1 (C1)|BIOLOGICAL: MVA.tHIVconsv3 (M3)|BIOLOGICAL: MVA.tHIVconsv4 (M4),University of Oxford,,INTERVENTIONAL,"July 3, 2021","July 3, 2021","August 3, 2022"
NCT05369221,Feasibility of ReSpace™ Hydrogel to Establish a Stable Cervical-rectal Space,RECRUITING,Uterine Cervical Neoplasms,DEVICE: ReSpace™,Peking Union Medical College Hospital,"Shanghai Reunion Biotech Co.,Ltd.",INTERVENTIONAL,"April 25, 2022","April 25, 2022",July 2022
NCT05081388,"COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease",COMPLETED,SARS-CoV-2,DRUG: REGN14256|DRUG: imdevimab|DRUG: casirivimab + imdevimab|DRUG: Placebo,Regeneron Pharmaceuticals,,INTERVENTIONAL,"November 8, 2021","November 8, 2021","June 30, 2022"
NCT04480788,CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study,RECRUITING,"T Lymphoblastic Leukemia/Lymphoma|Extramedullary NK-T-cell Lymphoma, Nasal Type|Peripheral T-cell Lymphoma, Nonspecific|Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Anaplastic Large Cell Lymphoma, ALK-negative|T-cell Lymphoblastic Leukemia",BIOLOGICAL: T cell injection targeting CD7 chimeric antigen receptor,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.",The First Affiliated Hospital of Zhengzhou University,INTERVENTIONAL,"November 24, 2020","November 24, 2020","August 1, 2022"
NCT03116529,Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma,RECRUITING,Soft Tissue Sarcoma,"COMBINATION_PRODUCT: Combination Radiation, Immunotherapy, Surgery","University of Maryland, Baltimore",AstraZeneca|University of Arizona|West Penn Allegheny Health System,INTERVENTIONAL,"June 21, 2017","June 21, 2017",June 2022
NCT04500860,Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.,COMPLETED,Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence,"DRUG: Low dose tadalafil 5 mg|DRUG: Tolterodine 4 Mg Oral Capsule, Extended Release|DRUG: Placebo",Kasr El Aini Hospital,,INTERVENTIONAL,"December 1, 2020","December 1, 2020","July 1, 2022"
NCT02980029,TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.,RECRUITING,Colon Cancer,DRUG: TVB-2640|OTHER: Placebo,Mark Evers,,INTERVENTIONAL,"October 6, 2017","October 6, 2017","August 31, 2022"
NCT05156229,A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).,TERMINATED,Cutaneous T-cell Lymphoma (CTCL),BIOLOGICAL: CDK-003,Codiak BioSciences,,INTERVENTIONAL,"September 6, 2021","September 6, 2021","August 24, 2022"
NCT03109353,Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease,RECRUITING,"Cutaneous T-Cell Lymphoma, Unspecified|Chronic Graft Versus Host Disease in Skin",DRUG: ECP with 5-aminolevulinic acid,St. Olavs Hospital,Norwegian University of Science and Technology|Oslo University Hospital,INTERVENTIONAL,"September 20, 2017","September 20, 2017",June 2022
NCT04976738,A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain,COMPLETED,"Chronic Pain|Neck Pain|Back Pain|Pain|Pain, Chronic|Pain, Back|Pain, Neck|CBD|THC",DRUG: Cybis™ 10:25 THC:CBD oil,Cymra Life Sciences,,INTERVENTIONAL,"September 20, 2021","September 20, 2021","June 15, 2022"
NCT05366738,A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants,COMPLETED,Healthy Volunteers,DRUG: Vonoprazan|DRUG: Vonoprazan,"Phathom Pharmaceuticals, Inc.",,INTERVENTIONAL,"May 18, 2022","May 18, 2022","July 1, 2022"
NCT05292638,Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines,RECRUITING,Glabellar Lines,DRUG: CKDB-501A|DRUG: Botox®,CKD Bio Corporation,,INTERVENTIONAL,"February 15, 2022","February 15, 2022","June 10, 2022"
NCT02992964,Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers,ACTIVE_NOT_RECRUITING,Refractory or Recurrent Hypermutated Malignancies|Biallelic Mismatch Repair Deficiency (bMMRD) Positive Patients,DRUG: Nivolumab,The Hospital for Sick Children,Bristol-Myers Squibb,INTERVENTIONAL,"May 15, 2017","May 15, 2017",September 2022
NCT02649764,"Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",COMPLETED,Chronic Myelomonocytic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory High Risk Myelodysplastic Syndrome,DRUG: Cytarabine|DRUG: Fludarabine Phosphate|OTHER: Laboratory Biomarker Analysis|DRUG: Prexasertib,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"May 4, 2016","May 4, 2016","July 12, 2022"
NCT05349864,A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults,RECRUITING,Healthy Participants,DRUG: PF-07284890 Treatment A|DRUG: PF-07284890 Treatment B|DRUG: PF-07284890 Treatment C,Pfizer,,INTERVENTIONAL,"April 22, 2022","April 22, 2022","July 1, 2022"
NCT05364164,A Food Effect Study of CT-L01 After Oral Administration in Healthy Volunteers,COMPLETED,Type 2 Diabetes,"DRUG: CT-L01 12.5/1,000 mg|DRUG: CT-L01 12.5/1,000 mg",Celltrion,,INTERVENTIONAL,"July 9, 2022","July 9, 2022","July 19, 2022"
NCT04086264,IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia,RECRUITING,Acute Myeloid Leukemia,DRUG: Azacitidine|DRUG: IMGN632|DRUG: Venetoclax,"ImmunoGen, Inc.",Jazz Pharmaceuticals,INTERVENTIONAL,"November 6, 2019","November 6, 2019","June 16, 2022"
NCT03784677,SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors,RECRUITING,Advanced Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm|Refractory Ovarian Carcinoma|Refractory Pancreatic Carcinoma|Stage II Pancreatic Cancer AJCC v8|Stage IIA Pancreatic Cancer AJCC v8|Stage IIB Pancreatic Cancer AJCC v8|Stage III Ovarian Cancer AJCC v8|Stage III Pancreatic Cancer AJCC v8|Stage III Prostate Cancer AJCC v8|Stage IIIA Ovarian Cancer AJCC v8|Stage IIIA Prostate Cancer AJCC v8|Stage IIIB Ovarian Cancer AJCC v8|Stage IIIB Prostate Cancer AJCC v8|Stage IIIC Ovarian Cancer AJCC v8|Stage IIIC Prostate Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Pancreatic Cancer AJCC v8|Stage IV Prostate Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Prostate Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Prostate Cancer AJCC v8,DRUG: TRPV6 Calcium Channel Inhibitor SOR-C13,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"July 29, 2019","July 29, 2019","August 9, 2022"
NCT04021277,Acoustic Cluster Therapy (ACT) With Chemotherapy in Metastatic Liver Metastases of Gastrointestinal Origin,UNKNOWN,Solid Tumor|Colorectal Cancer|Pancreatic Cancer,COMBINATION_PRODUCT: PS101 and Ultra Sound for escalation|COMBINATION_PRODUCT: PS101 and Ultra Sound for expansion,EXACT Therapeutics AS,,INTERVENTIONAL,"September 17, 2019","September 17, 2019",July 2022
NCT05152277,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects",COMPLETED,Type 2 Diabetes,DRUG: HRS9531|OTHER: placebo|DRUG: HRS9531|OTHER: placebo,"Fujian Shengdi Pharmaceutical Co., Ltd.",,INTERVENTIONAL,"December 6, 2021","December 6, 2021","August 24, 2022"
NCT03830177,Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult,RECRUITING,"Dermatitis, Seborrheic|Dry Skin; Eczema",DRUG: Natural Treatment,Ann & Robert H Lurie Children's Hospital of Chicago,"Feinberg School of Medicine, Northwestern University",INTERVENTIONAL,"May 6, 2019","May 6, 2019","August 1, 2022"
NCT04095221,"A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma",ACTIVE_NOT_RECRUITING,Desmoplastic Small Round Cell Tumor|Rhabdomyosarcoma,DRUG: Prexasertib|DRUG: Irinotecan,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL,"September 17, 2019","September 17, 2019",September 2022
NCT05363592,A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers,COMPLETED,Type 2 Diabetes,DRUG: CT-L01 12.5/500 mg|DRUG: Alogliptin Benzoate 12.5 mg|DRUG: Metformin HCl XR 500 mg,Celltrion,,INTERVENTIONAL,"June 25, 2022","June 25, 2022","July 5, 2022"
NCT03649321,Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer,TERMINATED,Cancer of Pancreas,DRUG: Bemcentinib|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Cisplatin,University of Texas Southwestern Medical Center,Triligent International|Translational Genomics Research Institute|BerGenBio ASA,INTERVENTIONAL,"January 3, 2019","January 3, 2019","June 27, 2022"
NCT05491330,"Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)",RECRUITING,Healthy,DRUG: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose)|DRUG: Nirmatrelvir 150 mg + Ritonavir 100 mg (test)|DRUG: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose),"Genuine Research Center, Egypt",Eva Pharma,INTERVENTIONAL,August 2022,August 2022,August 2022
NCT05470530,Dexamethasone Intravenous Versus Intrathecal in Spinal Anesthesia,COMPLETED,Healthy,DRUG: Dexamethasone,Ain Shams University,,INTERVENTIONAL,"March 10, 2022","March 10, 2022","July 10, 2022"
NCT03206021,COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors,ACTIVE_NOT_RECRUITING,"Recurrent Childhood CNS Tumor|Ependymoma, Recurrent Childhood|Childhood Solid Tumor",DRUG: 5 Azacytidine,The Hospital for Sick Children,,INTERVENTIONAL,"August 1, 2017","August 1, 2017","July 1, 2022"
NCT04791553,Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment,RECRUITING,Hepatic Impairment,DRUG: Cenobamate,"SK Life Science, Inc.",,INTERVENTIONAL,"June 17, 2021","June 17, 2021","June 7, 2022"
NCT03888053,BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers,ACTIVE_NOT_RECRUITING,Diabetic Foot Ulcer,BIOLOGICAL: BB-101,Blue Blood Biotech Corp.,,INTERVENTIONAL,"March 28, 2018","March 28, 2018","June 30, 2022"
NCT03631953,Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas,UNKNOWN,Meningioma,DRUG: Trametinib|DRUG: Alpelisib|BIOLOGICAL: Blood sample|DEVICE: MRI,Assistance Publique Hopitaux De Marseille,,INTERVENTIONAL,"September 30, 2019","September 30, 2019","September 1, 2022"
NCT04501653,Precision Functional Brain Mapping in Psilocybin,ACTIVE_NOT_RECRUITING,Psilocybin,DRUG: Psilocybin|DRUG: Methylphenidate,Washington University School of Medicine,,INTERVENTIONAL,"June 1, 2021","June 1, 2021","June 30, 2022"
NCT00392353,Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia,ACTIVE_NOT_RECRUITING,Acute Erythroid Leukemia|Acute Megakaryoblastic Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts|Myelodysplastic Syndrome With Ring Sideroblasts|Recurrent Adult Acute Myeloid Leukemia|Refractory Anemia,DRUG: Azacitidine|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Vorinostat,National Cancer Institute (NCI),,INTERVENTIONAL,"November 22, 2006","November 22, 2006","June 30, 2022"
NCT03083353,Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation,RECRUITING,"Nicotine Dependence|Smoking, Cigarette|Smoking Cessation|Smoking Behaviors|Smoking Reduction|Craving",DRUG: Isradipine|BEHAVIORAL: Cue Exposure,University of Texas at Austin,National Institute on Drug Abuse (NIDA),INTERVENTIONAL,"January 22, 2020","January 22, 2020",September 2022
NCT05084560,"Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug",NOT_YET_RECRUITING,"Filariasis, Lymphatic|Onchocerciasis",DRUG: AWZ1066S|DRUG: Placebo,Liverpool School of Tropical Medicine,Liverpool University Hospitals NHS Foundation Trust|Covance|Subiaco Associates Limited|Sylexis Limited|Eisai Limited,INTERVENTIONAL,"November 1, 2021","November 1, 2021","July 1, 2022"
NCT03910660,A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.,RECRUITING,Prostate Cancer|Neuroendocrine Tumors|Small Cell Carcinoma,DRUG: BXCL701 plus Pembrolizumab|DRUG: BXCL701 monotherapy,BioXcel Therapeutics Inc,,INTERVENTIONAL,"February 12, 2019","February 12, 2019","June 2, 2022"
NCT03798353,Pericardial Matrix With Mesenchymal Stem Cells for the Treatment of Patients With Infarcted Myocardial Tissue,ACTIVE_NOT_RECRUITING,Myocardial Infarction,COMBINATION_PRODUCT: PeriCord: Expanded and cryopreserved allogeneic umbilical cord Wharton´s jelly-derived adult mesenchymal stem cells colonized on human pericardial matrix.|PROCEDURE: Surgery by sternotomy,Fundació Institut Germans Trias i Pujol,Germans Trias i Pujol Hospital,INTERVENTIONAL,"May 13, 2019","May 13, 2019",September 2022
NCT02502253,BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM),COMPLETED,Mild Cognitive Impairment|Alzheimer's Disease,"DRUG: grape seed polyphenolic extract, resveratrol",Johns Hopkins University,Icahn School of Medicine at Mount Sinai,INTERVENTIONAL,June 2015,June 2015,"June 1, 2022"
NCT05015894,A Research Study Looking Into Blood Levels of the Medicine NNC0480-0389 in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function,COMPLETED,"Diabetes Mellitus, Type 2",DRUG: NNC0480-0389,Novo Nordisk A/S,,INTERVENTIONAL,"August 30, 2021","August 30, 2021","August 2, 2022"
NCT04634994,Novel Assessment of Synaptic Density in Progressive MS,RECRUITING,Primary Progressive Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Relapsing Multiple Sclerosis|Multiple Sclerosis,DRUG: [F-18]SDM-8,Brigham and Women's Hospital,Massachusetts General Hospital,INTERVENTIONAL,August 2021,August 2021,August 2022
NCT04495894,Pre-Incisional Ketorolac for Patients Undergoing Surgery for Non-Small Cell Lung Cancer and Renal Cell Carcinoma,RECRUITING,Non-small Cell Lung Cancer|Renal Cell Carcinoma,DRUG: Preoperative Ketorolac,Emory University,,INTERVENTIONAL,"August 24, 2020","August 24, 2020",August 2022
NCT04863794,A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants,COMPLETED,Angelman Syndrome,DRUG: RO7248824,Hoffmann-La Roche,,INTERVENTIONAL,"April 29, 2021","April 29, 2021","August 1, 2022"
NCT03589794,rCSP/AP10-602 [GLA-LSQ] Vaccine Trial,COMPLETED,Plasmodium Falciparum Infection,OTHER: AP10-602|OTHER: Malaria challenge|BIOLOGICAL: rCSP,National Institute of Allergy and Infectious Diseases (NIAID),,INTERVENTIONAL,"December 21, 2018","December 21, 2018","July 5, 2022"
NCT03311594,The Alcohol-Pain Connection: Mechanisms and Genetic/Psychological Correlates,COMPLETED,Pain|Alcohol Drinking|Acute Pain|Drinking Behavior,DRUG: Low Alcohol|DRUG: Moderate Alcohol|DRUG: Placebo Alcohol|OTHER: Pain Induction|OTHER: No Pain Induction,Syracuse University,National Institute on Alcohol Abuse and Alcoholism (NIAAA),INTERVENTIONAL,"May 12, 2019","May 12, 2019","June 30, 2022"
NCT04456777,Effect of Vortioxetine on Cognitive Symptoms in Patients With Schizophrenia,UNKNOWN,Cognitive Deficit,DRUG: Vortioxetine,Alen Greš,,INTERVENTIONAL,"July 1, 2020","July 1, 2020","July 1, 2022"
NCT04699877,A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function,ACTIVE_NOT_RECRUITING,Renal Impaired|Gilteritinib|Normal Renal Function|Pharmacokinetics of ASP2215,DRUG: Gilteritinib,"Astellas Pharma Global Development, Inc.",,INTERVENTIONAL,"January 28, 2021","January 28, 2021","August 31, 2022"
NCT05437094,Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740,RECRUITING,Clinical Pharmacology|Pharmacokinetics|Cardiovascular Diseases|Heart Failure,DRUG: CRD-740|DRUG: Itraconazole,"Cardurion Pharmaceuticals, Inc.",,INTERVENTIONAL,"June 27, 2022","June 27, 2022","August 10, 2022"
NCT02393794,Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),ACTIVE_NOT_RECRUITING,Triple-Negative Breast Cancer|Breast Cancer,DRUG: Romidepsin|DRUG: Cisplatin|DRUG: Nivolumab,Priyanka Sharma,Celgene Corporation|Bristol-Myers Squibb,INTERVENTIONAL,"July 17, 2015","July 17, 2015",July 2022
NCT05320094,A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants,RECRUITING,Healthy Participants,DRUG: Mavacamten|DRUG: Activated Charcoal with Sorbitol,Bristol-Myers Squibb,,INTERVENTIONAL,"April 20, 2022","April 20, 2022","July 28, 2022"
NCT02727764,A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis,UNKNOWN,"Arthritis, Rheumatoid|Osteo Arthritis",GENETIC: ART-I02,Arthrogen,Centre for Human Drug Research (CHDR),INTERVENTIONAL,"April 20, 2017","April 20, 2017",September 2022
NCT04737161,Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome,WITHDRAWN,Acute Respiratory Distress Syndrome|Covid19,BIOLOGICAL: T regulatory cells,Stanford University,,INTERVENTIONAL,March 2021,March 2021,September 2022
NCT01297764,"A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma",ACTIVE_NOT_RECRUITING,Multiple Myeloma,"DRUG: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone",Hackensack Meridian Health,,INTERVENTIONAL,April 2011,April 2011,August 2022
NCT05207761,"Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930",NOT_YET_RECRUITING,Glaucoma,DRUG: D565|DRUG: D930,Chong Kun Dang Pharmaceutical,,INTERVENTIONAL,"January 19, 2022","January 19, 2022","July 3, 2022"
NCT02635061,Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer,UNKNOWN,Non Small Cell Lung Cancer,DRUG: ACY-241|DRUG: Nivolumab,Celgene,,INTERVENTIONAL,"August 25, 2016","August 25, 2016","June 30, 2022"
NCT05153564,A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause,COMPLETED,"Diabetes Mellitus, Type 2",DRUG: Semaglutide 1.34 mg/mL|DRUG: Semaglutide 3.0 mg/mL|DRUG: NNC0480-0389 10 mg/mL|DRUG: NNC0480-0389 30 mg/mL|DRUG: Microgynon®,Novo Nordisk A/S,,INTERVENTIONAL,"December 13, 2021","December 13, 2021","August 13, 2022"
NCT04167761,Ertugliflozin: Cardioprotective Effects on Epicardial Fat,RECRUITING,Cardiovascular Diseases|Atherosclerosis|Type 2 Diabetes|Insulin Resistance,DRUG: Ertugliflozin|DRUG: Glipizide,Stanford University,Merck Sharp & Dohme LLC,INTERVENTIONAL,"July 1, 2020","July 1, 2020","July 31, 2022"
NCT04302961,Effects of Gait Retraining With Auditory Feedback,ACTIVE_NOT_RECRUITING,Ankle Injuries|Ankle Inversion Sprain,OTHER: Auditory Feedback|OTHER: No Feedback,"University of North Carolina, Charlotte",,INTERVENTIONAL,"October 5, 2020","October 5, 2020","June 30, 2022"
NCT05042934,Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma,WITHDRAWN,Metastatic Ewing Sarcoma|Recurrent Ewing Sarcoma,PROCEDURE: Fine-Needle Aspiration|DRUG: Irinotecan|DRUG: Irinotecan Hydrochloride|DRUG: Lurbinectedin,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"September 15, 2021","September 15, 2021","August 30, 2022"
NCT05492734,A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling,COMPLETED,Muscular Dystrophies,DRUG: EDG-5506,"Edgewise Therapeutics, Inc.",,INTERVENTIONAL,"August 12, 2022","August 12, 2022","August 19, 2022"
NCT05475834,Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants,NOT_YET_RECRUITING,COVID-19|Healthy Male Volunteers,DRUG: SIM0417,"Jiangsu Simcere Pharmaceutical Co., Ltd.",,INTERVENTIONAL,"July 23, 2022","July 23, 2022","August 1, 2022"
NCT04437836,Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampic,RECRUITING,Clinical Trial,DRUG: Evaluation of high dose rifampicin in children,Kilimanjaro Clinical Research Institute,European and Developing Countries Clinical Trials Partnership (EDCTP),INTERVENTIONAL,"July 1, 2019","July 1, 2019","July 1, 2022"
NCT04309734,Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects,WITHDRAWN,"Hepatitis C|Hepatitis C, Chronic|Chronic Hepatitis C|Hepatitis C Virus Infection|HCV Infection",DRUG: AT-777|DRUG: Placebo|DRUG: AT-527,"Atea Pharmaceuticals, Inc.",,INTERVENTIONAL,October 2021,October 2021,June 2022
NCT03888534,Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy),WITHDRAWN,Precursor Cell Lymphoblastic Leukemia-lymphoma,DRUG: Ixazomib,"Millennium Pharmaceuticals, Inc.",,INTERVENTIONAL,"October 31, 2020","October 31, 2020","August 30, 2022"
NCT05218434,"A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses",RECRUITING,Autoimmune Diseases,DRUG: AX-158,Artax Biopharma Inc,Simbec-Orion Group,INTERVENTIONAL,"December 14, 2021","December 14, 2021",August 2022
NCT05466734,BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers,ACTIVE_NOT_RECRUITING,Intermittent Claudication,DRUG: Cilostazol Tablet 100 mg|DRUG: PMR Tablet 135 mg,"Genovate Biotechnology Co., Ltd.,",,INTERVENTIONAL,"July 30, 2022","July 30, 2022","August 23, 2022"
NCT04712734,A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia,RECRUITING,Schizophrenia,DRUG: Iloperidone,Vanda Pharmaceuticals,,INTERVENTIONAL,"January 13, 2021","January 13, 2021",September 2022
NCT02909036,Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.,ACTIVE_NOT_RECRUITING,Multiple Myeloma|Amyloidosis,DEVICE: Melphalan|DRUG: Pegfilgrastim|PROCEDURE: Autologous Hematopoietic Progenitor Cell Transplant,Memorial Sloan Kettering Cancer Center,"Spectrum Pharmaceuticals, Inc",INTERVENTIONAL,September 2016,September 2016,September 2022
NCT02571036,"A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies",ACTIVE_NOT_RECRUITING,Gastrointestinal Stromal Tumors|Advanced Systemic Mastocytosis|Advanced Cancers,DRUG: DCC-2618|DRUG: DCC-2618,Deciphera Pharmaceuticals LLC,,INTERVENTIONAL,October 2015,October 2015,June 2022
NCT04742036,Capivasertib China PK Study,COMPLETED,Advanced Solid Tumours,DRUG: Capivasertib|DRUG: Paclitaxel,AstraZeneca,,INTERVENTIONAL,"February 22, 2021","February 22, 2021","July 29, 2022"
NCT03627741,A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors,COMPLETED,Fibromatosis,DRUG: Triamcinolone Acetonide,Mayo Clinic,,INTERVENTIONAL,"June 7, 2018","June 7, 2018","July 5, 2022"
NCT04896541,"Phase I Double-blind, Placebo-controlled Study of AZD7442",COMPLETED,COVID-19,BIOLOGICAL: AZD7442 300 mg IM(male)|BIOLOGICAL: AZD7442 600 mg IM (male)|BIOLOGICAL: AZD7442 300 mg IV (male and female)|BIOLOGICAL: AZD7442 1000 mg IV (male),AstraZeneca,,INTERVENTIONAL,"March 16, 2021","March 16, 2021","June 14, 2022"
NCT04656132,PAVS in Cardiology,COMPLETED,Cardiovascular Diseases,"BEHAVIORAL: Physical activity assessment, promotion and monitoring in a preventive cardiology clinic",NYU Langone Health,,INTERVENTIONAL,"July 14, 2021","July 14, 2021","August 10, 2022"
NCT02957032,A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation,ACTIVE_NOT_RECRUITING,"Acute Myeloid Leukemia, Relapsed, Adult",DRUG: F16IL2|DRUG: cytarabine,Philogen S.p.A.,,INTERVENTIONAL,"April 13, 2016","April 13, 2016",September 2022
NCT05276232,Detection of Cannabis Impairment With ISBRG's SpotLight-THC,RECRUITING,Cannabis,DRUG: Cannabis(THC) inhaled,ISBRG Corp,National Advanced Driving Simulator,INTERVENTIONAL,March 2022,March 2022,August 2022
NCT05108194,Feasibility of a Personalized SMS Intervention for Insomnia,RECRUITING,Insomnia|Sleep Disorder,BEHAVIORAL: SMS Personalized Sleep Intervention,"University of Missouri, St. Louis",,INTERVENTIONAL,"November 15, 2021","November 15, 2021","June 1, 2022"
NCT05321732,The Drug Interaction of DWP16001 and DWC202010 After Oral Administration in Healthy Adults,ENROLLING_BY_INVITATION,Healthy Volunteers,DRUG: DWP16001|DRUG: DWP202010,Daewoong Pharmaceutical Co. LTD.,,INTERVENTIONAL,"December 10, 2021","December 10, 2021",August 2022
NCT05321602,Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder,RECRUITING,Schizophrenia|Psychotic Disorders|Mood Disorders|Schizophrenia Spectrum and Other Psychotic Disorders|Mental Disorders|Antipsychotic Agents|Tranquilizing Agents|Central Nervous System Depression|Physiological Effects of Drugs|Psychotropic Drugs|Neurotransmitter Agents|Molecular Mechanisms of Pharmacological Action,"DRUG: LY03010 156 mg treatment group, deltoid|DRUG: LY03010 156 mg treatment group, gluteal|DRUG: LY03010 351 mg treatment group, deltoid|DRUG: LY03010 351 mg treatment group, gluteal",Luye Pharma Group Ltd.,,INTERVENTIONAL,"September 8, 2021","September 8, 2021","July 23, 2022"
NCT04994002,"A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations",WITHDRAWN,Lymphatic Malformation,DRUG: CERC-006,"Avalo Therapeutics, Inc.",,INTERVENTIONAL,"September 3, 2021","September 3, 2021",June 2022
NCT04848402,A Device Study in Healthy Participants,RECRUITING,Healthy,DEVICE: On-Body Delivery System (OBDS)/Multiple Bolus Injector|DEVICE: Single Auto Injector|DRUG: Placebo,Eli Lilly and Company,,INTERVENTIONAL,"September 27, 2021","September 27, 2021","July 22, 2022"
NCT04514302,Safety and Efficacy of Anti-SARS-CoV-2 Equine Antibody F(ab')2 Fragments (INOSARS) for Adult Patients With Mild COVID-19,COMPLETED,COVID-19,DRUG: Placebo|DRUG: Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments (INOSARS),Hospital San Jose Tec de Monterrey,Inosan Biopharma,INTERVENTIONAL,"December 7, 2021","December 7, 2021","August 1, 2022"
NCT03580902,CBT4CBT for Office Based Buprenorphine,COMPLETED,Opioid-use Disorder,BEHAVIORAL: CBT4CBT-Buprenorphine|DRUG: Buprenorphine/naloxone,"CBT4CBT, LLC",,INTERVENTIONAL,"January 22, 2019","January 22, 2019","July 5, 2022"
NCT04509102,Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder,ENROLLING_BY_INVITATION,Major Depressive Disorder,DRUG: Adderall-XR|DRUG: Placebo,"University of California, Los Angeles",,INTERVENTIONAL,"September 27, 2021","September 27, 2021","June 19, 2022"
NCT04167618,177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma,TERMINATED,"Medulloblastoma, Childhood",DRUG: 177Lu-DTPA-omburtamab,Y-mAbs Therapeutics,,INTERVENTIONAL,"September 30, 2021","September 30, 2021","August 11, 2022"
NCT04516902,Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects,COMPLETED,Healthy,"DRUG: Lysergic Acid Diethylamide|DRUG: 3,4-methylenedioxymethamphetamine|OTHER: LSD Placebo|OTHER: MDMA Placebo","University Hospital, Basel, Switzerland",,INTERVENTIONAL,"January 1, 2021","January 1, 2021","August 22, 2022"
NCT04388878,Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants,COMPLETED,Healthy,DRUG: PF-07054894|DRUG: Placebo,Pfizer,,INTERVENTIONAL,"July 27, 2020","July 27, 2020","June 21, 2022"
NCT05455502,A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-548,ACTIVE_NOT_RECRUITING,Pain,DRUG: VX-548,Vertex Pharmaceuticals Incorporated,,INTERVENTIONAL,"July 13, 2022","July 13, 2022",September 2022
NCT04891718,CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia,WITHDRAWN,Solid Tumour,BIOLOGICAL: MVC-101|BIOLOGICAL: Nivolumab|COMBINATION_PRODUCT: MVC-101 + Nivolumab,Presage Biosciences,Takeda,INTERVENTIONAL,"September 15, 2021","September 15, 2021","June 5, 2022"
NCT05150418,Supplemental Oxygen in Hypovolemia,COMPLETED,Hypovolemia|Hyperoxia,DRUG: Oxygen gas|DRUG: Air,Oslo University Hospital,Norwegian Air Ambulance Foundation,INTERVENTIONAL,"November 26, 2021","November 26, 2021","June 14, 2022"
NCT04561258,Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy,RECRUITING,HIV,BIOLOGICAL: AGT103-T,American Gene Technologies International Inc.,,INTERVENTIONAL,"October 12, 2020","October 12, 2020",June 2022
NCT05070702,First in Human Study of CT-1500 in Healthy Participants,COMPLETED,Healthy,DRUG: CT-1500|DRUG: Placebo,Circadian Therapeutics Ltd,Neuroscience Trials Australia,INTERVENTIONAL,"November 8, 2021","November 8, 2021","July 7, 2022"
NCT05198778,"A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment",RECRUITING,"Healthy, Renal Impairment",DRUG: URC102|DRUG: URC102,JW Pharmaceutical,,INTERVENTIONAL,"November 29, 2021","November 29, 2021",July 2022
NCT05335044,Phase 1 Study to Evaluate the Safety and Pharmacokinetics of CKD-331 in Healthy Adult Volunteers,NOT_YET_RECRUITING,Hypertension and Dyslipidemia,DRUG: CKD-331|DRUG: EX5619,Chong Kun Dang Pharmaceutical,,INTERVENTIONAL,"April 29, 2022","April 29, 2022","June 25, 2022"
NCT05390944,An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fasting Condition,NOT_YET_RECRUITING,Solid Tumor,DRUG: IMP4297(20mg)|DRUG: IMP4297(10mg),"Impact Therapeutics, Inc.",,INTERVENTIONAL,"June 8, 2022","June 8, 2022","June 21, 2022"
NCT04661644,Efficacy and Safety of Mesenchymal Stem Cell Clusters in Patients With Critical Limb Ischemia,RECRUITING,Critical Limb Ischemia,BIOLOGICAL: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)|BIOLOGICAL: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial),"S.Biomedics Co., Ltd.",Dt&Sanomedics,INTERVENTIONAL,"November 4, 2020","November 4, 2020",June 2022
NCT05158244,Study of Multiple Oral Doses of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus,COMPLETED,Type 2 Diabetes Mellitus,DRUG: PF-07081532|DRUG: Placebo,Pfizer,,INTERVENTIONAL,"December 22, 2021","December 22, 2021","June 14, 2022"
NCT05404724,Study on the Pharmacokinetic Effect of Itraconazole on SHR0302 Tablets in Healthy Subjects,ACTIVE_NOT_RECRUITING,Rheumatoid Arthritis,DRUG: itraconazole、 SHR0302 tablets,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"June 25, 2022","June 25, 2022","August 15, 2022"
NCT04511624,Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects,COMPLETED,Healthy Subjects,DRUG: IBI112 dose1|DRUG: IBI112 dose2|DRUG: IBI112 dose3|DRUG: IBI112 dose4|DRUG: IBI112 dose5|DRUG: IBI112 dose6|DRUG: IBI112 dose7,Innovent Biologics (Suzhou) Co. Ltd.,,INTERVENTIONAL,"August 27, 2020","August 27, 2020","July 22, 2022"
NCT02079740,Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors,RECRUITING,Metastatic Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm|Unresectable Malignant Solid Neoplasm,PROCEDURE: Biopsy|PROCEDURE: Biospecimen Collection|PROCEDURE: Computed Tomography|PROCEDURE: Magnetic Resonance Imaging|BIOLOGICAL: Navitoclax|PROCEDURE: Positron Emission Tomography|DRUG: Trametinib,National Cancer Institute (NCI),,INTERVENTIONAL,"March 7, 2014","March 7, 2014","September 1, 2022"
NCT05342974,Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy,RECRUITING,Abortion Early,DRUG: Atorvastatin|DRUG: Misoprostol,University of Utah,Grand Challenges Canada,INTERVENTIONAL,"April 19, 2022","April 19, 2022","July 31, 2022"
NCT04386174,Brain Activity in People With Chronic Neuropathic Pain and Spinal Cord Injury,RECRUITING,Neuropathic Pain|Spinal Cord Injury,OTHER: Neurofeedback,Kessler Foundation,University of Surrey,INTERVENTIONAL,"August 1, 2020","August 1, 2020",July 2022
NCT05324124,A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants,COMPLETED,Healthy,DRUG: Selpercatinib,"Loxo Oncology, Inc.",Eli Lilly and Company,INTERVENTIONAL,"April 19, 2022","April 19, 2022","June 22, 2022"
NCT03580824,"A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants",COMPLETED,"Malaria,Falciparum",BIOLOGICAL: R21 in Matrix- M adjuvant vaccine,University of Oxford,Kenya Medical Research Institute|European and Developing Countries Clinical Trials Partnership (EDCTP),INTERVENTIONAL,"April 30, 2019","April 30, 2019","June 14, 2022"
NCT04582201,Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2,COMPLETED,"Respiratory Distress Syndrome, Adult",DRUG: agenT-797,MiNK Therapeutics,,INTERVENTIONAL,"September 21, 2020","September 21, 2020","June 2, 2022"
NCT04570501,Angiotensin (1-7) for the Treatment of COVID-19 in Hospitalized Patients,WITHDRAWN,Covid19,DRUG: Angiotensin-(1-7)|DRUG: Placebo,Stanford University,,INTERVENTIONAL,February 2022,February 2022,August 2022
NCT03609424,PDR001 Plus Imatinib for Metastatic or Unresectable GIST,RECRUITING,Gastrointestinal Stromal Tumors,"DRUG: PDR001, Imatinib",Asan Medical Center,Novartis,INTERVENTIONAL,"February 14, 2019","February 14, 2019","August 30, 2022"
NCT05223101,A Bioequivalence Study Between Telmione 80 mg and Micardis 80 mg in Healthy Adult Volunteers,RECRUITING,Hypertension,DRUG: Telminone 80 mg|DRUG: Drug: Micardis 80 mg,HK inno.N Corporation,,INTERVENTIONAL,"January 19, 2022","January 19, 2022",July 2022
NCT03719001,Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study,COMPLETED,Vascular Diseases,DRUG: Phenylephrine|DRUG: Dexmedetomidine|DRUG: Clevidipine|OTHER: tetanic stimulus|OTHER: Increased venous pressure|DRUG: Calcium Chloride,"University of California, San Francisco",,INTERVENTIONAL,"October 23, 2018","October 23, 2018","June 15, 2022"
NCT01555281,Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma,TERMINATED,Multiple Myeloma,DRUG: Nelfinavir|DRUG: Lenalidomide|DRUG: Dexamethasone,Swiss Group for Clinical Cancer Research,,INTERVENTIONAL,"February 23, 2012","February 23, 2012","June 8, 2022"
NCT05487781,Phase 1 Clinical Study to Describe Biological Safety and Pharmacokinetics of Tyrphostin,ENROLLING_BY_INVITATION,Healthy,COMBINATION_PRODUCT: Tirfostina/L-Carnitina,Molecule X LLC,,INTERVENTIONAL,"May 24, 2022","May 24, 2022","June 28, 2022"
NCT05092581,"COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19",TERMINATED,COVID-19,DRUG: casirivimab+imdevimab,Regeneron Pharmaceuticals,,INTERVENTIONAL,"December 16, 2021","December 16, 2021","June 9, 2022"
NCT04906681,Implementation of a Rehabilitation Technology in Orthopedic and Neurological Rehabilitation to Increase Therapy Dosage: an Exploratory Study,NOT_YET_RECRUITING,Arthroplasty|Neurologic Disorder,DEVICE: i-ACT,PXL University College,"St-Trudo hospital, St-Truiden, Belgium",INTERVENTIONAL,"September 1, 2021","September 1, 2021","June 1, 2022"
NCT05032781,Intra-Arterial Neuroprotective Agents and Cold Saline in Ischemic Stroke Intervention,RECRUITING,"Stroke, Ischemic","DRUG: Intra-arterial cold saline, minocycline, and magnesium",Northwell Health,,INTERVENTIONAL,"June 1, 2021","June 1, 2021",June 2022
NCT04464070,Pathways of Eicosanoid Metabolism,ENROLLING_BY_INVITATION,Metabolism of Prostaglandin D2,DIETARY_SUPPLEMENT: niacin|DRUG: aspirin|OTHER: PGD2,Vanderbilt University,Vanderbilt University Medical Center,INTERVENTIONAL,"January 14, 2021","January 14, 2021",July 2022
NCT03261570,Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS,ACTIVE_NOT_RECRUITING,Postural Orthostatic Tachycardia Syndrome (POTS)|POTS|Orthostatic Intolerance,DRUG: Pyridostigmine|DRUG: Digoxin|DRUG: Placebo,New York Medical College,National Institutes of Health (NIH),INTERVENTIONAL,"July 1, 2017","July 1, 2017","June 1, 2022"
NCT03767270,"Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency",WITHDRAWN,Ornithine Transcarbamylase Deficiency,BIOLOGICAL: MRT5201|OTHER: Placebo,"Translate Bio, Inc.",,INTERVENTIONAL,December 2019,December 2019,July 2022
NCT04038840,Imaging Synapses With [11C] UCB-J in the Human Brain,ENROLLING_BY_INVITATION,Schizophrenia,DRUG: [11C]UCB-J radiotracer|DEVICE: PET-MR,"Davidzon, Guido, M.D.",Weston Havens Foundation,INTERVENTIONAL,"August 1, 2019","August 1, 2019",September 2022
NCT04870840,Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer,RECRUITING,Locally Advanced Head and Neck Squamous Cell Carcinoma|Locally Advanced Hypopharyngeal Squamous Cell Carcinoma|Locally Advanced Laryngeal Squamous Cell Carcinoma|Locally Advanced Nasopharyngeal Squamous Cell Carcinoma|Locally Advanced Oral Cavity Squamous Cell Carcinoma|Locally Advanced Oropharyngeal Squamous Cell Carcinoma|Malignant Posterior Tongue Neoplasm|Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage II Hypopharyngeal Carcinoma AJCC v8|Stage II Laryngeal Cancer AJCC v8|Stage II Nasopharyngeal Carcinoma AJCC v8|Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8|Stage III Hypopharyngeal Carcinoma AJCC v8|Stage III Laryngeal Cancer AJCC v8|Stage III Nasopharyngeal Carcinoma AJCC v8|Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Unresectable Head and Neck Squamous Cell Carcinoma|Unresectable Oropharyngeal Squamous Cell Carcinoma,RADIATION: Proton Beam Radiation Therapy|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"October 19, 2020","October 19, 2020","July 1, 2022"
NCT03834740,A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection,ACTIVE_NOT_RECRUITING,Glioblastoma Multiforme|Glioma of Brain,DRUG: Ribociclib|DRUG: Everolimus,"St. Joseph's Hospital and Medical Center, Phoenix",Ivy Brain Tumor Center|Barrow Neurological Institute,INTERVENTIONAL,"December 21, 2018","December 21, 2018","June 30, 2022"
NCT05113940,A Study of PF-07258669 In Healthy Adult Participants,RECRUITING,Healthy Participants,DRUG: PF-07258669|DRUG: Placebo|DRUG: Midazolam,Pfizer,,INTERVENTIONAL,"November 8, 2021","November 8, 2021","July 19, 2022"
NCT04709224,"Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia",RECRUITING,Schizophrenia,DRUG: Lumateperone Long-Acting Injectable,"Intra-Cellular Therapies, Inc.",,INTERVENTIONAL,"December 30, 2020","December 30, 2020",June 2022
NCT03455140,A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100),COMPLETED,Cancer|Pediatric Solid Tumor|Pediatric AML|Pediatric ALL,DRUG: PEG- BCT-100,University of Birmingham,,INTERVENTIONAL,"August 28, 2018","August 28, 2018","July 22, 2022"
NCT05332340,"Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered",NOT_YET_RECRUITING,Erectile Dysfunction Following Radical Prostatectomy|Erectile Dysfunction|Prostate Cancer|Radical Prostatectomy,DRUG: BZ371A,Biozeus Biopharmaceutical S.A.,Azidus Brasil Scientific Research and Development Ltda,INTERVENTIONAL,September 2022,September 2022,September 2022
NCT03989440,AXER-204 in Participants With Chronic Spinal Cord Injury,COMPLETED,Chronic Spinal Cord Injury,DRUG: AXER-204|DRUG: Placebo,"ReNetX Bio, Inc.",,INTERVENTIONAL,"July 16, 2019","July 16, 2019","June 21, 2022"
NCT05086523,"Cardiac Neuromodulation Therapy (CNT) ""Washout"" Sub-Study",RECRUITING,"Hypertension,Essential|Systolic Hypertension",DEVICE: Programmable Hypertension Control (BackBeat Moderato)|DEVICE: Pacing (BackBeat Moderato),BackBeat Medical Inc,,INTERVENTIONAL,"September 27, 2021","September 27, 2021",August 2022
NCT02149823,Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations,SUSPENDED,Borderline Personality Disorder|BPD|Schizotypal Personality Disorder|SPD|Autism Spectrum Disorder|Schizophrenia|Schizoaffective Disorder|Bipolar Disorder,DRUG: Syntocinon 24 Intranasal Units (IU)|DRUG: Syntocinon 40 Intranasal Units (IU)|DRUG: Intranasal Placebo,Maria de las Mercedes Perez Rodriguez,"James J. Peters Veterans Affairs Medical Center|VISN 3 Mental Illness Research, Education and Clinical Center",INTERVENTIONAL,September 2013,September 2013,July 2022
NCT04406623,Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer,RECRUITING,Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma,DRUG: SL-172154,"Shattuck Labs, Inc.",,INTERVENTIONAL,"June 29, 2020","June 29, 2020",July 2022
NCT05324423,"To Evaluate Drug Interactions Between XNW3009, Febuxostat, and Colchicine in Patients With Gout",RECRUITING,Gout,DRUG: Colchicine,The Affiliated Hospital of Qingdao University,,INTERVENTIONAL,"October 18, 2021","October 18, 2021","August 1, 2022"
NCT05429723,First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383,RECRUITING,Cough,DRUG: HS-10383|DRUG: HS-10383 Placebo,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",,INTERVENTIONAL,"March 1, 2022","March 1, 2022","June 30, 2022"
NCT03382184,Fractional Photothermolysis for Hair Follicle Induction,ACTIVE_NOT_RECRUITING,Alopecia,DEVICE: Fraxel Dual laser|DEVICE: Halo laser,"University of California, Irvine",Beckman Laser Institute,INTERVENTIONAL,"October 20, 2017","October 20, 2017",June 2022
NCT04353024,Effects of Dimethyltryptamine in Healthy Subjects,RECRUITING,Healthy,DRUG: Dimethyltryptamine (DMT)|DRUG: Saline,"University Hospital, Basel, Switzerland",,INTERVENTIONAL,"June 18, 2021","June 18, 2021","July 1, 2022"
NCT04093076,"Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana",ACTIVE_NOT_RECRUITING,Lassa Fever,DRUG: INO-4500|DEVICE: CELLECTRA™ 2000|DRUG: Placebo,Inovio Pharmaceuticals,Coalition for Epidemic Preparedness Innovations,INTERVENTIONAL,"January 27, 2021","January 27, 2021",September 2022
NCT03064074,Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta,COMPLETED,Osteogenesis Imperfecta,DRUG: Fresolimumab,Baylor College of Medicine,"Genzyme, a Sanofi Company|Oregon Health and Science University",INTERVENTIONAL,"November 15, 2017","November 15, 2017","July 4, 2022"
NCT01113476,"Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies",COMPLETED,Advanced Cancer,DRUG: Nab-paclitaxel|DRUG: Bevacizumab|DRUG: Gemcitabine,M.D. Anderson Cancer Center,,INTERVENTIONAL,"April 27, 2010","April 27, 2010","August 12, 2022"
NCT05497674,Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects,COMPLETED,Type 2 Diabetes Mellitus,DRUG: Rongliflozin|DRUG: Rifampin|DRUG: Rongliflozin|DRUG: Probenecid,"Sunshine Lake Pharma Co., Ltd.",,INTERVENTIONAL,"February 21, 2022","February 21, 2022","July 20, 2022"
NCT05371574,Clonidine Versus Tranexamic Acid in Reduction of Blood Loss,RECRUITING,Blood Loss,DRUG: clonidine group,Uwakwe Emmanuel Chijioke,,INTERVENTIONAL,"January 3, 2022","January 3, 2022","August 3, 2022"
NCT03745144,Effects of Cladribine Tablets on the PK of Microgynon®,ACTIVE_NOT_RECRUITING,Relapsing Multiple Sclerosis (RMS),DRUG: Cladribine|DRUG: Placebo|DRUG: Microgynon®,"Merck KGaA, Darmstadt, Germany",,INTERVENTIONAL,"January 17, 2019","January 17, 2019","June 3, 2022"
NCT05409157,A Study to Evaluate the Drug Levels of BMS-986166 in Healthy Male Participants,NOT_YET_RECRUITING,Healthy Participants,DRUG: BMS-986166|DRUG: Bisacodyl,Bristol-Myers Squibb,,INTERVENTIONAL,"June 17, 2022","June 17, 2022","July 29, 2022"
NCT04741698,Propranolol for Protracted Labor,COMPLETED,Labour;Obstructed|Labor Dystocia,DRUG: Propranolol,Christiana Care Health Services,,INTERVENTIONAL,"July 27, 2021","July 27, 2021","June 11, 2022"
NCT04382157,Magnesium Replacement and Hyperglycemia After Kidney Transplantation,RECRUITING,Hypomagnesemia|Kidney Transplantation,DRUG: Mablet 360 mg|DRUG: Placebo,Oslo University Hospital,,INTERVENTIONAL,"February 25, 2020","February 25, 2020","August 31, 2022"
NCT04993157,Pharmacokinetics Study of FIA586 in Participants With Mild and Moderate Hepatic Impairment,COMPLETED,Hepatic Impairment,DRUG: FIA586,Novartis Pharmaceuticals,,INTERVENTIONAL,"December 10, 2021","December 10, 2021","June 28, 2022"
NCT04393311,Ulinastatin for the Treatment of COVID-19 in Hospitalized Patients,WITHDRAWN,COVID-19,DRUG: Ulinastatin|DRUG: Placebo,Stanford University,,INTERVENTIONAL,February 2022,February 2022,August 2022
NCT04861311,Testing the Efficacy of a Mindfulness- and Acceptance-Based Smartphone App for PTSD: A Randomized Controlled Trial,NOT_YET_RECRUITING,Posttraumatic Stress Disorder,BEHAVIORAL: Mindfulness/Acceptance-Based Smartphone App (MABSA) Intervention,"University of Nevada, Las Vegas",,INTERVENTIONAL,"January 1, 2022","January 1, 2022","June 30, 2022"
NCT04919954,Tebipenem (SPR994) Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis,ENROLLING_BY_INVITATION,Diabetes|Wound Infection|ABSSSI|Healthy Volunteers,DRUG: Tebipenem Pivoxil Hydrobromide,Hartford Hospital,Spero Therapeutics Inc,INTERVENTIONAL,"July 1, 2021","July 1, 2021",August 2022
NCT03565003,A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China,RECRUITING,Non-small Cell Lung Cancer|Head and Neck Cancer|Esophageal Cancer|Other Metastatic Solid Tumors,DRUG: JAB-3068,"Jacobio Pharmaceuticals Co., Ltd.",,INTERVENTIONAL,"November 20, 2018","November 20, 2018",July 2022
NCT04930354,ECP-1014 Treatment for Patients With Solid Tumor Cancers,NOT_YET_RECRUITING,Solid Tumor,DRUG: ECP-1014,"Euclises Pharmaceuticals, Inc.",,INTERVENTIONAL,August 2021,August 2021,June 2022
NCT04047303,"CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma",ACTIVE_NOT_RECRUITING,Astrocytoma|Glioblastoma,DRUG: CC-90010,Celgene,,INTERVENTIONAL,"January 2, 2020","January 2, 2020","September 1, 2022"
NCT04715750,Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity,RECRUITING,Alzheimer Disease|Progressive Supranuclear Palsy,DRUG: [18F]-PI2620,Life Molecular Imaging GmbH,Life Molecular Imaging SA,INTERVENTIONAL,"November 12, 2020","November 12, 2020",June 2022
NCT02643550,Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,ACTIVE_NOT_RECRUITING,Head and Neck Neoplasms,BIOLOGICAL: Monalizumab|BIOLOGICAL: Cetuximab|BIOLOGICAL: Anti-PD(L)1,Innate Pharma,AstraZeneca,INTERVENTIONAL,December 2015,December 2015,September 2022
NCT04129775,OTO-413 in Subjects With Speech-in-Noise Hearing Impairment,ACTIVE_NOT_RECRUITING,Sensorineural Hearing Loss,DRUG: OTO-413|DRUG: Placebo,"Otonomy, Inc.",,INTERVENTIONAL,"October 1, 2019","October 1, 2019",June 2022
NCT04430959,Candesartan as an Adjunctive Treatment for Bipolar Depression,WITHDRAWN,Bipolar Disorder Depression,DRUG: Candesartan|DRUG: Placebo,"The University of Texas Health Science Center, Houston",,INTERVENTIONAL,"October 1, 2020","October 1, 2020","July 1, 2022"
NCT05003427,68Ga-FAPI-04 PET/CT for the Detection of Oral Carcinoma,RECRUITING,Oral Carcinoma,DRUG: 68Ga-FAPI-04,Peking Union Medical College Hospital,,INTERVENTIONAL,"April 1, 2021","April 1, 2021","July 1, 2022"
NCT05073627,The Effect of Dicloxacillin on Oral Absorption of Drugs,COMPLETED,Healthy Volunteers|Drug-drug Interaction,DRUG: Dicloxacillin,University of Southern Denmark,,INTERVENTIONAL,"February 7, 2022","February 7, 2022","June 22, 2022"
NCT05407779,"Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 in Healthy Volunteers",RECRUITING,Healthy,"BIOLOGICAL: BCD-180, dose 1|BIOLOGICAL: BCD-180, dose 2|BIOLOGICAL: BCD-180, dose 3|BIOLOGICAL: BCD-180, dose 4|BIOLOGICAL: BCD-180, dose 5|BIOLOGICAL: BCD-180, dose 6|BIOLOGICAL: BCD-180, dose 7",Biocad,,INTERVENTIONAL,"January 22, 2021","January 22, 2021",September 2022
NCT05327491,A Study in Healthy Volunteers to Compare the Pharmacokinetics of Sotorasib Administered as 1 or 2 Tablets,COMPLETED,Healthy Participants,DRUG: Sotorasib,Amgen,,INTERVENTIONAL,"April 18, 2022","April 18, 2022","July 17, 2022"
NCT05457491,Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE),COMPLETED,Skin Aging,BIOLOGICAL: Human platelet extract (cosmetic product)|OTHER: Vanicream Gentle Facial Cleanser|OTHER: EltaMD UV Daily Broad-Spectrum SPF 40|OTHER: EltaMD PM Therapy Facial Moisturizer|OTHER: Vanicream Lite Lotion,Mayo Clinic,,INTERVENTIONAL,"October 1, 2021","October 1, 2021","July 7, 2022"
NCT05467709,Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects,COMPLETED,Health Volunteers,DRUG: Midazolam|DRUG: CTP-543,Concert Pharmaceuticals,,INTERVENTIONAL,"June 21, 2022","June 21, 2022","June 30, 2022"
NCT04691427,Effectiveness of Virtual Reality Vision Therapy - VERVE,ACTIVE_NOT_RECRUITING,Convergence Insufficiency,DEVICE: Virtual Eye Rotation Vision Exercises (VERVE),OculoMotor Technologies,New Jersey Institute of Technology|Salus University,INTERVENTIONAL,"October 14, 2021","October 14, 2021","July 28, 2022"
NCT04643808,taVNS Paired With Bottle Feeding in Infants Failing Oral Feeds,COMPLETED,Poor Feeding|Infant Development|Vagus Nerve Stimulation,DEVICE: transcutaneous auricular vagus nerve stimulation,Medical University of South Carolina,National Institute of General Medical Sciences (NIGMS)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),INTERVENTIONAL,"October 1, 2017","October 1, 2017","June 1, 2022"
NCT04930809,Single and Multiple Dose Study of VER-01 in Healthy Volunteers,COMPLETED,Healthy,DRUG: VER-01,Vertanical GmbH,,INTERVENTIONAL,"November 25, 2021","November 25, 2021","July 4, 2022"
NCT04444427,Evaluation of GLR2007 for Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,Non-small Cell Lung Cancer|Glioblastoma Multiforme,DRUG: GLR2007,"Gan and Lee Pharmaceuticals, USA",,INTERVENTIONAL,"July 15, 2020","July 15, 2020",September 2022
NCT04999527,"Study to Evaluate the Safety, Tolerability, PK and PD of DISC-0974 in Healthy Subjects",COMPLETED,Healthy Volunteer,DRUG: DISC-0974|DRUG: Placebo,"Disc Medicine, Inc",,INTERVENTIONAL,"August 10, 2021","August 10, 2021","June 30, 2022"
NCT03833427,Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001),COMPLETED,Advanced/Metastatic Solid Tumors,DRUG: Selumetinib|BIOLOGICAL: Pembrolizumab,Merck Sharp & Dohme LLC,,INTERVENTIONAL,"March 18, 2019","March 18, 2019","June 28, 2022"
NCT04855526,THC + CBD and Memory Study,NOT_YET_RECRUITING,Marijuana Use|Cannabis Use|Cannabis Intoxication,DRUG: High THC/No CBD Marihuana|DRUG: High THC/High CBD Marihuana|DRUG: No THC/No CBD Marihuana,Hartford Hospital,Yale University,INTERVENTIONAL,"April 1, 2022","April 1, 2022","June 30, 2022"
NCT05095337,Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR1459 in Healthy Adult Male Volunteers,ACTIVE_NOT_RECRUITING,Healthy Adult Male Volunteers,DRUG: [14C]SHR1459,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"June 7, 2022","June 7, 2022","July 5, 2022"
NCT04536337,"A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects",RECRUITING,Chronic Hepatitis B,DRUG: ALG-000184|DRUG: Placebo,Aligos Therapeutics,,INTERVENTIONAL,"October 22, 2020","October 22, 2020","July 1, 2022"
NCT05166837,The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects,RECRUITING,Healthy,DRUG: STSA-1002 injection|DRUG: Placebo|DRUG: STSA-1002 injection|DRUG: Placebo|DRUG: STSA-1002 injection|DRUG: Placebo|DRUG: STSA-1002 injection|DRUG: Placebo|DRUG: STSA-1002 injection|DRUG: Placebo,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",,INTERVENTIONAL,"January 10, 2022","January 10, 2022",July 2022
NCT05147337,A Study to Assess the Safety and Tolerability of E2511 in Healthy Adult and Elderly Participants,COMPLETED,Healthy Volunteers,DRUG: E2511|DRUG: Placebo,Eisai Inc.,,INTERVENTIONAL,"December 1, 2021","December 1, 2021","August 18, 2022"
NCT03635437,Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes,RECRUITING,Type 1 Diabetes Mellitus,DRUG: Gamma-Aminobutyric Acid (GABA)|DRUG: Alprazolam,Per-Ola Carlsson,Diamyd Medical AB,INTERVENTIONAL,"September 5, 2018","September 5, 2018","August 30, 2022"
NCT03374007,Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma,RECRUITING,Advanced Solid Tumor|Recurrent Solid Tumor|Lymphoma|Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma,"BIOLOGICAL: Geptanolimab Injection 1mg/kg|BIOLOGICAL: Geptanolimab Injection 3mg/kg|BIOLOGICAL: Geptanolimab Injection 10mg/kg|BIOLOGICAL: Geptanolimab Injection 1mg/kg, q2w*6|BIOLOGICAL: Geptanolimab Injection 3mg/kg, q2w*6|BIOLOGICAL: Geptanolimab Injection 10mg/kg, , q2w*6|BIOLOGICAL: Geptanolimab Injection 280mg, q3w|BIOLOGICAL: Geptanolimab Injection 3mg/kg, q2w","Genor Biopharma Co., Ltd.",,INTERVENTIONAL,"October 19, 2017","October 19, 2017",June 2022
NCT05181683,COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers,COMPLETED,Healthy|Chronic Stable Illness,DRUG: Casirivimab+Imdevimab,Regeneron Pharmaceuticals,,INTERVENTIONAL,"January 7, 2022","January 7, 2022","June 3, 2022"
NCT04805983,"Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923",ACTIVE_NOT_RECRUITING,Alzheimer Disease,DRUG: BMS-984923,Yale University,National Institute on Aging (NIA),INTERVENTIONAL,"March 25, 2021","March 25, 2021","September 1, 2022"
NCT04806737,Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease,RECRUITING,Celiac Disease,DRUG: Teriflunomide Oral Tablet,Oslo University Hospital,,INTERVENTIONAL,"April 16, 2021","April 16, 2021","August 15, 2022"
NCT04243837,LYT-100 in Healthy Volunteers and BCRL,RECRUITING,Breast Cancer Related Lymphoedema|Lymphoedema,DRUG: LYT-100|OTHER: Matching Placebo|DRUG: LYT-100 Food Effect|DRUG: LYT-100 BCRL|DRUG: Placebo BCRL,PureTech,Novotech (Australia) Pty Limited,INTERVENTIONAL,"March 1, 2020","March 1, 2020",June 2022
NCT02549937,"A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors",COMPLETED,Tumors,DRUG: surufatinib,Hutchison Medipharma Limited,,INTERVENTIONAL,November 2015,November 2015,"June 7, 2022"
NCT04596033,"TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy",TERMINATED,Melanoma|Non-small Cell Lung Cancer|Squamous Cell Carcinoma of Head and Neck|Urothelial Carcinoma|Renal Cell Carcinoma|Small-cell Lung Cancer|Cutaneous Squamous Cell Carcinoma|Anal Squamous Cell Carcinoma|Merkel Cell Carcinoma,BIOLOGICAL: GEN-011|DRUG: IL-2|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Genocea Biosciences, Inc.",,INTERVENTIONAL,"November 11, 2020","November 11, 2020","June 27, 2022"
NCT05032833,Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects,RECRUITING,Pharmacokinetics in Healthy Adults,DRUG: 5-MeO-DMT|OTHER: Placebo,Beckley Psytech Limited,,INTERVENTIONAL,"September 22, 2021","September 22, 2021",July 2022
NCT05336071,The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy Subjects,ACTIVE_NOT_RECRUITING,Diabetes Mellitus,DRUG: INS068 injection|DRUG: INS068 injection,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"May 12, 2022","May 12, 2022","June 15, 2022"
NCT05293171,Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects,ACTIVE_NOT_RECRUITING,Healthy Subjects,DRUG: 1.25 mg/kg BL-8040 + BL-8040-matching placebo|DRUG: 2 mg/kg BL-8040|DRUG: BL-8040-matching placebo|DRUG: 400 mg Moxifloxacin (1x400 mg tablet),"BioLineRx, Ltd.",Celerion,INTERVENTIONAL,"June 11, 2021","June 11, 2021",June 2022
NCT02892071,Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma,WITHDRAWN,Melasma,DRUG: 22% TCA peel|DEVICE: CO2 laser|DEVICE: Qs-NdYag laser,SUZAN OBAGI,,INTERVENTIONAL,December 2020,December 2020,September 2022
NCT03695939,"Evaluation of Safety, Tolerability and Efficacy of Xeno-Skin® for Temporary Closure of Severe Burn Wounds",COMPLETED,Deep Full-thickness Burn Injury (Disorder),BIOLOGICAL: Xeno-Skin™|BIOLOGICAL: Human Cadaver Allograft,"XenoTherapeutics, Inc.","Massachusetts General Hospital|Joseph M. Still Research Foundation, Inc.",INTERVENTIONAL,"March 15, 2019","March 15, 2019","June 6, 2022"
NCT04966871,"Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults",COMPLETED,Malaria,BIOLOGICAL: PfSPZ Vaccine|BIOLOGICAL: PfSPZ Challenge (7G8) for CHMI|OTHER: Normal Saline,Sanaria Inc.,Fred Hutchinson Cancer Center,INTERVENTIONAL,"September 27, 2021","September 27, 2021","June 21, 2022"
NCT03822871,A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer,ACTIVE_NOT_RECRUITING,Prostate Cancer,DRUG: CTT1403|DRUG: CTT1057|DRUG: 68Ga-PSMA-11,Cancer Targeted Technology,"University of California, San Francisco",INTERVENTIONAL,"April 1, 2019","April 1, 2019","June 1, 2022"
NCT02580539,A Study of the Safety and Efficacy of EBV Specific T-cell Lines,RECRUITING,Epstein-Barr Virus Infections|Post-Transplant Lymphoproliferative Disorder|Lymphoma,BIOLOGICAL: Group A|BIOLOGICAL: Group B,"Dr. Jean-Sebastien Delisle, MD, PhD",,INTERVENTIONAL,November 2015,November 2015,August 2022
NCT04123626,A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene,ACTIVE_NOT_RECRUITING,"Autosomal Dominant Retinitis Pigmentosa|Eye Diseases|Eye Diseases, Hereditary|Retinal Dystrophies|Retinal Disease|Retinitis|Vision Tunnel|Vision Disorders",DRUG: QR-1123|OTHER: Sham procedure,ProQR Therapeutics,,INTERVENTIONAL,"October 7, 2019","October 7, 2019","June 7, 2022"
NCT04135352,A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001),COMPLETED,Neoplasm Metastasis,DRUG: 200 mg of pembrolizumab|BIOLOGICAL: V938,Merck Sharp & Dohme LLC,,INTERVENTIONAL,"November 4, 2019","November 4, 2019","August 24, 2022"
NCT03919526,Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for MRD Positive ALL,RECRUITING,MRD-positive|Acute Lymphoblastic Leukemia,BIOLOGICAL: anti-CD19/CD22 CAR-T cells|DRUG: Fludarabine|DRUG: Cyclophosphamide,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",,INTERVENTIONAL,"August 11, 2019","August 11, 2019","August 1, 2022"
NCT00954226,Standard-Dose or High-Dose Erlotinib Hydrochloride Before Surgery in Treating Patients With Head and Neck Cancer,ACTIVE_NOT_RECRUITING,Recurrent Head and Neck Carcinoma|Recurrent Salivary Gland Carcinoma|Recurrent Skin Carcinoma|Skin Squamous Cell Carcinoma,DRUG: Erlotinib Hydrochloride|OTHER: Laboratory Biomarker Analysis,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"August 5, 2009","August 5, 2009","August 31, 2022"
NCT03136497,A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma,ACTIVE_NOT_RECRUITING,Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma,DRUG: ABT-199|DRUG: Ibrutinib|DRUG: Rituximab,Hackensack Meridian Health,"Janssen Scientific Affairs, LLC|Genentech, Inc.",INTERVENTIONAL,"September 5, 2017","September 5, 2017",September 2022
NCT05230797,Zincoxide-propolis vs Zincoxide-eugenol Pulpectomy,NOT_YET_RECRUITING,Pulp Necroses,DRUG: Zinc oxide Propolis|DRUG: Zinc Oxide-Eugenol Cement,Cairo University,,INTERVENTIONAL,April 2022,April 2022,August 2022
NCT04839367,Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER),ACTIVE_NOT_RECRUITING,Prostatic Neoplasms,DRUG: 64Cu-SAR-bisPSMA,Clarity Pharmaceuticals Ltd,,INTERVENTIONAL,"July 13, 2021","July 13, 2021",August 2022
NCT04886167,Dysport Dose-Ranging Treatment of Platysmal Bands,RECRUITING,Platysma Bands,DRUG: AbobotulinumtoxinA,Clinical Testing of Beverly Hills,Galderma R&D,INTERVENTIONAL,"May 30, 2021","May 30, 2021","June 1, 2022"
NCT02680067,NIR Fluorescence Imaging of Lymphatic Transport Using ICG,ACTIVE_NOT_RECRUITING,Rheumatoid Arthritis,DRUG: Indocyanine Green|DEVICE: MultiSpectral Imaging System,University of Rochester,National Institutes of Health (NIH)|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),INTERVENTIONAL,"December 8, 2015","December 8, 2015",July 2022
NCT05026567,Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®,COMPLETED,Healthy,DRUG: 2 ml of DORMICUM® Midazolam Hydrochloride (15 mg/3 mL)|COMBINATION_PRODUCT: ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thigh|COMBINATION_PRODUCT: ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area|COMBINATION_PRODUCT: ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thigh,Crossject,,INTERVENTIONAL,"May 9, 2022","May 9, 2022","July 14, 2022"
NCT01946867,NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx,RECRUITING,Head and Neck Cancer,DEVICE: NBTXR3 activated by IMRT,Nanobiotix,,INTERVENTIONAL,"January 3, 2014","January 3, 2014",September 2022
NCT04509167,Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms,COMPLETED,Neoplasms,BIOLOGICAL: Neoantigen Peptides,Instituto de Medicina Regenerativa,,INTERVENTIONAL,"August 10, 2020","August 10, 2020","June 24, 2022"
NCT05407467,KurCoSmart Effects on People With Type 2 DM,NOT_YET_RECRUITING,"Diabetes Mellitus, Type 2|Insulin Resistance|Inflammation|Body Weight",DIETARY_SUPPLEMENT: Curcumin and virgin coconut oil extract (KurCo Smart),Universitas Sebelas Maret,,INTERVENTIONAL,June 2022,June 2022,August 2022
NCT01855685,Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD),ACTIVE_NOT_RECRUITING,X-Linked Chronic Granulomatous Disease,GENETIC: X vivo gene therapy,Genethon,,INTERVENTIONAL,"June 24, 2013","June 24, 2013",September 2022
NCT04998487,A Single-Dose Study of LY3471851 in Healthy Participants,COMPLETED,Healthy,DRUG: LY3471851,Eli Lilly and Company,,INTERVENTIONAL,"August 16, 2021","August 16, 2021","July 6, 2022"
NCT02035085,19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction,WITHDRAWN,Breast Cancer,DRUG: CS-1000 labeled SVF cells,Johns Hopkins University,Cosmeticsurg.net,INTERVENTIONAL,June 2014,June 2014,June 2022
NCT02415387,Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer,ACTIVE_NOT_RECRUITING,Cognitive Side Effects of Cancer Therapy|Depression|Recurrent Breast Carcinoma|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer,BIOLOGICAL: typhoid vaccine|OTHER: Placebo,Ohio State University Comprehensive Cancer Center,,INTERVENTIONAL,"January 1, 2014","January 1, 2014","September 1, 2022"
NCT04390685,Prevention of Breast Cancer-related Lymphedma With Tacrolimus,ACTIVE_NOT_RECRUITING,Lymphedema,DRUG: Tacrolimus ointment,Odense University Hospital,,INTERVENTIONAL,"February 26, 2020","February 26, 2020",September 2022
NCT05233085,A Safety Study of AZD4041 in Healthy Volunteers,COMPLETED,Opioid Use Disorder (OUD),DRUG: AZD4041|OTHER: Placebo,AstraZeneca,"Altasciences Company, Inc.",INTERVENTIONAL,"December 17, 2021","December 17, 2021","June 7, 2022"
NCT05459285,A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects,COMPLETED,Type 2 Diabetes,BIOLOGICAL: 14028 injection|BIOLOGICAL: dulaglutide injection,"Sunshine Lake Pharma Co., Ltd.",,INTERVENTIONAL,"May 31, 2022","May 31, 2022","July 2, 2022"
NCT03548207,"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma",COMPLETED,Multiple Myeloma,BIOLOGICAL: JNJ-68284528,"Janssen Research & Development, LLC",,INTERVENTIONAL,"June 29, 2018","June 29, 2018","August 23, 2022"
NCT02902107,Intraoperative Radiation Therapy for Locally Advanced or Recurrent Abdomino-pelvic Solid Tumors With the CivaSheet,ACTIVE_NOT_RECRUITING,Abdominal Malignancy|Pelvic Malignancy,DEVICE: CivaSheet|RADIATION: Brachytherapy|PROCEDURE: surgical resection,Memorial Sloan Kettering Cancer Center,CivaTech Oncology,INTERVENTIONAL,September 2016,September 2016,September 2022
NCT05105607,"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants",RECRUITING,Neovascular Age-related Macular Degeneration|Diabetic Macular Edema,DRUG: D-4517.2,"Ashvattha Therapeutics, Inc.",,INTERVENTIONAL,"January 11, 2022","January 11, 2022",August 2022
NCT04686383,"Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors",RECRUITING,Resistant or Refractory Solid Tumors,DRUG: CAL056 mesylate,"Calgent Biotechnology Co., Ltd",,INTERVENTIONAL,"December 29, 2020","December 29, 2020",September 2022
NCT05280483,ABSK021 Food Effect Study in Healthy Subjects,NOT_YET_RECRUITING,Neoplasms,DRUG: ABSK021 with fed state|DRUG: ABSK021 with fasted state,"Abbisko Therapeutics Co, Ltd",,INTERVENTIONAL,"March 19, 2022","March 19, 2022","June 30, 2022"
NCT03144583,Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy,ACTIVE_NOT_RECRUITING,Leukemia|Lymphoma,BIOLOGICAL: Adult differentiated autologous T-cells,Sara V. Latorre,Instituto de Salud Carlos III,INTERVENTIONAL,"June 15, 2017","June 15, 2017",September 2022
NCT03890900,T2DXcel Mobile Application,COMPLETED,"Diabetes Mellitus, Type 2",OTHER: T2DXcel mobile application,Montefiore Medical Center,,INTERVENTIONAL,"March 1, 2020","March 1, 2020","July 1, 2022"
NCT05164614,Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule,RECRUITING,Healthy Volunteers,COMBINATION_PRODUCT: RT-102|DRUG: Forteo,RANI Therapeutics,,INTERVENTIONAL,"February 21, 2022","February 21, 2022","July 1, 2022"
NCT02911714,Contrast-Enhanced Ultrasound for Kidney Transplant,RECRUITING,Kidney Transplantation,DRUG: Lumason Contrast-Enhanced Ultrasound,Isaac E. Hall,National Kidney Foundation|American Heart Association,INTERVENTIONAL,"February 21, 2018","February 21, 2018",September 2022
NCT04808414,SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers,COMPLETED,Bacterial Infections,DRUG: QPX9003 for IV Infusion|DRUG: Placebo for IV infusion,"Qpex Biopharma, Inc.",Biomedical Advanced Research and Development Authority,INTERVENTIONAL,"June 3, 2021","June 3, 2021","July 14, 2022"
NCT03556800,"Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.",RECRUITING,Menopause,DRUG: Estrogel,Viramal Limited,Simbec Research,INTERVENTIONAL,"May 22, 2018","May 22, 2018","June 30, 2022"
NCT04818086,Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder,RECRUITING,"Drug Interaction|Analgesics, Opioid",DRUG: Lemborexant|DRUG: Placebo,Virginia Commonwealth University,National Institute on Drug Abuse (NIDA),INTERVENTIONAL,"May 3, 2021","May 3, 2021",September 2022
NCT04480086,Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis,ACTIVE_NOT_RECRUITING,Myelofibrosis (MF),DRUG: Mivebresib|DRUG: Navitoclax|DRUG: Ruxolitinib,AbbVie,,INTERVENTIONAL,"March 17, 2021","March 17, 2021","June 15, 2022"
NCT05330286,"Study to Compare the Pharmacokinetics, Safety and Tolerability of the Pediatric and Adult Branaplam Formulation in Healthy Adults and the Effect of Food on the Latter.",RECRUITING,Healthy Volunteers,DRUG: LMI070|DRUG: LMI070|DRUG: LMI070|DRUG: LMI070,Novartis Pharmaceuticals,,INTERVENTIONAL,"April 13, 2022","April 13, 2022","August 25, 2022"
NCT04762186,Viable Human SARS-CoV-2 Specific T Cell Transfer in Patients at Risk for Severe COVID-19,TERMINATED,Moderate COVID-19-infection,DRUG: human SARS-CoV 2 specific T lymphocytes,Universitätsklinikum Köln,ZKS Köln|Hannover Medical School|Miltenyi Biomedicine GmbH,INTERVENTIONAL,"December 8, 2021","December 8, 2021","August 3, 2022"
NCT03684213,Local Antioxidant Therapy Vasoconstriction Effects in Different Races,RECRUITING,Cardiovascular Diseases|Cardiovascular Risk Factor|Vasoconstriction,DRUG: Control (Norepinephrine)|DRUG: Norepinephrine + Ascorbic Acid|DRUG: Norepinephrine + L-NAME|DRUG: Norepinephrine + L-NAME + Ascorbic Acid,The University of Texas at Arlington,,INTERVENTIONAL,"October 15, 2018","October 15, 2018","August 31, 2022"
NCT03434769,AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma,ACTIVE_NOT_RECRUITING,Non-Hodgkin Lymphoma,DRUG: Cyclophosphamide|DRUG: Fludarabine|BIOLOGICAL: CAR-T Cells,Benjamin Tomlinson,,INTERVENTIONAL,"July 9, 2018","July 9, 2018",July 2022
NCT02394535,"Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer",COMPLETED,Borderline Resectable Pancreatic Adenocarcinoma|Locally Advanced Pancreatic Adenocarcinoma|Pancreatic Adenocarcinoma|Stage II Pancreatic Cancer AJCC v6 and v7|Stage IIA Pancreatic Cancer AJCC v6 and v7|Stage IIB Pancreatic Cancer AJCC v6 and v7|Stage III Pancreatic Cancer AJCC v6 and v7,DRUG: Capecitabine|OTHER: Laboratory Biomarker Analysis|DRUG: Nab-paclitaxel|OTHER: Questionnaire Administration|RADIATION: Radiation Therapy,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"November 12, 2015","November 12, 2015","August 31, 2022"
NCT04296474,"Follow up Study 5-6 Years After ILIT With 2 Concomitant Allergens, Birch and Grass",ACTIVE_NOT_RECRUITING,Allergic Rhinitis,DRUG: ALK Alutard 5-grasses and birch|DRUG: ALK Diluent,Lars Olaf Cardell,,INTERVENTIONAL,"May 15, 2018","May 15, 2018","June 20, 2022"
NCT04643769,Evaluation of Oral ORIN1001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF),RECRUITING,Idiopathic Pulmonary Fibrosis,DRUG: ORIN1001|DRUG: Placebo,"Orinove, Inc.",Vanderbilt University,INTERVENTIONAL,"February 9, 2021","February 9, 2021","July 30, 2022"
NCT04946669,An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis,RECRUITING,Dermatomyositis|Abatacept,DRUG: Abatacept,The First Affiliated Hospital with Nanjing Medical University,National Natural Science Foundation of China,INTERVENTIONAL,"February 1, 2021","February 1, 2021","July 31, 2022"
NCT05435170,Food Effect Study of Linerixibat Tablets in Healthy Adult Participants,NOT_YET_RECRUITING,Pruritus,DRUG: linerixibat,GlaxoSmithKline,,INTERVENTIONAL,"June 27, 2022","June 27, 2022","August 11, 2022"
NCT05012670,"Mass Balance Recovery, Metabolite Profile, and Metabolite Identification of [14C]-Paxalisib in Healthy Male Subjects",ACTIVE_NOT_RECRUITING,Healthy,DRUG: [14C]-Paxalisib Capsule,Kazia Therapeutics Limited,Quotient Sciences,INTERVENTIONAL,"August 18, 2021","August 18, 2021",August 2022
NCT04032535,"Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects",RECRUITING,COPD,DRUG: CHF6523,Chiesi Farmaceutici S.p.A.,,INTERVENTIONAL,"July 24, 2019","July 24, 2019","July 30, 2022"
NCT05349435,A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate,TERMINATED,Hyperammonemia,DRUG: Fezagepras|DRUG: Sodium phenylbutyrate,Liminal BioSciences Ltd.,,INTERVENTIONAL,"May 13, 2022","May 13, 2022","June 30, 2022"
NCT04241835,A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies,RECRUITING,Hepatic Impairment|Advanced Malignant Solid Tumor,DRUG: Tazemetostat,"Epizyme, Inc.",Sponsor GmbH,INTERVENTIONAL,"January 28, 2020","January 28, 2020",July 2022
NCT04971135,First-in-human Study of SAN711 in Healthy Participants,RECRUITING,Healthy,DRUG: SAN711|OTHER: Placebo,Saniona,"Medpace, Inc.",INTERVENTIONAL,"June 30, 2021","June 30, 2021",June 2022
NCT04952935,Acupuncture for the Treatment of Medication-Dependent Hypotension in Heart Failure,RECRUITING,Congestive Heart Failure|Hypotension,PROCEDURE: True Acupuncture|PROCEDURE: Sham Acupuncture,Scripps Health,,INTERVENTIONAL,"April 20, 2021","April 20, 2021","July 1, 2022"
NCT02502006,Variability in Response to Non-steroidal Anti-inflammatory Drugs,ACTIVE_NOT_RECRUITING,Healthy,DRUG: Celecoxib|DRUG: Naproxen|DRUG: Placebo,University of Pennsylvania,"National Heart, Lung, and Blood Institute (NHLBI)",INTERVENTIONAL,November 2015,November 2015,September 2022
NCT03599206,ONES Grant: CXCL10/CXCR3 Regulation of Ozone-Induced Epithelial Permeability,RECRUITING,Environmental and Genetic Factors on Lung Function,DRUG: Ozone|OTHER: Filtered Air,"Robert Tighe, MD",,INTERVENTIONAL,"September 18, 2019","September 18, 2019",August 2022
NCT05147727,Drug-drug Interaction Study Between Fluconazole and Famitinib in Healthy Subjects,NOT_YET_RECRUITING,Tumor,DRUG: Fluconazole、Famitinib,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,January 2022,January 2022,June 2022
NCT04596527,18F-FMPP PET MPI in the Detection of Coronary Artery Disease,RECRUITING,Coronary Disease,DRUG: 18F-FMPP,Peking Union Medical College Hospital,,INTERVENTIONAL,"September 15, 2020","September 15, 2020",June 2022
NCT03410927,A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities,ACTIVE_NOT_RECRUITING,Advanced Solid Tumors With HER2 Abnormalities|Advanced Solid Tumors With HER3 Abnormalities,DRUG: TAS0728,"Taiho Oncology, Inc.",,INTERVENTIONAL,"April 6, 2018","April 6, 2018","June 30, 2022"
NCT04798027,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,TERMINATED,COVID-19,BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 1|BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 2|BIOLOGICAL: SARS-CoV-2 mRNA vaccine formulation 3|BIOLOGICAL: Placebo (0.9% normal saline),"Sanofi Pasteur, a Sanofi Company",,INTERVENTIONAL,"March 12, 2021","March 12, 2021","June 27, 2022"
NCT04973527,LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor,TERMINATED,T Cell Lymphoma|T-cell Leukemia,DRUG: Efficacy of LCAR-T2C CAR-T cells,Beijing Boren Hospital,Nanjing Legend Biotech Co.,INTERVENTIONAL,"July 2, 2021","July 2, 2021","July 11, 2022"
NCT04903509,A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide,COMPLETED,Healthy,DRUG: BI 1820237|DRUG: Placebo|DRUG: Saxenda®|DRUG: Paracetamol-ratiopharm®,Boehringer Ingelheim,,INTERVENTIONAL,"June 8, 2021","June 8, 2021","August 26, 2022"
NCT05440006,A Study of Food Effect on the Pharmacokinetics of Fuzuloparib Capsules in Chinese Healthy Adult Subjects,COMPLETED,Solid Tumor,DRUG: Fuzuloparib,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"July 3, 2022","July 3, 2022","July 20, 2022"
NCT04385849,Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19,ACTIVE_NOT_RECRUITING,COVID-19,BIOLOGICAL: N-803|OTHER: Saline,"ImmunityBio, Inc.",,INTERVENTIONAL,"July 22, 2020","July 22, 2020","July 11, 2022"
NCT04730349,"A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer",COMPLETED,"Ependymoma|Ewing Sarcoma|High-grade Glioma|Leukemia and Lymphoma|Medulloblastoma|Miscellaneous Brain Tumors|Miscellaneous Solid Tumors|Neuroblastoma|Relapsed, Refractory Malignant Neoplasms|Rhabdomyosarcoma",BIOLOGICAL: Nivolumab|BIOLOGICAL: NKTR-214,Bristol-Myers Squibb,Nektar Therapeutics,INTERVENTIONAL,"June 3, 2021","June 3, 2021","June 22, 2022"
NCT01148849,Safety Study of MGAH22 in HER2-positive Carcinomas,COMPLETED,Breast Cancer|Gastric Cancer,BIOLOGICAL: margetuximab,MacroGenics,Green Cross Corporation|National Cancer Institute (NCI),INTERVENTIONAL,July 2010,July 2010,"June 14, 2022"
NCT05236049,Use of an Allograft Set-up (SclerFIX) as Replacement of Sclera Graft for Support of Enucleation Implant,RECRUITING,Enucleated; Eye|Eye Cancer,BIOLOGICAL: SclerFIX,TBF Genie Tissulaire,,INTERVENTIONAL,"July 12, 2019","July 12, 2019",July 2022
NCT03118349,Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy,SUSPENDED,Pancreatic Carcinoma|Tumors That Express CA 19-9,DRUG: MVT-1075|DRUG: MVT-5873,"BioNTech Research & Development, Inc.",,INTERVENTIONAL,"June 1, 2017","June 1, 2017",September 2022
NCT03772249,Study of Safety and Tolerability of DCR HBVS,ACTIVE_NOT_RECRUITING,"Hepatitis B, Chronic",DRUG: DCR-HBVS|DRUG: Placebo for DCR-HBVS,"Dicerna Pharmaceuticals, Inc.",,INTERVENTIONAL,"December 28, 2018","December 28, 2018",July 2022
NCT04634149,"A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment",COMPLETED,Moderate Liver Impairment|Severe Liver Impairment,DRUG: BMS-986036,Bristol-Myers Squibb,,INTERVENTIONAL,"November 23, 2020","November 23, 2020","June 2, 2022"
NCT05220605,Nebulised BromAc in Healthy Volunteers,COMPLETED,COVID-19 Pneumonia|Bromelains Adverse Reaction|Acetylcysteine Adverse Reaction|Mucus; Plug|COVID-19 Acute Respiratory Distress Syndrome,DRUG: BromAc,Mucpharm Pty Ltd,"St George Hospital, Australia|Mobius Medical Pty Ltd.",INTERVENTIONAL,"July 27, 2022","July 27, 2022","August 14, 2022"
NCT05151705,A Trial of HR17031 Injection With Hepatic Insufficiency,NOT_YET_RECRUITING,Improved Glycemic Control in Patients With Type 2 Diabetes,DRUG: HR17031 injection|DRUG: HR17031 injection|DRUG: HR17031 injection,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"December 20, 2021","December 20, 2021","June 15, 2022"
NCT02403505,Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating COVID-19,ACTIVE_NOT_RECRUITING,COVID-19,BIOLOGICAL: Ad26 COVID-19 Spike plus TICE® BCG Mix for Intradermal Injection,"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair",PPD,INTERVENTIONAL,"December 28, 2021","December 28, 2021","August 28, 2022"
NCT05320705,The Effect of Intra Operative Dexmedetomidine in Prevention of Early Postoperative Atrial Fibrillation,RECRUITING,Postoperative Atrial Fibrillation,DRUG: Intra Operative Dexmedetomidine,Kasr El Aini Hospital,,INTERVENTIONAL,"April 15, 2022","April 15, 2022",September 2022
NCT05496205,"A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers",RECRUITING,Osteoarthritis|Pain,DRUG: iN1011-N17|DRUG: Placebo,"iN Therapeutics Co., Ltd.",,INTERVENTIONAL,"September 30, 2020","September 30, 2020","August 24, 2022"
NCT05069350,Bupivacaine vs Oxybuprocaine Topical Anesthesia in IVI,COMPLETED,"Pain, Acute",DRUG: bupivacaine 0.5% and oxubuprocaine,"Research Institute of Ophthalmology, Egypt",,INTERVENTIONAL,"September 1, 2021","September 1, 2021","August 1, 2022"
NCT05428150,"Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers",RECRUITING,Idiopathic Pulmonary Fibrosis,"DRUG: Esbriet 267 MG Oral Capsule|DRUG: EXCL-100, 600 MG Oral Tablet","Excalibur Pharmaceuticals, Inc.",,INTERVENTIONAL,"August 8, 2022","August 8, 2022","August 31, 2022"
NCT04557150,A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of RO7425781 in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM),RECRUITING,Multiple Myeloma,DRUG: RO7425781,Hoffmann-La Roche,,INTERVENTIONAL,"November 11, 2020","November 11, 2020","July 13, 2022"
NCT03851250,A Study of MRx-4DP0004 in Asthma,ACTIVE_NOT_RECRUITING,Asthma,DRUG: MRx-4DP0004|DRUG: Placebo,4D pharma plc,,INTERVENTIONAL,"July 4, 2019","July 4, 2019",September 2022
NCT04972175,Safety and Efficacy of BC LisPram,RECRUITING,Type1 Diabetes Mellitus,DRUG: 50-Hour Intervention - Rapid Insulin lispro|DRUG: 50-Hour Intervention - BC LisPram,Michael Tsoukas,Adocia,INTERVENTIONAL,"July 28, 2021","July 28, 2021",June 2022
NCT05095350,Effect of Probiotics on Primary Hypertension,RECRUITING,Hypertension,BIOLOGICAL: Probiotic powder|BIOLOGICAL: Placebo powder,"Chinese Academy of Medical Sciences, Fuwai Hospital",Beijing Municipal Education Commission,INTERVENTIONAL,"December 5, 2021","December 5, 2021",June 2022
NCT05288075,Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product,COMPLETED,Healthy Volunteers,DRUG: Indacaterol/glycopyrronium,"Orion Corporation, Orion Pharma",,INTERVENTIONAL,"February 28, 2022","February 28, 2022","June 27, 2022"
NCT05407220,"A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.",NOT_YET_RECRUITING,Healthy,DRUG: HCP1904-1|DRUG: HCP1904-3,Hanmi Pharmaceutical Company Limited,,INTERVENTIONAL,"June 8, 2022","June 8, 2022","July 16, 2022"
NCT03829020,"Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma",RECRUITING,Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma,DRUG: Bortezomib|DRUG: Metformin Hydrochloride|DRUG: Nelfinavir Mesylate,Mayo Clinic,National Cancer Institute (NCI),INTERVENTIONAL,"April 17, 2019","April 17, 2019","August 21, 2022"
NCT04151082,High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors,RECRUITING,Cranial Nerve Disorder|Head and Neck Carcinoma|Oropharyngeal Carcinoma,DRUG: Methylprednisolone|DRUG: Prednisone|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"October 31, 2019","October 31, 2019","July 31, 2022"
NCT03430882,"Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors",COMPLETED,Recurrent Malignant Solid Neoplasm|Refractory Malignant Solid Neoplasm,DRUG: Carboplatin|DRUG: Paclitaxel|DRUG: Sapanisertib,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"March 12, 2018","March 12, 2018","June 8, 2022"
NCT03970382,A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors,SUSPENDED,Solid Tumor,BIOLOGICAL: NeoTCR-P1 adoptive cell therapy|BIOLOGICAL: nivolumab|BIOLOGICAL: IL-2,"PACT Pharma, Inc.",,INTERVENTIONAL,"July 3, 2019","July 3, 2019","August 12, 2022"
NCT04542382,Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP),RECRUITING,Healthy Volunteers,DRUG: Rosuvastatin|DRUG: Rosuvastatin (Inhibitor arm)|DRUG: Eltrombopag,"University of California, San Francisco",Food and Drug Administration (FDA),INTERVENTIONAL,"February 1, 2022","February 1, 2022",September 2022
NCT03401320,"Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)",ACTIVE_NOT_RECRUITING,Healthy,DRUG: Letrozole ISM,Rovi Pharmaceuticals Laboratories,,INTERVENTIONAL,"November 6, 2017","November 6, 2017","July 14, 2022"
NCT03868020,Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease,ACTIVE_NOT_RECRUITING,Metastatic Head and Neck Squamous Cell Carcinoma|Metastatic Squamous Cell Carcinoma in Cervical Lymph Node,PROCEDURE: Computed Tomography|RADIATION: Fluciclovine F18|PROCEDURE: Positron Emission Tomography,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"April 24, 2019","April 24, 2019","August 31, 2022"
NCT05093205,"STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS",COMPLETED,Healthy Adults,DRUG: PF-06882961|DRUG: Atorvastatin|DRUG: Midazolam|DRUG: Levonorgestrel & Ethinyl Estradiol,Pfizer,,INTERVENTIONAL,"October 25, 2021","October 25, 2021","July 6, 2022"
NCT05306405,Comparative Study Between Only Vaginal Misoprostol and Vaginal Misoprostol and Estradiol Cream,RECRUITING,Cervix; Pregnancy,DRUG: Vaginal Tablet,Ain Shams University,,INTERVENTIONAL,"February 20, 2022","February 20, 2022","August 1, 2022"
NCT04340752,Optimal Dosing of IC-Green for Visualization of Rotator Cuff Vascularity Using Advanced Imaging Modality Arthroscopy,RECRUITING,Rotator Cuff Tears,DRUG: Indocyanine Green,NYU Langone Health,,INTERVENTIONAL,"January 27, 2021","January 27, 2021","September 1, 2022"
NCT04594005,"CDK4/6 Tumor, Abemaciclib, Paclitaxel",ACTIVE_NOT_RECRUITING,Tumors,DRUG: abemaciclib+paclitaxel,Yonsei University,,INTERVENTIONAL,"February 25, 2021","February 25, 2021","August 10, 2022"
NCT03652805,A Study of IPL344 in the Treatment of ALS Patients,UNKNOWN,Amyotrophic Lateral Sclerosis,DRUG: IPL344,Immunity Pharma Ltd.,,INTERVENTIONAL,"August 1, 2018","August 1, 2018","July 15, 2022"
NCT02254863,UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells,RECRUITING,"Adrenoleukodystrophy|Batten Disease|Mucopolysaccharidosis II|Leukodystrophy, Globoid Cell|Leukodystrophy, Metachromatic|Neimann Pick Disease|Pelizaeus-Merzbacher Disease|Sandhoff Disease|Tay-Sachs Disease|Brain Diseases, Metabolic, Inborn|Alpha-Mannosidosis|Sanfilippo Mucopolysaccharidoses",BIOLOGICAL: DUOC-01,"Joanne Kurtzberg, MD",The Marcus Foundation,INTERVENTIONAL,September 2014,September 2014,September 2022
NCT05468749,Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543,RECRUITING,Renal Impairment,DRUG: CTP-543,Concert Pharmaceuticals,,INTERVENTIONAL,"June 6, 2022","June 6, 2022",September 2022
NCT04979663,GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer,RECRUITING,Biliary Tract Carcinoma,"COMBINATION_PRODUCT: Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab",Fudan University,,INTERVENTIONAL,"December 1, 2020","December 1, 2020",June 2022
NCT04730193,Caffeine and Cerebrovascular Reactivity,COMPLETED,Caffeine,DRUG: Caffeine|DRUG: Placebo,University of Oklahoma,,INTERVENTIONAL,"February 1, 2021","February 1, 2021","August 1, 2022"
NCT03773393,A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF),ACTIVE_NOT_RECRUITING,Bone Marrow Disease,BIOLOGICAL: CK0801,"Cellenkos, Inc.",,INTERVENTIONAL,"May 30, 2019","May 30, 2019","August 25, 2022"
NCT04631549,An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants,RECRUITING,Hepatic Impairment|Healthy Participants,DRUG: SHR3680,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"February 3, 2021","February 3, 2021",July 2022
NCT04979520,Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa,COMPLETED,Hidradenitis Suppurativa|Acne Inversa,DRUG: Brodalumab,Rockefeller University,,INTERVENTIONAL,"August 5, 2021","August 5, 2021","July 25, 2022"
NCT03143920,Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder,TERMINATED,Chronic Interstitial Cystitis|Painful Bladder Syndrome|Recurrent Urinary Tract Infection,COMBINATION_PRODUCT: Hyperbaric Oxygen Therapy-,"University of California, San Diego",,INTERVENTIONAL,"November 1, 2017","November 1, 2017","July 7, 2022"
NCT05152420,Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects,RECRUITING,Coagulation Disorder,DRUG: VMX-C001|DRUG: Placebo|DRUG: Apixaban|DRUG: Rivaroxaban|DRUG: Edoxaban,VarmX B.V.,,INTERVENTIONAL,"October 29, 2021","October 29, 2021",July 2022
NCT05303220,"A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants",RECRUITING,Healthy Volunteers,DRUG: Branebrutinib|DRUG: Placebo,Bristol-Myers Squibb,,INTERVENTIONAL,"April 8, 2022","April 8, 2022","August 1, 2022"
NCT03041363,Treatment Development of Triheptanoin (G1D),ACTIVE_NOT_RECRUITING,"Epilepsy|GLUT1DS1|Glut1 Deficiency Syndrome 1, Autosomal Recessive|Glucose Metabolism Disorders|Glucose Transport Defect|Glucose Transporter Type 1 Deficiency Syndrome|Glucose Transporter Protein Type 1 Deficiency Syndrome",DRUG: Triheptanoin,Juan Pascual,National Institute of Neurological Disorders and Stroke (NINDS),INTERVENTIONAL,"March 29, 2017","March 29, 2017","July 31, 2022"
NCT04098393,Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation,RECRUITING,Hematologic Malignancies,DRUG: Busulfan 3.2 mg/kg/day|DRUG: Fludarabine|DRUG: Melphalan|DRUG: Antithymocyte globulin (ATG)|DRUG: Busulfan 0.8 mg/kg|PROCEDURE: Allogeneic hematopoietic cell transplantation (Allo-HCT),Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL,"September 18, 2019","September 18, 2019",September 2022
NCT04200963,A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma,RECRUITING,"Urothelial Carcinoma|Urothelial Carcinoma Bladder|Bladder Cancer|Bladder Disease|Solid Tumor|Solid Carcinoma|Solid Tumor, Adult|Metastatic Cancer|Advanced Solid Tumor|Advanced Cancer|Metastatic Bladder Cancer|Metastatic Urothelial Carcinoma|Locally Advanced Solid Tumor|Neoplasms|Neoplasm Metastasis|Neoplasm Malignant|Neoplasm, Bladder|Urothelial Neoplasm|Neoplasm, Urinary Bladder|Bladder Neoplasm|Bladder Urothelial Carcinoma",DRUG: IK-175|DRUG: IK-175 and nivolumab,Ikena Oncology,Bristol-Myers Squibb,INTERVENTIONAL,"December 18, 2019","December 18, 2019",September 2022
NCT04611763,Effect of Preemptive Analgesia With Flurbiprofen Axetil on Perioperative Sleep Quality and Postoperative Pain in Patients Undergoing Sevoflurane Inhalation.,RECRUITING,Flurbiprofen Axetil|Preemptive Analgesia|Postoperative Pain|Perioperative Sleep Quality|Postoperative Inflammatory Markers,DRUG: Flurbiprofen axetil preoperatively|DRUG: Flurbiprofen axetil postoperatively,Beijing Friendship Hospital,,INTERVENTIONAL,"September 1, 2021","September 1, 2021","June 30, 2022"
NCT03840915,M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC),COMPLETED,"Carcinoma, Non-Small-Cell Lung",DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Pemetrexed|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Docetaxel|DRUG: M7824|DRUG: Carboplatin|DRUG: Carboplatin|DRUG: M7824|DRUG: Paclitaxel,"EMD Serono Research & Development Institute, Inc.","Merck KGaA, Darmstadt, Germany",INTERVENTIONAL,"April 2, 2019","April 2, 2019","July 29, 2022"
NCT05165550,"Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects",RECRUITING,HIV-1-infection,DRUG: Elsulfavirine,Viriom,,INTERVENTIONAL,"April 12, 2022","April 12, 2022","June 12, 2022"
NCT05116215,To Evaluate the Safety of Treating Autoimmune Diseases With Molecular Hydrogen Supplement,RECRUITING,Autoimmune Diseases,DRUG: Hydrogen,HoHo Biotech,Tri-Service General Hospital,INTERVENTIONAL,"August 13, 2021","August 13, 2021","August 12, 2022"
NCT05400915,"Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients",ACTIVE_NOT_RECRUITING,Gastric Cancer,"DRUG: Variltinib, Paclitaxel",Yonsei University,,INTERVENTIONAL,"July 23, 2019","July 23, 2019",June 2022
NCT03167216,Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction,RECRUITING,Chronic Prostatitis With Chronic Pelvic Pain Syndrome,DRUG: Cromolyn Sodium|DRUG: Cetirizine Hydrochloride,Northwestern University,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),INTERVENTIONAL,"August 1, 2017","August 1, 2017","June 30, 2022"
NCT03301896,Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,TERMINATED,Solid Tumors,DRUG: LHC165|BIOLOGICAL: PDR001,Novartis Pharmaceuticals,,INTERVENTIONAL,"January 31, 2018","January 31, 2018","June 30, 2022"
NCT05368935,Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects,RECRUITING,Renal Impairment|Renal Disease|Kidney Disease,DRUG: Nitazoxanide,Genfit,,INTERVENTIONAL,"April 25, 2022","April 25, 2022",September 2022
NCT03761095,A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS),RECRUITING,Leiomyosarcoma,DRUG: Unesbulin|DRUG: Dacarbazine,PTC Therapeutics,,INTERVENTIONAL,"March 13, 2019","March 13, 2019","August 30, 2022"
NCT03122496,Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,COMPLETED,Metastatic Anaplastic Thyroid Cancer,DRUG: durvalumab|DRUG: tremelimumab|RADIATION: Stereotactic Body Radiotherapy (SBRT),Memorial Sloan Kettering Cancer Center,AstraZeneca,INTERVENTIONAL,"April 25, 2017","April 25, 2017","June 3, 2022"
NCT05298696,Efficacy of Cilostazol in Prevention of Peripheral Neuropathy,RECRUITING,Peripheral Neuropathy|Breast Cancer,DRUG: Cilostazol|DRUG: Placebo,Mansoura University,,INTERVENTIONAL,"March 17, 2022","March 17, 2022",July 2022
NCT05143996,CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML),RECRUITING,Relapsed/Refractory AML,DRUG: CLN-049,"Cullinan Oncology, LLC",,INTERVENTIONAL,"November 18, 2021","November 18, 2021",July 2022
NCT05259995,Sustained Acoustic Medicine Ultrasound Diathermy Clinical Performance,RECRUITING,Measurement of Diathermy on Anatomical Locations of the Body,DEVICE: Sustained Acoustic Medicine,"ZetrOZ, Inc.",,INTERVENTIONAL,"February 14, 2022","February 14, 2022","June 30, 2022"
NCT03763396,Azoles Targeting Recurrent High Grade Gliomas,ACTIVE_NOT_RECRUITING,"Brain Tumor, Recurrent|Cancer, Advanced|Glioma of Brain",DRUG: Ketoconazole (KCZ)|DRUG: Posaconazole (PCZ),"University Health Network, Toronto",,INTERVENTIONAL,"August 1, 2019","August 1, 2019",August 2022
NCT04397796,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,ACTIVE_NOT_RECRUITING,COVID,BIOLOGICAL: BM-Allo.MSC|BIOLOGICAL: Placebo,"ImmunityBio, Inc.",,INTERVENTIONAL,"August 3, 2020","August 3, 2020",June 2022
NCT05069896,A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants,COMPLETED,Healthy,DRUG: Mirikizumab Prefilled Syringe|DRUG: Mirikizumab Autoinjector,Eli Lilly and Company,,INTERVENTIONAL,"October 5, 2021","October 5, 2021","June 22, 2022"
NCT04934891,"A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547",ACTIVE_NOT_RECRUITING,Healthy Volunteers,DRUG: ION547|DRUG: Placebo,"Ionis Pharmaceuticals, Inc.",,INTERVENTIONAL,"March 24, 2021","March 24, 2021",September 2022
NCT04885491,"A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Covid-19 Patients With aPH",RECRUITING,"Hypertension, Pulmonary|Covid19",DRUG: Placebo|DRUG: PDNO,Attgeno AB,Vinnova,INTERVENTIONAL,"May 7, 2021","May 7, 2021","July 15, 2022"
NCT05256108,Assessment of Abuse Potential of Cebranopadol in Humans,COMPLETED,Human Abuse Potential,DRUG: Oxycodone 40 mg|DRUG: Tramadol 600 mg|DRUG: Placebo|DRUG: Cebranopadol 600 µg|DRUG: Cebranopadol 1000 µg,"Tris Pharma, Inc.",,INTERVENTIONAL,"March 28, 2022","March 28, 2022","July 12, 2022"
NCT04834908,Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection,ACTIVE_NOT_RECRUITING,SARS-CoV-2 Infection,BIOLOGICAL: Equine COVID-19 Antiserum|DRUG: Standard of care,Bharat Serums and Vaccines Limited,,INTERVENTIONAL,"July 27, 2021","July 27, 2021",August 2022
NCT05334108,Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport,ACTIVE_NOT_RECRUITING,Drug Interaction,DRUG: Ecopipam|COMBINATION_PRODUCT: Cohort 1 Probe Substrate Cocktail|DRUG: Cohort 2 Probe Substrate|COMBINATION_PRODUCT: Cohort 3 Probe Substrate Cocktail,Emalex Biosciences Inc.,ICON Early Phase Services|Nuventra,INTERVENTIONAL,"April 26, 2022","April 26, 2022","August 1, 2022"
NCT05087108,Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow,RECRUITING,Venous Thromboses|Venous Stasis,DEVICE: OsciPulse system|DEVICE: Reference Therapy 1|DEVICE: Refence Therapy 2,OsciFlex LLC,"University of Pennsylvania|National Heart, Lung, and Blood Institute (NHLBI)",INTERVENTIONAL,"March 20, 2022","March 20, 2022","June 30, 2022"
NCT05309304,Cefazolin PK Study 3g vs 2g,RECRUITING,Healthy,DRUG: Cefazolin,Baxter Healthcare Corporation,,INTERVENTIONAL,"February 14, 2022","February 14, 2022","August 27, 2022"
NCT04602104,A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS,RECRUITING,Acute Respiratory Distress Syndrome,BIOLOGICAL: low dose hMSC-Exos|BIOLOGICAL: medium dose hMSC-Exos|BIOLOGICAL: high dose hMSC-Exos|BIOLOGICAL: Dosage 1of hMSC-Exos|BIOLOGICAL: Dosage 2 of hMSC-Exos|BIOLOGICAL: No hMSC-derived exosomes,Ruijin Hospital,Cellular Biomedicine Group Ltd.,INTERVENTIONAL,"November 30, 2020","November 30, 2020",June 2022
NCT05301504,A Study in Tanzania of a New Vaccine Against Two Types of Ebola,RECRUITING,Ebola,BIOLOGICAL: ChAdOx1 biEBOV,University of Oxford,,INTERVENTIONAL,"March 30, 2022","March 30, 2022",July 2022
NCT04556617,PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC),TERMINATED,Metastatic Castration-resistant Prostate Cancer,DRUG: PLX2853|DRUG: Olaparib|DRUG: Abiraterone acetate|DRUG: Prednisone,Opna-IO LLC,,INTERVENTIONAL,"September 21, 2020","September 21, 2020","June 30, 2022"
NCT05395104,A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants,COMPLETED,Healthy Volunteers,DRUG: Midazolam|DRUG: Cefiderocol,Shionogi,,INTERVENTIONAL,"May 23, 2022","May 23, 2022","July 9, 2022"
NCT04989517,Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa,RECRUITING,Hidradenitis Suppurativa,DRUG: AT193,Azora Therapeutics Australia Pty Ltd,,INTERVENTIONAL,"November 23, 2021","November 23, 2021","June 15, 2022"
NCT04993404,Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function,RECRUITING,Hepatic Insufficiency|Healthy Subjects,DRUG: Jaktinib Hydrochloride Tablets,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",,INTERVENTIONAL,"August 27, 2021","August 27, 2021",August 2022
NCT03034304,A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors,UNKNOWN,Advanced Solid Tumors,BIOLOGICAL: MASCT-I|DRUG: Ifosfamide|DRUG: PD1 antibody,SYZ Cell Therapy Co..,,INTERVENTIONAL,January 2017,January 2017,July 2022
NCT05184517,A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers,NOT_YET_RECRUITING,Dry Eye Syndromes,DRUG: Oph1|DRUG: Restasis,OphRx Ltd.,,INTERVENTIONAL,March 2022,March 2022,July 2022
NCT02735239,Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer,COMPLETED,Esophageal Cancer,DRUG: Durvalumab|DRUG: Tremelimumab|DRUG: Oxaliplatin|DRUG: Capecitabine|RADIATION: Radiotherapy|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: 5-fluorouracil (5-FU)|DRUG: Leucovorin|DRUG: docetaxel,Ludwig Institute for Cancer Research,AstraZeneca,INTERVENTIONAL,"June 24, 2016","June 24, 2016","June 16, 2022"
NCT05496179,The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients,COMPLETED,Enteral Feeding Intolerance,DRUG: Prucalopride|DRUG: Metoclopramide,Ain Shams University,Future University in Egypt,INTERVENTIONAL,"March 7, 2022","March 7, 2022","July 10, 2022"
NCT03875079,"A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma",COMPLETED,Metastatic Melanoma,DRUG: RO6874281|DRUG: Pembrolizumab,Hoffmann-La Roche,,INTERVENTIONAL,"June 24, 2019","June 24, 2019","July 14, 2022"
NCT05336279,Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition,ACTIVE_NOT_RECRUITING,Solid Tumor,DRUG: famitinib malate T(5 mg*4)、famitinib malate R(20 mg)|DRUG: famitinib malate T(5 mg*4)、famitinib malate R(20 mg),"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"May 18, 2022","May 18, 2022","June 30, 2022"
NCT04260191,Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma,COMPLETED,Gastric and Gastroesophageal Junction Adenocarcinoma,DRUG: AMG 910,Amgen,,INTERVENTIONAL,"June 29, 2020","June 29, 2020","June 2, 2022"
NCT03024008,Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II,RECRUITING,Bone Fracture,BIOLOGICAL: BonoFill-II,BonusBio Group Ltd,,INTERVENTIONAL,"July 27, 2017","July 27, 2017",June 2022
NCT02644291,Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors,COMPLETED,"Medulloblastoma|Astrocytoma, Grade III|Glioblastoma|Anaplastic Astrocytoma|Brain Stem Neoplasms, Malignant|Oligodendroblastoma|Anaplastic Oligodendroglioma|Malignant Glioma",DRUG: Mebendazole,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,,INTERVENTIONAL,May 2016,May 2016,"June 9, 2022"
NCT04535804,Aspirin in the Treatment of Pregnant Women With Adenomyosis on Reducing Preterm Delivery,UNKNOWN,Adenomyosis of Uterus,DRUG: Aspirin/placebo,Shanghai First Maternity and Infant Hospital,,INTERVENTIONAL,October 2020,October 2020,September 2022
NCT05001204,68Ga-NOTA-RM26 PET/CT for the Detection of Gastrointestinal Stromal Tumor,RECRUITING,Gastrointestinal Stromal Tumors,DRUG: 68Ga-NOTA-RM26,Peking Union Medical College Hospital,,INTERVENTIONAL,"May 1, 2021","May 1, 2021","August 31, 2022"
NCT04950504,"Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy",TERMINATED,Peanut Allergy,DRUG: CNP-201|DRUG: Placebo,"COUR Pharmaceutical Development Company, Inc.",,INTERVENTIONAL,"June 2, 2021","June 2, 2021","June 24, 2022"
NCT02912104,A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure,RECRUITING,Primary Ovarian Insufficiency|Premature Ovarian Failure|Infertility,BIOLOGICAL: human amniotic epithelial cells (hAECs) transplantation,International Peace Maternity and Child Health Hospital,"Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China",INTERVENTIONAL,"June 20, 2020","June 20, 2020",June 2022
NCT05206604,A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955,COMPLETED,Healthy,DRUG: PF-07295324|DRUG: PF-07259955,Pfizer,,INTERVENTIONAL,"February 9, 2022","February 9, 2022","August 12, 2022"
NCT05342727,Transcranial Direct and Alternating Stimulation of the Prefrontal Cortex for Cognitive Improvement in Schizophrenia,COMPLETED,Schizophrenia|Cognitive Dysfunction,DEVICE: transcranial direct current stimulation (tDCS)|DEVICE: transcranial alternating current stimulation (tACS),The National Brain Mapping Laboratory (NBML),Ardabil University of Medical Sciences|Leibniz-Institut für Arbeitsforschung,INTERVENTIONAL,"April 1, 2021","April 1, 2021","July 15, 2022"
NCT04781127,Home-administered tDCS for Treatment of Depression,RECRUITING,Unipolar Depression|Treatment Resistant Depression,DEVICE: Soterix Medical mini-CT tDCS stimulator,Soterix Medical,NYU Langone Health,INTERVENTIONAL,"February 10, 2021","February 10, 2021","August 10, 2022"
NCT05202379,CC-42344 Safety Study in Healthy Participants,RECRUITING,Influenza A,DRUG: CC-42344|DRUG: Placebo,"Cocrystal Pharma, Inc.",Cocrystal Pharma Australia Pty Ltd.|Linear Clinical Research,INTERVENTIONAL,"February 11, 2022","February 11, 2022",September 2022
NCT03802071,A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma,ACTIVE_NOT_RECRUITING,Sarcoma,DRUG: Durvalumab+doxorubicin cobination,Yonsei University,,INTERVENTIONAL,"September 16, 2019","September 16, 2019","August 10, 2022"
NCT05371379,Multiple Ascending Dose Study of CM338 in Healthy Volunteers,NOT_YET_RECRUITING,Healthy Subjects,BIOLOGICAL: CM338 Injection,Keymed Biosciences Co.Ltd,,INTERVENTIONAL,"June 1, 2022","June 1, 2022","June 1, 2022"
NCT05194579,Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe,COMPLETED,Healthy Volunteers,COMBINATION_PRODUCT: PF-06881894 by on-body injector|COMBINATION_PRODUCT: PF-06881894 by prefilled syringe,Pfizer,,INTERVENTIONAL,"February 10, 2022","February 10, 2022","August 10, 2022"
NCT01562405,Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,Multiple Myeloma,DRUG: ACE-011|DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Pomalidomide,Massachusetts General Hospital,Multiple Myeloma Research Consortium,INTERVENTIONAL,May 2012,May 2012,June 2022
NCT05382104,Maribavir Food-Effect Study in Healthy Adults Participants,COMPLETED,Healthy Volunteers,DRUG: Maribavir,Takeda,"Takeda Development Center Americas, Inc.",INTERVENTIONAL,"June 1, 2022","June 1, 2022","July 1, 2022"
NCT02869217,Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors,RECRUITING,NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients|Synovial Sarcoma|Melanoma|Esophageal Cancer|Ovarian Cancer|Lung Cancer|Bladder Cancer|Liver Cancer,DRUG: Cyclophosphamide|BIOLOGICAL: TBI-1301|DRUG: Fludarabine,"University Health Network, Toronto",Takara Bio Inc.,INTERVENTIONAL,September 2016,September 2016,September 2022
NCT04132817,A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread,ACTIVE_NOT_RECRUITING,Breast Cancer,BIOLOGICAL: Nivolumab|BIOLOGICAL: Ipilimumab|DRUG: Nab-paclitaxel,Bristol-Myers Squibb,,INTERVENTIONAL,"September 22, 2020","September 22, 2020","August 30, 2022"
NCT03948763,A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001),COMPLETED,"Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms|Colorectal Neoplasms",BIOLOGICAL: V941|BIOLOGICAL: Pembrolizumab,Merck Sharp & Dohme LLC,,INTERVENTIONAL,"June 26, 2019","June 26, 2019","August 25, 2022"
NCT02247349,BMS-986012 in Relapsed/Refractory SCLC,ACTIVE_NOT_RECRUITING,Small Cell Lung Cancer,BIOLOGICAL: BMS-986012 (anti-fucosyl-GM1)|BIOLOGICAL: Nivolumab,Bristol-Myers Squibb,,INTERVENTIONAL,"November 14, 2014","November 14, 2014","June 23, 2022"
NCT03593226,Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour,ACTIVE_NOT_RECRUITING,"Superficial, Palpable, Unresectable/Metastatic Solid Tumour",DRUG: AGI-134,Agalimmune Ltd.,,INTERVENTIONAL,"November 15, 2018","November 15, 2018",September 2022
NCT04817605,Effects of Therapeutic Exercise in Patients With Fibromyalgia,RECRUITING,Therapeutic Exercise|Chronic Pain,OTHER: Therapeutic Exercise,Universidad de Zaragoza,,INTERVENTIONAL,"March 10, 2021","March 10, 2021","June 10, 2022"
NCT02914405,Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma,RECRUITING,Neuroblastoma,DRUG: Nivolumab|DRUG: Ch14.18/CHO,University Hospital Southampton NHS Foundation Trust,"University College London Hospitals|University of Wisconsin, Madison|University Hospital Greifswald|Solving Kids' Cancer US/EU|Joining Against Cancer in Kids|The Band of Parents",INTERVENTIONAL,"May 24, 2018","May 24, 2018",June 2022
NCT05150405,A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors,RECRUITING,Advanced Malignant Neoplasm,DRUG: QLF31907,"Qilu Pharmaceutical Co., Ltd.",,INTERVENTIONAL,"September 6, 2021","September 6, 2021",July 2022
NCT04060849,"Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY",SUSPENDED,Hematopoietic and Lymphoid Cell Neoplasm|Malignant Solid Neoplasm|Solid Neoplasm,DRUG: Nozin|OTHER: Best Practice,Fred Hutchinson Cancer Center,Global Life Technologies Corp.,INTERVENTIONAL,"September 3, 2019","September 3, 2019","August 1, 2022"
NCT03835949,Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer,ACTIVE_NOT_RECRUITING,Solid Tumor|Metastatic Cancer,DRUG: TJ004309|DRUG: Atezolizumab,Tracon Pharmaceuticals Inc.,,INTERVENTIONAL,"July 16, 2019","July 16, 2019",June 2022
NCT04585009,"Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics",RECRUITING,"Pulmonary Disease, Chronic Obstructive",DRUG: GSK3923868|DRUG: Matching placebo|DEVICE: Monodose RS01,GlaxoSmithKline,,INTERVENTIONAL,"March 18, 2021","March 18, 2021","June 15, 2022"
NCT04823208,A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM),COMPLETED,"Diabetes Mellitus, Type 2",DRUG: LY3437943|DRUG: Placebo,Eli Lilly and Company,,INTERVENTIONAL,"May 24, 2021","May 24, 2021","June 23, 2022"
NCT01995708,"CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",COMPLETED,Multiple Myeloma,"BIOLOGICAL: CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|OTHER: Standard of care",Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL,"January 31, 2014","January 31, 2014","June 20, 2022"
NCT01687608,Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B,ACTIVE_NOT_RECRUITING,Hemophilia B,BIOLOGICAL: AskBio009,Baxalta now part of Shire,,INTERVENTIONAL,"February 11, 2013","February 11, 2013","July 31, 2022"
NCT03251508,Salvage Peanut Oral Immunotherapy Study,ENROLLING_BY_INVITATION,Peanut Allergy,DRUG: Peanut OIT,"University of North Carolina, Chapel Hill",,INTERVENTIONAL,"January 3, 2018","January 3, 2018",September 2022
NCT05362695,A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects,COMPLETED,Healthy Volunteers,DRUG: IW-3300|DRUG: Placebo,"Ironwood Pharmaceuticals, Inc.",,INTERVENTIONAL,"May 17, 2022","May 17, 2022","July 13, 2022"
NCT05196295,To Evaluate the Safety of Treating Rheumatologic and Metabolic Patients With Molecular Hydrogen Supplement.,RECRUITING,Autoimmune Diseases|Metabolic Disease,DRUG: Hydrogen,HoHo Biotech,,INTERVENTIONAL,"January 11, 2022","January 11, 2022","July 30, 2022"
NCT03393013,A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis,ACTIVE_NOT_RECRUITING,Lupus Nephritis|Systemic Lupus Erythematosus,DRUG: KZR-616,"Kezar Life Sciences, Inc.",,INTERVENTIONAL,"March 7, 2018","March 7, 2018","August 31, 2022"
NCT05245396,Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy Participants,RECRUITING,Healthy,DRUG: Ref (TF2)|DRUG: Evobrutinib MR-T1|DRUG: Evobrutinib MR-T2|DRUG: Evobrutinib MR-T3|DRUG: Evobrutinib MR-T4|DRUG: Evobrutinib MUPS-C1|DRUG: Evobrutinib MUPS-C2|DRUG: Evobrutinib MUPS-C3|DRUG: Evobrutinib MUPS-C4,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","Merck KGaA, Darmstadt, Germany",INTERVENTIONAL,"February 2, 2022","February 2, 2022","August 2, 2022"
NCT03802695,A Phase 1 Study of Engineered Donor Grafts (OrcaGraft/Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies,RECRUITING,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Myelodysplastic Syndromes|Acute Leukemia,BIOLOGICAL: OrcaGraft (Orca-Q),"Orca Biosystems, Inc.",,INTERVENTIONAL,"April 8, 2019","April 8, 2019","July 1, 2022"
NCT05467696,Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers,COMPLETED,Health Volunteers,DRUG: CTP-543,Concert Pharmaceuticals,,INTERVENTIONAL,"June 14, 2022","June 14, 2022","June 26, 2022"
NCT05344495,Efficacy of Median Nerve Hydrodissection by Hyalase Versus Midazolam in the Treatment of Carpal Tunnel Syndrome:,RECRUITING,"Pain, Neuropathic",DRUG: hyalase group|DRUG: midazolam group,Minia University,,INTERVENTIONAL,"January 10, 2022","January 10, 2022","July 20, 2022"
NCT03815396,"Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency",COMPLETED,Alpha-1 Antitrypsin Deficiency|AATD,DRUG: INBRX-101/rhAAT-Fc,"Inhibrx, Inc.",,INTERVENTIONAL,"July 19, 2019","July 19, 2019","August 18, 2022"
NCT03767335,MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer,ACTIVE_NOT_RECRUITING,Advanced or Metastatic Breast Cancer,DRUG: MEN1611|DRUG: Trastuzumab|DRUG: Fulvestrant,Menarini Group,,INTERVENTIONAL,"July 19, 2018","July 19, 2018","July 31, 2022"
NCT04383496,Increasing Activity for Veterans With PTSD,COMPLETED,"Stress Disorders, Post-Traumatic",BEHAVIORAL: Physical Activity,VA Office of Research and Development,,INTERVENTIONAL,"March 2, 2021","March 2, 2021","June 28, 2022"
NCT04983680,Remote-delivered MBCT for SCAD Survivors,ACTIVE_NOT_RECRUITING,Acute Coronary Syndrome|Coronary Artery Disease|Anxiety|Sleep,BEHAVIORAL: MBCT,Massachusetts General Hospital,,INTERVENTIONAL,"November 4, 2021","November 4, 2021",July 2022
NCT04776980,Multimodality MRI and Liquid Biopsy in GBM,WITHDRAWN,"Glioblastoma Multiforme|Brain Tumor, Adult: Glioblastoma|Brain Tumor, Recurrent|Brain Tumor, Primary",DIAGNOSTIC_TEST: Post Feraheme Infusion MRI,Abramson Cancer Center of the University of Pennsylvania,,INTERVENTIONAL,June 2022,June 2022,June 2022
NCT05078580,"Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.",COMPLETED,Hepatic Impairment,DRUG: Iptacopan|DRUG: Iptacopan|DRUG: Iptacopan|DRUG: Iptacopan,Novartis Pharmaceuticals,,INTERVENTIONAL,"November 10, 2021","November 10, 2021","June 20, 2022"
NCT05274880,Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393,NOT_YET_RECRUITING,Type II Diabetes Mellitus,DRUG: CKD-393,Chong Kun Dang Pharmaceutical,,INTERVENTIONAL,"June 7, 2022","June 7, 2022","July 15, 2022"
NCT04736134,"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants",RECRUITING,Healthy Participants,BIOLOGICAL: BMS-986326|OTHER: Placebo matching BMS-986326,Bristol-Myers Squibb,,INTERVENTIONAL,"March 3, 2021","March 3, 2021","July 20, 2022"
NCT03209401,Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies,RECRUITING,"Solid Tumor, Adult|Homologous Recombination Deficiency",DRUG: Niraparib|DRUG: Carboplatin,Georgetown University,"Thomas Jefferson University|Tesaro, Inc.",INTERVENTIONAL,"October 13, 2017","October 13, 2017",August 2022
NCT05397834,A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions,ACTIVE_NOT_RECRUITING,Asthma|Bioequivalence,DRUG: Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals|DRUG: FLOVENT DISKUS,Respirent Pharmaceuticals Co Ltd.,Becro Ltd.,INTERVENTIONAL,"May 11, 2022","May 11, 2022","June 21, 2022"
NCT04155580,A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML),TERMINATED,Acute Myeloid Leukemia,DRUG: ASTX660|DRUG: ASTX727,"Astex Pharmaceuticals, Inc.",,INTERVENTIONAL,"June 12, 2020","June 12, 2020","August 29, 2022"
NCT05164536,Plasma P-tau2017 and Quantitative Amyloid PET Imaging,RECRUITING,Alzheimer Disease,DRUG: Amyvid,Invicro,,INTERVENTIONAL,"August 27, 2021","August 27, 2021","September 1, 2022"
NCT05064436,"A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis",RECRUITING,Multiple Sclerosis (MS),DRUG: 11C-BMS-986196,Bristol-Myers Squibb,,INTERVENTIONAL,"December 10, 2021","December 10, 2021","July 20, 2022"
NCT05293236,ApTOLL for the Treatment of COVID-19,RECRUITING,COVID-19,DRUG: ApTOLL|OTHER: Saline,Macarena Hernández Jiménez,Centro para el Desarrollo Tecnológico Industrial,INTERVENTIONAL,"January 14, 2022","January 14, 2022",June 2022
NCT04986436,"Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.",NOT_YET_RECRUITING,Healthy,DRUG: HS-10360|DRUG: Placebo,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",,INTERVENTIONAL,July 2021,July 2021,June 2022
NCT04557436,TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL),RECRUITING,B Acute Lymphoblastic Leukemia,DRUG: PBLTT52CAR19,Great Ormond Street Hospital for Children NHS Foundation Trust,"University College, London",INTERVENTIONAL,"August 12, 2020","August 12, 2020","June 30, 2022"
NCT04180436,Pharmacokinetics of Rivaroxaban After Bariatric Surgery,COMPLETED,Bariatric Surgery|Morbid Obesity,DRUG: rivaroxaban 20 mg once daily 8 days,"University Hospital, Brest",Bayer,INTERVENTIONAL,"January 15, 2020","January 15, 2020","June 21, 2022"
NCT05330936,Comparison of Cyanocobalamin in Avocado Oil Cream With Steroid Combination Ointment,RECRUITING,Plaque Psoriasis,COMBINATION_PRODUCT: Potent topical steroid,Pak Emirates Military Hospital,,INTERVENTIONAL,"March 15, 2022","March 15, 2022","August 15, 2022"
NCT05408234,Modified Foot Exercise to Improve Sensitivity and Perfussion on Type 2 Diabetes Patients,RECRUITING,"Diabetes Mellitus, Type 2",OTHER: Smart Foot Exercise,Universitas Sebelas Maret,,INTERVENTIONAL,June 2022,June 2022,August 2022
NCT04610736,"TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide",RECRUITING,Pediatric Cancer,DRUG: Temozolomide Oral Suspension,Orphelia Pharma,ClinSearch,INTERVENTIONAL,"March 16, 2021","March 16, 2021",August 2022
NCT03151057,Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies,ACTIVE_NOT_RECRUITING,B Cells-Tumors|B Cell Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis),DRUG: Idelalisib 100 MG|DRUG: Placebo Oral Tablet,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Gilead Sciences,INTERVENTIONAL,"July 31, 2018","July 31, 2018",September 2022
NCT03091257,A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,RECRUITING,Multiple Myeloma,DRUG: Dabrafenib|DRUG: Trametinib,Massachusetts General Hospital,Novartis|Multiple Myeloma Research Consortium|Barbara Ann Karmanos Cancer Institute,INTERVENTIONAL,"June 21, 2017","June 21, 2017",September 2022
NCT02422524,Pretomanid in Adults With Hepatic Impairment,RECRUITING,Tuberculosis,DRUG: PA-824,National Institute of Allergy and Infectious Diseases (NIAID),,INTERVENTIONAL,"December 11, 2017","December 11, 2017","August 31, 2022"
NCT05419401,"A Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib)",COMPLETED,Healthy Volunteer,"DRUG: Capivasertib film-coated tablet, 200 mg|DRUG: [14C]AZD5363 (Capivasertib)",AstraZeneca,Quotient Sciences,INTERVENTIONAL,"April 11, 2022","April 11, 2022","July 12, 2022"
NCT03589898,Study of Neuroimaging Biomarkers of Social Cognition Deficits in Adolescents (Age 13-17) With Autism Spectrum Disorder and Effects of Gabapentin,RECRUITING,Autism Spectrum Disorder,DRUG: Gabapentin,"University of Massachusetts, Worcester",National Institute of Mental Health (NIMH)|Johns Hopkins University,INTERVENTIONAL,"September 14, 2017","September 14, 2017","August 31, 2022"
NCT05001698,Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE),COMPLETED,Systemic Lupus Erythematosus,BIOLOGICAL: Anifrolumab,AstraZeneca,,INTERVENTIONAL,"July 27, 2021","July 27, 2021","June 2, 2022"
NCT04277598,A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer,RECRUITING,Diabetic Foot Ulcer (DFU),BIOLOGICAL: APO-2|OTHER: Placebo,Aposcience AG,FGK Clinical Research GmbH,INTERVENTIONAL,"October 9, 2020","October 9, 2020",September 2022
NCT04785144,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults,ACTIVE_NOT_RECRUITING,COVID-19|COVID-19 Immunisation,BIOLOGICAL: mRNA-1273|BIOLOGICAL: mRNA-1273.351,National Institute of Allergy and Infectious Diseases (NIAID),"ModernaTX, Inc.",INTERVENTIONAL,"March 29, 2021","March 29, 2021","August 31, 2022"
NCT05347498,A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults,NOT_YET_RECRUITING,Primary Gout With Hyperuricemia in Adults,DRUG: HR091506 tablets + placebo of febuxostat tablets|DRUG: febuxostat tablets + placebo of HR091506 tablets,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"April 30, 2022","April 30, 2022","July 31, 2022"
NCT04112498,"A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab",ACTIVE_NOT_RECRUITING,Cancer,DRUG: relatlimab|DRUG: nivolumab|DRUG: rHuPH20,Bristol-Myers Squibb,,INTERVENTIONAL,"October 1, 2019","October 1, 2019","August 17, 2022"
NCT05142098,Comparison of the Anti-Inflammatory Efficacy of Preemptive Dexamethasone and Etoricoxib,NOT_YET_RECRUITING,Effect of Drug,DRUG: Dexamethasone|DRUG: Etoricoxib 60 mg,Dow University of Health Sciences,,INTERVENTIONAL,"January 1, 2022","January 1, 2022","July 1, 2022"
NCT05096598,A First-in-human Study Looking at the Safety of ZP8396 and How it Works in the Body of Healthy Trial Participants,RECRUITING,Overweight|Healthy Volunteers,DRUG: ZP8396|DRUG: Placebo (ZP8396),Zealand Pharma,,INTERVENTIONAL,"October 19, 2021","October 19, 2021",September 2022
NCT04562298,"A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer",TERMINATED,Epithelial Ovarian Cancer,BIOLOGICAL: LCAR-M23 cells,Shanghai East Hospital,Nanjing Legend Biotech Co.|East Clinical Center of Oncology|Anhui Provincial Hospital,INTERVENTIONAL,"October 21, 2020","October 21, 2020","June 7, 2022"
NCT04810598,Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function,COMPLETED,Renal Impairment|Renal Disease,DRUG: Venetoclax,AbbVie,Roche-Genentech,INTERVENTIONAL,"July 8, 2021","July 8, 2021","August 16, 2022"
NCT02817698,Imaging the Neurochemistry of Drug Addiction With PET,RECRUITING,Smoking|Cannabis,DRUG: cannabis,Yale University,National Institute on Drug Abuse (NIDA),INTERVENTIONAL,"November 29, 2017","November 29, 2017",September 2022
NCT04959344,Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V),ACTIVE_NOT_RECRUITING,Klebsiella Pneumoniae Infection,BIOLOGICAL: Kleb4V target dose|BIOLOGICAL: Kleb4V target dose + AS03|BIOLOGICAL: Kleb4V low dose|BIOLOGICAL: Kleb4V low dose + AS03|BIOLOGICAL: Placebo,LimmaTech Biologics AG,GlaxoSmithKline,INTERVENTIONAL,"July 5, 2021","July 5, 2021",September 2022
NCT02460484,Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal Arterial Ischemic Stroke,SUSPENDED,Perinatal Arterial Ischemic Stroke,BIOLOGICAL: Autologous Cord Blood Infusion,"James Baumgartner, MD","Cord Blood Registry, Inc.",INTERVENTIONAL,April 2015,April 2015,June 2022
NCT02303028,Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid Tumours,COMPLETED,Solid Tumors,DRUG: Topotecan and Pazopanib,The Hospital for Sick Children,C17 Council,INTERVENTIONAL,March 2015,March 2015,"June 17, 2022"
NCT01481818,Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis,UNKNOWN,Epigallocatechin Gallate|Radio Dermatitis|Radiation Mucositis,DRUG: EGCG,Shandong Cancer Hospital and Institute,,INTERVENTIONAL,September 2011,September 2011,June 2022
NCT04261218,"Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer",COMPLETED,Breast Cancer,DRUG: tomivosertib|DRUG: paclitaxel,Translational Research in Oncology,Effector Therapeutics|Stand Up To Cancer,INTERVENTIONAL,"August 25, 2020","August 25, 2020","July 4, 2022"
NCT05245084,A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(3) 80/20/10mg,NOT_YET_RECRUITING,Hypertension and Dyslipidemia,"DRUG: CKD-386(3)|DRUG: D013, D326, D337",Chong Kun Dang Pharmaceutical,,INTERVENTIONAL,"March 14, 2022","March 14, 2022","June 6, 2022"
NCT03305341,Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologics,ACTIVE_NOT_RECRUITING,Covid19,BIOLOGICAL: COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection,"Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair",PPD,INTERVENTIONAL,"July 18, 2020","July 18, 2020","June 28, 2022"
NCT05247528,Safety And Tolerability Of Subcutaneous MANP In Difficult To Control/Resistant Hypertensive Subjects,RECRUITING,Resistant Hypertension|Difficult to Control Hypertension,DRUG: MANP|DRUG: Placebo,"E-Star BioTech, LLC",Mayo Clinic|Integrium,INTERVENTIONAL,"December 20, 2021","December 20, 2021","June 30, 2022"
NCT03872128,"The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders",COMPLETED,Alcohol Use Disorder,DRUG: Pregnenolone300|DRUG: Pregnenolone500|DRUG: Placebo,Yale University,,INTERVENTIONAL,"September 27, 2018","September 27, 2018","June 17, 2022"
NCT03748784,ADVM-022 Intravitreal Gene Therapy for Wet AMD,ACTIVE_NOT_RECRUITING,Wet Age-related Macular Degeneration|Neovascular Age-related Macular Degeneration,BIOLOGICAL: ADVM-022,"Adverum Biotechnologies, Inc.",,INTERVENTIONAL,"November 14, 2018","November 14, 2018",June 2022
NCT05141084,Weight Loss in Primary Care With Targeted Education and Frequent Follow Ups,NOT_YET_RECRUITING,Obesity,"OTHER: Education, lifestyle",University of Arizona,,INTERVENTIONAL,"December 1, 2021","December 1, 2021","June 30, 2022"
NCT05464628,Drug Interaction Study of ASC42 With Atorvastatin,RECRUITING,Healthy,DRUG: Atorvastatin|DRUG: ASC42,"Gannex Pharma Co., Ltd.",,INTERVENTIONAL,"July 6, 2022","July 6, 2022","August 22, 2022"
NCT04875728,The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma,RECRUITING,Clinical Stage I Cutaneous Melanoma AJCC v8|Clinical Stage IA Cutaneous Melanoma AJCC v8|Clinical Stage IB Cutaneous Melanoma AJCC v8|Clinical Stage II Cutaneous Melanoma AJCC v8|Clinical Stage IIA Cutaneous Melanoma AJCC v8|Clinical Stage IIB Cutaneous Melanoma AJCC v8|Clinical Stage IIC Cutaneous Melanoma AJCC v8|Pathologic Stage I Cutaneous Melanoma AJCC v8|Pathologic Stage IA Cutaneous Melanoma AJCC v8|Pathologic Stage IB Cutaneous Melanoma AJCC v8|Pathologic Stage II Cutaneous Melanoma AJCC v8|Pathologic Stage IIA Cutaneous Melanoma AJCC v8|Pathologic Stage IIB Cutaneous Melanoma AJCC v8|Pathologic Stage IIC Cutaneous Melanoma AJCC v8,DRUG: Cefazolin|PROCEDURE: Resection,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"September 8, 2020","September 8, 2020","August 31, 2022"
NCT05363384,"A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers",COMPLETED,Type 2 Diabetes,"DRUG: CT-L01|DRUG: Alogliptin Benzoate 25 mg|DRUG: Metformin HCl XR 1,000 mg",Celltrion,,INTERVENTIONAL,"June 11, 2022","June 11, 2022","June 21, 2022"
NCT04883528,Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019,RECRUITING,Covid19,DRUG: Sacubitril / Valsartan Oral Tablet [Entresto]|DRUG: Placebo,Duke University,Novartis Pharmaceuticals,INTERVENTIONAL,"August 6, 2021","August 6, 2021","August 30, 2022"
NCT04955223,Yinhu Qingwen Granule in the Treatment of Viral Pneumonia,NOT_YET_RECRUITING,Viral Pneumonia,DRUG: Yinhu Qingwen Granules,Zhong Wang,,INTERVENTIONAL,August 2021,August 2021,July 2022
NCT05268523,Self-Management Interventions for Long-COVID,RECRUITING,COVID-19,BEHAVIORAL: Education and Strategies Intervention|BEHAVIORAL: Mindfulness Skills Intervention,Toronto Rehabilitation Institute,"Canadian Institutes of Health Research (CIHR)|University Health Network, Toronto",INTERVENTIONAL,"November 23, 2021","November 23, 2021","June 1, 2022"
NCT02611323,"A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",COMPLETED,Non-Hodgkin's Lymphoma,DRUG: Obinutuzumab|DRUG: Rituximab|DRUG: Polatuzumab Vedotin|DRUG: Venetoclax,Hoffmann-La Roche,,INTERVENTIONAL,"March 9, 2016","March 9, 2016","August 4, 2022"
NCT05197023,"A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS",NOT_YET_RECRUITING,Moderate to Severe Atopic Dermatitis,DRUG: SHR-1819 injection or placebo,"Shanghai Hengrui Pharmaceutical Co., Ltd.",,INTERVENTIONAL,January 2022,January 2022,"June 8, 2022"
NCT05277623,Effect of Mannitol on Postreperfusion Syndrome During Living Donor Liver Transplant,RECRUITING,Liver Transplant Disorder,DRUG: Mannitol|OTHER: 0.9% normal saline,Ain Shams University,,INTERVENTIONAL,"March 7, 2022","March 7, 2022",August 2022
NCT05229653,The Using Postoperative Ketamine and Exploring the Effect on Endometriosis Pain (UPKEEEP) Study,RECRUITING,Endometriosis|Post Operative Pain,DRUG: Ketamine|DRUG: Placebo,NYU Langone Health,,INTERVENTIONAL,"April 12, 2022","April 12, 2022",June 2022
NCT05355129,A Phase 1 Study of TT-00920 in Healthy Subjects,RECRUITING,Healthy,DRUG: TT-00920|DRUG: TT-00920 Placebo,"TransThera Sciences (Nanjing), Inc.",,INTERVENTIONAL,"November 3, 2021","November 3, 2021","July 1, 2022"
NCT04273932,Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease.,ACTIVE_NOT_RECRUITING,Parkinson Disease,DRUG: Lithium,University at Buffalo,,INTERVENTIONAL,"October 17, 2019","October 17, 2019","July 1, 2022"
NCT04552418,Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors,RECRUITING,Solid Tumor,DRUG: Potato starch,University of Michigan Rogel Cancer Center,,INTERVENTIONAL,"June 2, 2021","June 2, 2021",September 2022
NCT05226923,Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects,RECRUITING,Bacterial Infections,DRUG: KSP-1007|OTHER: Placebo:0.9% sodium chloride|DRUG: Meropenem,"Sumitovant Biopharma, Inc.",,INTERVENTIONAL,"January 12, 2022","January 12, 2022","July 7, 2022"
NCT05083078,A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis,TERMINATED,"Arthritis, Psoriatic|Healthy",DRUG: Guselkumab|DRUG: Risankizumab,"Janssen Research & Development, LLC",,INTERVENTIONAL,"November 4, 2021","November 4, 2021","July 1, 2022"
NCT05246878,A Study of EDP-235 in Healthy Subjects,COMPLETED,SARS CoV 2 Infection,DRUG: EDP-235|DRUG: Placebo,"Enanta Pharmaceuticals, Inc",,INTERVENTIONAL,"January 28, 2022","January 28, 2022","July 20, 2022"
NCT05330858,Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants,ACTIVE_NOT_RECRUITING,Pharmacokinetics,DRUG: ESK-001|DRUG: Rabeprazole,Alumis Inc,,INTERVENTIONAL,"March 17, 2022","March 17, 2022","June 30, 2022"
NCT00813423,Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy,ACTIVE_NOT_RECRUITING,Adult Solid Neoplasm,DRUG: Hydroxychloroquine|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study|DRUG: Sunitinib Malate,National Cancer Institute (NCI),,INTERVENTIONAL,"January 27, 2010","January 27, 2010","September 1, 2022"
NCT04742023,Post-operative Complications and Graft Survival With Conventional Versus Continuous Glucose Monitoring in Patients With Diabetes Mellitus Undergoing Renal Transplantation,ENROLLING_BY_INVITATION,Diabetes Mellitus,DEVICE: Continuous Glucose Monitor Application|DIAGNOSTIC_TEST: Finger Stick Glucose Measurement|DRUG: Insulin|DEVICE: Continuous Glucose Monitor Placebo Applied,Northwell Health,,INTERVENTIONAL,"April 21, 2020","April 21, 2020","July 21, 2022"
NCT02850146,18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study,ACTIVE_NOT_RECRUITING,Cognition Disorders,DRUG: 18F-AV-1451,University of Southern California,Alzheimer's Therapeutic Research Institute|Alzheimer's Association|Avid Radiopharmaceuticals,INTERVENTIONAL,August 2016,August 2016,June 2022
NCT03266146,36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI,ACTIVE_NOT_RECRUITING,"Drug-induced Liver Injury,Chronic",DRUG: 36 Weeks Methylprednisolone|DRUG: 48 weeks Methylprednisolone,Beijing 302 Hospital,,INTERVENTIONAL,"September 2, 2017","September 2, 2017","July 31, 2022"
NCT02687646,Clinical Trial With MSC for Graft Versus Host Disease Treatment,ACTIVE_NOT_RECRUITING,Acute Graft Versus Host Disease,DRUG: Adult Allogeneic Mesenchymal cells from adipose tissue.,Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud,Andalusian Initiative for Advanced Therapies,INTERVENTIONAL,May 2016,May 2016,June 2022
NCT05091528,A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers,TERMINATED,HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER2-positive Colorectal Cancer|HER2-expressing Non-small Cell Lung Cancer,DRUG: SBT6050|DRUG: trastuzumab deruxtecan|DRUG: tucatinib|DRUG: trastuzumab|DRUG: capecitabine|DRUG: trastuzumab deruxtecan,Silverback Therapeutics,,INTERVENTIONAL,"February 8, 2022","February 8, 2022","July 7, 2022"
NCT05248841,A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers,COMPLETED,Type 1 Diabetes Mellitus|Type 2 Diabetes Mellitus,DRUG: HEC-Glargine|DRUG: US-Lantus,"Lannett Company, Inc.",Parexel|FARMOVS (Pty) Ltd,INTERVENTIONAL,"March 8, 2022","March 8, 2022","August 31, 2022"
NCT05320302,A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants,COMPLETED,Healthy Participants,DRUG: [11C]-Lu AF88370,H. Lundbeck A/S,,INTERVENTIONAL,"March 31, 2022","March 31, 2022","June 15, 2022"
NCT03220711,Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon,RECRUITING,Colonic Dysplasia|Adenomatous Polyps|Irritable Bowel Disease,DEVICE: confocal endomicroscope|DRUG: Fluorescein,University of Michigan,,INTERVENTIONAL,"July 28, 2017","July 28, 2017",June 2022
NCT05138770,Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects,COMPLETED,Inflammatory Bowel Diseases,DRUG: VC005 Tablets|DRUG: VC005 Tablets Placebo|DRUG: VC005 Tablets food effects group,"Jiangsu vcare pharmaceutical technology co., LTD",,INTERVENTIONAL,"November 18, 2021","November 18, 2021","August 26, 2022"
NCT03945799,A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence,TERMINATED,Hepatocellular Carcinoma,DRUG: Anlotinib Hydrochloride,Zhejiang University,"Shulan Hospital of Hangzhou|West China Hospital|Huashan Hospital|Third Affiliated Hospital, Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University|The First Hospital of Jilin University|Tianjin First Central Hospital|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",INTERVENTIONAL,"April 22, 2019","April 22, 2019","June 25, 2022"
NCT03250299,Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma,ACTIVE_NOT_RECRUITING,Glioblastoma|MGMT-Unmethylated Glioblastoma,DRUG: Microtubule-Targeted Agent BAL101553|RADIATION: Radiation Therapy|OTHER: Laboratory Biomarker Analysis|OTHER: Pharmacological Study,Basilea Pharmaceutica,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,INTERVENTIONAL,"June 7, 2017","June 7, 2017","June 6, 2022"
NCT05090111,A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia,RECRUITING,NASH - Nonalcoholic Steatohepatitis,DRUG: ALG-055009|DRUG: Placebo,Aligos Therapeutics,,INTERVENTIONAL,"December 1, 2021","December 1, 2021",September 2022
NCT04210713,Neuroimmune Dysfunction in Alcohol Use Disorder,RECRUITING,Alcohol Drinking|Alcohol-Related Disorders|Disease|Inflammation|Alcoholism|Cognitive Dysfunction|Pathologic Processes|Drinking Behavior|Substance-Related Disorders|Chemically-Induced Disorders|Mental Disorder|Cognition Disorder|Neurocognitive Disorders|Minocycline|Anti-Bacterial Agents|Anti-Infective Agents,DRUG: Minocycline|DRUG: Sugar pill,"University of Maryland, Baltimore",National Institute on Alcohol Abuse and Alcoholism (NIAAA),INTERVENTIONAL,"February 3, 2020","February 3, 2020","August 31, 2022"
NCT05398913,Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury,RECRUITING,Spinal Cord Injuries,DRUG: Rimonabant,Hospital Nacional de Parapléjicos de Toledo,,INTERVENTIONAL,"May 12, 2021","May 12, 2021","June 30, 2022"
NCT04166942,KD025 Hepatic Impairment Study With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment,COMPLETED,Hepatic Impairment,DRUG: KD025,"Kadmon, a Sanofi Company",,INTERVENTIONAL,"December 11, 2019","December 11, 2019","June 6, 2022"
NCT05526742,A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects,RECRUITING,Healthy Volunteers,DRUG: CKD-510 capsule (reference)|DRUG: CKD-510 tablet (test)|DRUG: CKD-510 tablet (test),Chong Kun Dang Pharmaceutical,,INTERVENTIONAL,"August 24, 2022","August 24, 2022",September 2022
NCT05162365,"A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19",RECRUITING,COVID-19,BIOLOGICAL: IBI314|OTHER: Placebo,Innovent Biologics (Suzhou) Co. Ltd.,,INTERVENTIONAL,"January 6, 2022","January 6, 2022","July 31, 2022"
NCT04457765,Betadine Effect on Nasal Mucosa Cilia,WITHDRAWN,Rhinoplasty,DRUG: Povidone-Iodine (PVP-I),Boston Medical Center,,INTERVENTIONAL,April 2021,April 2021,September 2022
NCT01899989,Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer,ACTIVE_NOT_RECRUITING,Non-small Cell Lung Cancer,RADIATION: Stereotactic Body Radiation Therapy (SBRT)|DRUG: cisplatin or carboplatin-based,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL,"July 5, 2013","July 5, 2013",July 2022
NCT05246046,Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler,COMPLETED,Healthy Volunteers,DRUG: Tiotropium Bromide Monohydrate,"Orion Corporation, Orion Pharma",,INTERVENTIONAL,"February 16, 2022","February 16, 2022","August 3, 2022"
NCT04895410,Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma,TERMINATED,Multiple Myeloma,BIOLOGICAL: Lemzoparlimab|DRUG: Dexamethasone|DRUG: Carfilzomib|DRUG: Pomalidomide|BIOLOGICAL: Daratumumab,AbbVie,,INTERVENTIONAL,"January 17, 2022","January 17, 2022","June 24, 2022"
NCT03881488,Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies,RECRUITING,Locally Advanced Solid Tumor|Metastatic Cancer,DRUG: CTX-471,Compass Therapeutics,Iqvia Pty Ltd,INTERVENTIONAL,"May 17, 2019","May 17, 2019",July 2022
NCT05236738,A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions,NOT_YET_RECRUITING,Healthy Participants,DRUG: Atazanavir|DRUG: Cobicistat|DRUG: Atazanavir/Cobicistat Mini-tablet,Bristol-Myers Squibb,,INTERVENTIONAL,"May 28, 2022","May 28, 2022","July 2, 2022"
NCT02616172,Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss,SUSPENDED,Sensorineural Hearing Loss,GENETIC: Autologous Bone Marrow Infusion,"James Baumgartner, MD",,INTERVENTIONAL,October 2015,October 2015,September 2022
NCT02885272,FDG PET Imaging in Diagnosing Patients With Glioblastoma,COMPLETED,Brain Glioblastoma,PROCEDURE: Computed Tomography|RADIATION: Fludeoxyglucose F-18|PROCEDURE: Magnetic Resonance Imaging|PROCEDURE: Positron Emission Tomography,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"October 28, 2016","October 28, 2016","July 12, 2022"
NCT02737462,Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome,RECRUITING,Myelodysplastic Syndrome,DRUG: CG200745 PPA,"CrystalGenomics, Inc.",,INTERVENTIONAL,June 2016,June 2016,September 2022
NCT05127564,"A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (DRF) in Chinese and Caucasian Adult Healthy Participants",COMPLETED,Healthy Volunteers,DRUG: Diroximel fumarate,Biogen,,INTERVENTIONAL,"December 3, 2021","December 3, 2021","June 9, 2022"
NCT04940364,"A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers",COMPLETED,Healthy,DRUG: Pozelimab|DRUG: Cemdisiran,Regeneron Pharmaceuticals,,INTERVENTIONAL,"August 4, 2021","August 4, 2021","June 22, 2022"
NCT02203773,Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML),TERMINATED,Acute Myelogenous Leukemia|Myelogenous Leukemia|Treatment Naive AML,DRUG: Posaconazole|DRUG: ABT-199|DRUG: Decitabine|DRUG: Azacitidine,AbbVie,"Genentech, Inc.",INTERVENTIONAL,"October 6, 2014","October 6, 2014","June 16, 2022"
NCT05216510,Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens,ACTIVE_NOT_RECRUITING,Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2,BIOLOGICAL: TNX-2110|BIOLOGICAL: TNX-2120|BIOLOGICAL: TNX-2130|BIOLOGICAL: CANDIN|BIOLOGICAL: Diluent,"Tonix Pharmaceuticals, Inc.",Premier Research Group plc,INTERVENTIONAL,"January 7, 2022","January 7, 2022",June 2022
NCT05222646,Metoclopramide Versus Hyoscine Butylbromide in Shortening Duration of First Stage of Labour,RECRUITING,Duration of Labour,DRUG: Metoclopramide,Uwakwe Emmanuel Chijioke,,INTERVENTIONAL,"January 3, 2022","January 3, 2022","August 3, 2022"
NCT04002310,A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy,TERMINATED,Macular Degeneration,DRUG: BI 754132,Boehringer Ingelheim,,INTERVENTIONAL,"July 26, 2019","July 26, 2019","August 9, 2022"
NCT05283746,A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function,COMPLETED,Renal Insufficiency,DRUG: Epetraborole,"AN2 Therapeutics, Inc",,INTERVENTIONAL,"February 21, 2022","February 21, 2022","June 10, 2022"
NCT03671746,Inflammatory Markers in Trauma Patient Outcomes,RECRUITING,Polytrauma,DRUG: Ketorolac|DRUG: Saline Solution,Arun Aneja,,INTERVENTIONAL,"February 1, 2019","February 1, 2019",September 2022
NCT04900246,Evaluation of Different Methods for the Diagnosis of Primary Caries Lesions,NOT_YET_RECRUITING,Caries Class II,PROCEDURE: Visual Inspection|RADIATION: BWX Radiographic Assessment|DEVICE: Assessment of the iTero Element 5D scan,University of Nove de Julho,,INTERVENTIONAL,"January 20, 2022","January 20, 2022","June 20, 2022"
NCT03612713,Influence of Medication on Functional Connectivity,COMPLETED,Prescription Drug Abuse (Not Dependent),DRUG: Oxycodone Medication First|DRUG: Placebo First,Yale University,National Institute on Drug Abuse (NIDA),INTERVENTIONAL,"October 30, 2018","October 30, 2018","June 2, 2022"
NCT03205670,Tissue-engineered Construct Based on Buccal Mucosa Cells and Matrix From Collagen and Polylactoglycolide Fibers,UNKNOWN,Urethral Stricture,PROCEDURE: Urethroplasty with a tissue-engineered construct,I.M. Sechenov First Moscow State Medical University,,INTERVENTIONAL,"June 1, 2017","June 1, 2017","June 1, 2022"
NCT04890548,Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure,WITHDRAWN,Heart Failure,DRUG: AZD3427,AstraZeneca,Parexel,INTERVENTIONAL,"November 23, 2021","November 23, 2021","August 2, 2022"
NCT04443751,A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),ACTIVE_NOT_RECRUITING,AML|MDS,DRUG: SHR-1702,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"September 10, 2020","September 10, 2020",June 2022
NCT04744051,"ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion",RECRUITING,Post-Concussion Syndrome,DRUG: 50 Adipose Derived Stem Cell Infusion|DRUG: 150 Adipose Derived Stem Cell Infusion|DRUG: 300 Adipose Derived Stem Cell Infusion|DRUG: Placebo Infusion,American CryoStem Corporation,,INTERVENTIONAL,"February 1, 2021","February 1, 2021",June 2022
NCT05402189,Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioids in Cleft Palate Repaire,RECRUITING,Ketodex Versus Opioids Based Anaesthesia in Cleft Palate Repair,"DRUG: Ketodex, Fentanyl",Ain Shams University,,INTERVENTIONAL,"February 1, 2022","February 1, 2022","June 10, 2022"
NCT03138889,Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors,TERMINATED,Non-Small Cell Lung Cancer,DRUG: NKTR-214|DRUG: Pembrolizumab|DRUG: NKTR-214|DRUG: NKTR-214|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Nab paclitaxel|DRUG: Paclitaxel|DRUG: Pemetrexed,Nektar Therapeutics,,INTERVENTIONAL,"June 9, 2017","June 9, 2017","July 5, 2022"
NCT04839042,"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers",RECRUITING,Covid19,BIOLOGICAL: SC-Ad6-1|BIOLOGICAL: SC-Ad6-1,Tetherex Pharmaceuticals Corporation,,INTERVENTIONAL,"June 28, 2021","June 28, 2021","August 31, 2022"
NCT04809389,A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19,ACTIVE_NOT_RECRUITING,Covid19,BIOLOGICAL: DelNS1-nCoV-RBD LAIV|BIOLOGICAL: Matching placebo,The University of Hong Kong,,INTERVENTIONAL,"March 29, 2021","March 29, 2021",September 2022
NCT03744312,Imaging Inflammation in Alzheimer's Disease With 11C-ER176,COMPLETED,Alzheimer Disease,DRUG: 11C-ER176|DRUG: Florbetaben,Columbia University,,INTERVENTIONAL,"September 10, 2018","September 10, 2018","July 20, 2022"
NCT04758312,A Mobile Intervention Merging Yoga and Self-Management Skills,RECRUITING,Chronic Disease,BEHAVIORAL: MY-Skills Mobile,"University of Colorado, Denver",Colorado State University|Clemson University|University of Southern California,INTERVENTIONAL,"March 1, 2021","March 1, 2021",August 2022
NCT04201821,Fecal Microbial Transplantation for the Treatment of Fecal Incontinence in Women,RECRUITING,Fecal Incontinence,BIOLOGICAL: fecal microbial transplantation (FMT),University of Pennsylvania,,INTERVENTIONAL,"January 14, 2021","January 14, 2021","September 1, 2022"
NCT05088655,A Bioequivalence Study of Hetrombopag in Healthy Subjects,ACTIVE_NOT_RECRUITING,Sever Aplastic Anaemia,DRUG: Hetrombopag Olamine Tablet,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"June 25, 2021","June 25, 2021","July 30, 2022"
NCT04646889,Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment,COMPLETED,Renal Impairment,DRUG: AR882 Single Dose|DRUG: AR882 Multiple Dose,Arthrosi Therapeutics,Iqvia Pty Ltd,INTERVENTIONAL,"January 14, 2021","January 14, 2021","June 27, 2022"
NCT05130788,WeChat Quit Coach Pilot Study,RECRUITING,Smoking Cessation,BEHAVIORAL: WeChat Quit Coach|BEHAVIORAL: Leaflet|DRUG: Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges,NYU Langone Health,Asian Americans for Equality|Chinese American Planning Council,INTERVENTIONAL,"January 10, 2022","January 10, 2022","July 31, 2022"
NCT04154488,A Study of Mavorixafor in Participants With Severe Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders,RECRUITING,Neutropenia,DRUG: Mavorixafor,X4 Pharmaceuticals,,INTERVENTIONAL,"October 16, 2020","October 16, 2020","June 30, 2022"
NCT05413096,Combination of Diclofenac Potassium and Propolis in the Therapy of Oral Aphthosis,ACTIVE_NOT_RECRUITING,Oral Mucositis|ORAS|Oral Infection|Oral Ulcer,COMBINATION_PRODUCT: Combination of diclofenac potassium and propolis,Al-Azhar University,,INTERVENTIONAL,"June 1, 2021","June 1, 2021","June 30, 2022"
NCT04587830,ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme,RECRUITING,Glioblastoma Multiforme (GBM),DRUG: ADI-PEG20|DRUG: Temozolomide,Polaris Group,,INTERVENTIONAL,"September 14, 2020","September 14, 2020","July 31, 2022"
NCT04921930,Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA),NOT_YET_RECRUITING,Friedreich Ataxia,DRUG: Artesunate Oral Product,"Institut National de la Santé Et de la Recherche Médicale, France",Imagine Institute,INTERVENTIONAL,"July 1, 2021","July 1, 2021","June 30, 2022"
NCT04349930,The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC),WITHDRAWN,Interstitial Cystitis|Bladder Pain Syndrome,DRUG: Cannabidiol vaginal suppository|DRUG: Placebo vaginal suppository,University of New Mexico,,INTERVENTIONAL,January 2021,January 2021,July 2022
NCT04602221,"A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine",COMPLETED,Healthy,DRUG: Lamotrigine|DRUG: BI 409306|DRUG: Placebo|DRUG: BI 425809,Boehringer Ingelheim,,INTERVENTIONAL,"December 1, 2020","December 1, 2020","August 1, 2022"
NCT04088630,Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage,RECRUITING,"Intracerebral Hemorrhage|Cerebral Edema|Stroke Hemorrhagic|Intracerebral Hemorrhage, Hypertensive|Intracerebral Hemorrhage Intraparenchymal",DRUG: Fingolimod 0.5 mg|DRUG: Placebo|OTHER: Standard of care,Wake Forest University Health Sciences,,INTERVENTIONAL,"August 7, 2020","August 7, 2020",September 2022
NCT05304130,A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab,NOT_YET_RECRUITING,"Arthritis, Rheumatoid",BIOLOGICAL: Otilimab,GlaxoSmithKline,,INTERVENTIONAL,"March 23, 2022","March 23, 2022","June 10, 2022"
NCT04114292,TUDCA as a Therapy for Ulcerative Colitis (UC),RECRUITING,Ulcerative Colitis,"DRUG: Tauroursoursodeoxycholic acid, brand name Tudcabil",Washington University School of Medicine,Crohn's and Colitis Foundation,INTERVENTIONAL,"January 17, 2019","January 17, 2019","July 31, 2022"
NCT04728230,"Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial",RECRUITING,Extensive Stage Lung Small Cell Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,DRUG: Carboplatin|BIOLOGICAL: Durvalumab|DRUG: Etoposide|DRUG: Olaparib|RADIATION: Radiation Therapy,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"January 5, 2021","January 5, 2021","July 1, 2022"
NCT02626130,Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer,COMPLETED,Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Cancer|Stage IV Renal Cell Cancer AJCC v7,PROCEDURE: Cryosurgery|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Therapeutic Conventional Surgery|BIOLOGICAL: Tremelimumab,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"March 30, 2016","March 30, 2016","June 20, 2022"
NCT04493619,PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer,TERMINATED,Gynecologic Neoplasms|Epithelial Ovarian Cancer,DRUG: PLX2853|DRUG: Carboplatin,Opna-IO LLC,,INTERVENTIONAL,"August 11, 2020","August 11, 2020","June 30, 2022"
NCT04219319,LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma,TERMINATED,CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia),DRUG: Efficacy of LCAR-T2C CAR-T cells,The First Affiliated Hospital with Nanjing Medical University,Nanjing Legend Biotechnology Co. The First Affiliated Hospital of USTC west district；The First Affiliated Hospital of the Air Force Medical University,INTERVENTIONAL,"December 15, 2021","December 15, 2021","July 20, 2022"
NCT04283019,The Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabidiol (CBD) Under Acute and Chronic Exposure Conditions,RECRUITING,"Cannabis, Drug Effects",DRUG: CBD|DRUG: THC,Johns Hopkins University,,INTERVENTIONAL,"August 15, 2021","August 15, 2021","September 1, 2022"
NCT03477019,Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer,RECRUITING,Colorectal Neoplasms|Breast Neoplasms,DRUG: SonoVue|PROCEDURE: Focused Ultrasound,St. Olavs Hospital,,INTERVENTIONAL,"November 12, 2018","November 12, 2018",September 2022
NCT05306366,A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants,COMPLETED,Healthy Young Men,DRUG: [11C]-Lu AF90103,H. Lundbeck A/S,,INTERVENTIONAL,"March 23, 2022","March 23, 2022","June 7, 2022"
NCT04959266,"A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib",TERMINATED,Advanced Solid Tumours,DRUG: Adavosertib|DRUG: Itraconazole|DRUG: Rifampicin|DRUG: Omeprazole,AstraZeneca,Parexel,INTERVENTIONAL,"June 28, 2021","June 28, 2021","June 1, 2022"
NCT04058392,Camu Camu in ART-treated People Living With HIV,COMPLETED,HIV Infections,BIOLOGICAL: Camu Camu Capsules,McGill University Health Centre/Research Institute of the McGill University Health Centre,,INTERVENTIONAL,"November 9, 2020","November 9, 2020","July 20, 2022"
NCT04554992,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),ACTIVE_NOT_RECRUITING,Covid19,BIOLOGICAL: COVID 19 Convalescent Plasma,The Methodist Hospital Research Institute,,INTERVENTIONAL,"March 20, 2020","March 20, 2020",June 2022
NCT05351892,"A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants",COMPLETED,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men|Hot Flashes|Healthy Volunteers,DRUG: Elinzanetant (BAY3427080),Bayer,,INTERVENTIONAL,"May 4, 2022","May 4, 2022","June 9, 2022"
NCT05047692,Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers,ACTIVE_NOT_RECRUITING,Covid19,BIOLOGICAL: AdCLD-CoV19-1,"Cellid Co., Ltd.",,INTERVENTIONAL,"September 9, 2021","September 9, 2021",September 2022
NCT04258592,18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors,TERMINATED,Neural Crest Tumor|Neuroendocrine Tumors,DRUG: (18F)MFBG|DEVICE: PET/CT|OTHER: Venous blood samples,Universitaire Ziekenhuizen Leuven,,INTERVENTIONAL,"February 7, 2020","February 7, 2020","July 7, 2022"
NCT05111392,Hydration Dynamics and Influence of Beverage Composition,RECRUITING,Hydration|Fluid Retention|Dehydration,BIOLOGICAL: Placebo|BIOLOGICAL: Oral Rehydration Solution 1|BIOLOGICAL: Oral Rehydration Solution 2,University of Illinois at Chicago,,INTERVENTIONAL,"September 3, 2021","September 3, 2021",June 2022
NCT04065555,Intratumoral Microdosing of TAK-981 in Head and Neck Cancer,COMPLETED,Head and Neck Cancer,DRUG: TAK-981|BIOLOGICAL: Cetuximab|BIOLOGICAL: Avelumab|COMBINATION_PRODUCT: TAK-981 + Cetuximab|COMBINATION_PRODUCT: TAK-981 + Avelumab,Presage Biosciences,Takeda,INTERVENTIONAL,"October 7, 2020","October 7, 2020","June 20, 2022"
NCT04916431,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults",COMPLETED,Healthy Volunteers,DRUG: mRNA-6231,"ModernaTX, Inc.",,INTERVENTIONAL,"July 28, 2021","July 28, 2021","August 2, 2022"
NCT02963831,"A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",COMPLETED,Colorectal Cancer|Platinum-resistant Ovarian Cancer|Appendiceal Cancer,BIOLOGICAL: ONCOS-102|DRUG: Durvalumab,Ludwig Institute for Cancer Research,"Cancer Research Institute, New York City|MedImmune LLC|Targovax ASA",INTERVENTIONAL,"September 7, 2017","September 7, 2017","June 25, 2022"
NCT05381142,"A Study to Learn More About How the Study Treatment Elinzanetant (or BAY3427080) Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body After Taking Single and Multiple Doses in Healthy Women Aged 40 to 65 Years",COMPLETED,Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men|Hot Flashes|Healthy Volunteers,DRUG: Elinzanetant (BAY3427080)|DRUG: Placebo,Bayer,,INTERVENTIONAL,"May 23, 2022","May 23, 2022","July 11, 2022"
NCT05392842,Corchorus Olitorius Buccal Films for the Treatment of Recurrent Minor Aphthous Ulcerations,COMPLETED,Aphthous Ulcer Recurrent,DIETARY_SUPPLEMENT: Corchorus Olitorius Buccal fast dissolving Films|DIETARY_SUPPLEMENT: plain mucoadhesive fast dissolving film,Deraya University,,INTERVENTIONAL,"April 10, 2022","April 10, 2022","June 18, 2022"
NCT04766931,The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection,RECRUITING,Covid19,DRUG: FB2001|DRUG: FB2001 Placebo,Frontier Biotechnologies Inc.,,INTERVENTIONAL,"March 26, 2021","March 26, 2021",July 2022
NCT03953131,Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas,UNKNOWN,Meningioma,PROCEDURE: Computed Tomography|RADIATION: Gallium Ga 68-DOTATATE|PROCEDURE: Positron Emission Tomography,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"January 10, 2019","January 10, 2019","September 1, 2022"
NCT04201431,"Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1",RECRUITING,"Malaria, Vivax",BIOLOGICAL: PvDBPII/Matrix-M1,University of Oxford,,INTERVENTIONAL,"January 24, 2020","January 24, 2020",August 2022
NCT04935931,Naltrexone Neuroimaging,COMPLETED,Eating Disorders|Binge Eating|Purging (Eating Disorders),DRUG: Naltrexone,Children's Mercy Hospital Kansas City,University of Kansas Medical Center,INTERVENTIONAL,"July 16, 2021","July 16, 2021","June 15, 2022"
NCT04852419,A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS,COMPLETED,Breast Neoplasms,DRUG: ZN-c5,Zentera Therapeutics HK Limited,,INTERVENTIONAL,"May 31, 2021","May 31, 2021","June 23, 2022"
NCT03893019,MB-CART20.1 Melanoma,RECRUITING,Melanoma (Skin),BIOLOGICAL: MB-CART20.1,Miltenyi Biomedicine GmbH,DLR German Aerospace Center,INTERVENTIONAL,"March 8, 2019","March 8, 2019",July 2022
NCT00167219,Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML),RECRUITING,Juvenile Myelomonocytic Leukemia,BIOLOGICAL: Stem Cell Transplant|DRUG: Preparative Regimen,"Masonic Cancer Center, University of Minnesota",,INTERVENTIONAL,"November 18, 1999","November 18, 1999","July 28, 2022"
NCT04933019,Detection of Clindamycin Resistance Antibiotic Genes Among Staphylococcus Isolates by Using Real Time PCR,NOT_YET_RECRUITING,Staphylococcus Isolates,GENETIC: Detection of Clinclidamycin Resistance Antibiotic Genes among Staphylococcus Isolates by Using Real Time PCR,Sohag University,,INTERVENTIONAL,"July 1, 2021","July 1, 2021","July 1, 2022"
NCT04478019,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,COMPLETED,COVID-19|SARS-CoV 2,DRUG: 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse,"University of Wisconsin, Madison",,INTERVENTIONAL,"July 7, 2020","July 7, 2020","June 30, 2022"
NCT04685486,Virtual Reality for Pain Management in Burn Patients,RECRUITING,Pain,OTHER: Virtual Reality,Weill Medical College of Cornell University,,INTERVENTIONAL,"June 1, 2018","June 1, 2018",August 2022
NCT05105919,Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes,RECRUITING,"Diabetes Mellitus, Type 2",DRUG: Aspirin 80 mg EC Tab,Montreal Heart Institute,Institut de Recherches Cliniques de Montreal,INTERVENTIONAL,"August 26, 2021","August 26, 2021","August 1, 2022"
NCT00797719,Short Neoadjuvant Hemithoracic IMRT for MPM,RECRUITING,Malignant Pleural Mesothelioma,OTHER: Pre-op RT +/- chemotherapy,"University Health Network, Toronto",,INTERVENTIONAL,October 2008,October 2008,July 2022
NCT04249219,Responses to E-Cigarette Advertising,COMPLETED,E-Cig Use,OTHER: Viewing e-cigarette ads,"University of Massachusetts, Worcester",National Institute on Drug Abuse (NIDA),INTERVENTIONAL,"August 4, 2021","August 4, 2021","August 15, 2022"
NCT05083286,Duration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines,RECRUITING,Glabellar Frown Lines,DRUG: OnabotulinumtoxinA,Clinical Testing of Beverly Hills,Allergan,INTERVENTIONAL,"October 20, 2021","October 20, 2021","August 1, 2022"
NCT05364255,"A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833",COMPLETED,"ER-positive, HER2-negative Breast Cancer","DRUG: [14C]AZD9833 Oral Solution, 75 mg",AstraZeneca,Quotient Sciences,INTERVENTIONAL,"May 10, 2022","May 10, 2022","June 20, 2022"
NCT05202912,Food Effect Study of IDX-1197 in Healthy Subjects,COMPLETED,Healthy Male,DRUG: IDX-1197(After a meal)|DRUG: IDX-1197(fasting),"Idience Co., Ltd.",,INTERVENTIONAL,"January 16, 2022","January 16, 2022","July 23, 2022"
NCT04014712,O2 Transport and Utilization in Health and Lung Disease,UNKNOWN,COPD|Tetrahydrobiopterin Deficiency|Oxidative Stress,DRUG: Tetrahydrobiopterin|DRUG: Placebo oral tablet,"University of Massachusetts, Amherst",,INTERVENTIONAL,August 2019,August 2019,August 2022
NCT04607655,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis",WITHDRAWN,Non-alcoholic Steatohepatitis (NASH),DRUG: GB1211|DRUG: Placebo,Galecto Biotech AB,Covance,INTERVENTIONAL,March 2021,March 2021,July 2022
NCT05310487,"Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects",RECRUITING,Chronic Hepatitis B,BIOLOGICAL: 162|OTHER: Placebo,"Yangshengtang Co., Ltd",Syneos Health,INTERVENTIONAL,"May 30, 2022","May 30, 2022","August 23, 2022"
NCT03594487,Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis,ACTIVE_NOT_RECRUITING,Relapsing Remitting Multiple Sclerosis,DRUG: FMP30 Donor Stool|PROCEDURE: Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool|OTHER: Observational Control,Jeffrey Gelfand,,INTERVENTIONAL,"November 16, 2018","November 16, 2018","July 1, 2022"
NCT05216887,"A Study to Assess the Pharmacokinetic (PK) Comparability of 2 Fixed Subcutaneous (SC) Doses of Aducanumab (BIIB037) With a Single, Weight-Based Intravenous (IV) Dose in Healthy Volunteers",COMPLETED,Healthy Volunteer,BIOLOGICAL: Aducanumab,Biogen,,INTERVENTIONAL,"February 1, 2022","February 1, 2022","July 27, 2022"
NCT05376085,"Bioequivalence Study Between ""DA-5215 Tab"" and ""DA-5215-R Tab""",NOT_YET_RECRUITING,Healthy,DRUG: DA-5215 Tab|DRUG: DA-5215-R Tab,"Dong-A ST Co., Ltd.",,INTERVENTIONAL,May 2022,May 2022,June 2022
NCT05351086,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults",RECRUITING,Healthy,DRUG: PUR3100|DRUG: Dihydroergotamine (D.H.E 45)|OTHER: Matching Placebo for PUR3100|OTHER: Matching Placebo for D.H.E 45,Pulmatrix Inc.,,INTERVENTIONAL,"June 9, 2022","June 9, 2022","July 18, 2022"
NCT05411965,A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.,COMPLETED,"Diabetes Mellitus, Type 2",DRUG: BR3003(T)|DRUG: BR3003B(R1)|DRUG: BR3003C(R2),"Boryung Pharmaceutical Co., Ltd",,INTERVENTIONAL,"April 28, 2022","April 28, 2022","July 3, 2022"
NCT03212989,Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on ART,COMPLETED,HIV-1 Infection,DRUG: Vorinostat|BIOLOGICAL: HXTC,"University of North Carolina, Chapel Hill","National Heart, Lung, and Blood Institute (NHLBI)",INTERVENTIONAL,"June 27, 2017","June 27, 2017","June 7, 2022"
NCT03781219,A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation,RECRUITING,Solid Tumor,DRUG: HL-085|DRUG: Vemurafenib,"Shanghai Kechow Pharma, Inc.",,INTERVENTIONAL,"July 1, 2018","July 1, 2018","August 1, 2022"
NCT05206019,Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection,NOT_YET_RECRUITING,HIV/AIDS,DRUG: Albuvirtide,Frontier Biotechnologies Inc.,,INTERVENTIONAL,"February 1, 2022","February 1, 2022","July 15, 2022"
NCT05418712,A Microneurography (MNG) Study of VX-150 in Healthy Participants,RECRUITING,Pain,DRUG: Placebo|DRUG: VX-150,Vertex Pharmaceuticals Incorporated,,INTERVENTIONAL,"June 16, 2022","June 16, 2022",September 2022
NCT04278287,Chemoradiotherapy in Unresectable Esophageal Cancer,RECRUITING,Esophageal Cancer|Chemoradiotherapy|Albumin-bound Paxlitaxel|Unresectable Malignant Neoplasm,RADIATION: Radiotherapy|DRUG: Albumin-Bound Paclitaxel|DRUG: Cisplatin,Chinese Academy of Medical Sciences,,INTERVENTIONAL,"October 1, 2019","October 1, 2019",September 2022
NCT05275751,"Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3",RECRUITING,Pain,DRUG: TRPA1-inhibitor|DRUG: TRPV1-inhibitor|DRUG: TRPM3-inhibitor|DRUG: Placebo|DRUG: Chloride-channel inhibitor,Medical University of Vienna,,INTERVENTIONAL,"June 13, 2022","June 13, 2022",August 2022
NCT05129319,Jeuveau Treatment of Glabellar Lines Using OLD Versus COLD,RECRUITING,Glabellar Frown Lines,DRUG: prabotulinumtoxinA,Clinical Testing of Beverly Hills,"Evolus, Inc.",INTERVENTIONAL,"December 16, 2021","December 16, 2021",August 2022
NCT05089019,A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants,COMPLETED,Healthy,DRUG: Selpercatinib,"Loxo Oncology, Inc.",Eli Lilly and Company,INTERVENTIONAL,"October 29, 2021","October 29, 2021","July 19, 2022"
NCT03893695,Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC),ACTIVE_NOT_RECRUITING,Metastatic Hepatocellular Carcinoma|HCC|Combinations of Drugs; Dependence,DRUG: GT90001 and Nivolumab,"Suzhou Kintor Pharmaceutical Inc,",,INTERVENTIONAL,"May 25, 2019","May 25, 2019","June 25, 2022"
NCT04051307,Dual Vaccine Trial in Myeloproliferative Neoplasms,UNKNOWN,Polycythemia Vera|Essential Thrombocythemia,DRUG: PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL|DRUG: Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL,Inge Marie Svane,,INTERVENTIONAL,"July 10, 2019","July 10, 2019","July 10, 2022"
NCT03634683,A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation,WITHDRAWN,Recurrent Hepatocellular Carcinoma,BIOLOGICAL: LioCyx,Lion TCR Pte. Ltd.,,INTERVENTIONAL,August 2018,August 2018,August 2022
NCT04261387,LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients,COMPLETED,Radiation Dermatitis,DRUG: LUT014 Gel|DRUG: Placebo for LUT014 Gel,Lutris Pharma Ltd.,,INTERVENTIONAL,"January 30, 2021","January 30, 2021","June 16, 2022"
NCT03008187,SEL24/MEN1703 in Patients With Acute Myeloid Leukemia,ACTIVE_NOT_RECRUITING,Acute Myeloid Leukemia,DRUG: SEL24/MEN1703,Menarini Group,"Medpace, Inc.|Theradex",INTERVENTIONAL,"March 10, 2017","March 10, 2017",September 2022
NCT04863287,First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People,COMPLETED,Lyme Disease,BIOLOGICAL: 2217LS|OTHER: 0.9% Sodium Chloride (NaCl),MassBiologics,Celerion,INTERVENTIONAL,"February 11, 2021","February 11, 2021","August 16, 2022"
NCT04211766,Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer,COMPLETED,Healthy Subject,DIETARY_SUPPLEMENT: Dietary Fiber|DIETARY_SUPPLEMENT: Fish Oil|OTHER: Placebo|OTHER: Placebo,Fred Hutchinson Cancer Center,National Cancer Institute (NCI)|Texas A&M University,INTERVENTIONAL,"January 5, 2021","January 5, 2021","August 16, 2022"
NCT02298348,Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,ACTIVE_NOT_RECRUITING,Neuroblastoma,DRUG: Sorafenib|DRUG: Cyclophosphamide|DRUG: Topotecan,New Approaches to Neuroblastoma Therapy Consortium,"University of California, San Francisco|Children's Hospital Los Angeles|Lucile Packard Children's Hospital|Children's Hospital Medical Center, Cincinnati|University of Michigan|Seattle Children's Hospital|Dana-Farber Cancer Institute|The Hospital for Sick Children|Children's Healthcare of Atlanta|University of Chicago|Cook Children's Health Care System|Children's Hospital Colorado",INTERVENTIONAL,April 2015,April 2015,July 2022
NCT05201651,Creatine and Motor Skill Acquisition,RECRUITING,Young Healthy Adults (no Medical Condition/Disease),DIETARY_SUPPLEMENT: Creatine Monohydrate|DIETARY_SUPPLEMENT: Maltodextrin Placebo,University of Regina,,INTERVENTIONAL,"February 10, 2022","February 10, 2022","August 31, 2022"
NCT04227600,A Study of JR-171 in Patients With Mucopolysaccharidosis I,COMPLETED,Mucopolysaccharidosis I,DRUG: JR-171,"JCR Pharmaceuticals Co., Ltd.",,INTERVENTIONAL,"September 1, 2020","September 1, 2020","August 2, 2022"
NCT05457400,ENSO 16 - Study in Healthy Subjects,RECRUITING,"Sugar; Blood, Low",DRUG: ENSO 16|DRUG: Glucose Powder,Alpha Republic GmbH,Vienna General Hospital,INTERVENTIONAL,"April 28, 2022","April 28, 2022","June 14, 2022"
NCT05001022,"A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects",ACTIVE_NOT_RECRUITING,Chronic Hepatitis B,DRUG: ALG-020572|DRUG: Placebo,Aligos Therapeutics,,INTERVENTIONAL,"September 29, 2021","September 29, 2021","June 30, 2022"
NCT05203822,Tepotinib Drug-Drug Interaction Study With Itraconazole in Healthy Participants,COMPLETED,Healthy,DRUG: Tepotinib (HydroChloride hydrate)|DRUG: Itraconazole,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",,INTERVENTIONAL,"January 21, 2022","January 21, 2022","July 5, 2022"
NCT04330248,A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants,COMPLETED,Healthy,DRUG: Erdafitinib|DRUG: Carbamazepine,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",,INTERVENTIONAL,"March 31, 2020","March 31, 2020","June 14, 2022"
NCT05402748,Safety and Efficacy of Injection of Human Placenta Mesenchymal Stem Cells Derived Exosomes for Treatment of Complex Anal Fistula,RECRUITING,Fistula Perianal,OTHER: placenta-MSCs derived exosomes,Tehran University of Medical Sciences,,INTERVENTIONAL,"December 22, 2021","December 22, 2021","July 22, 2022"
NCT04111666,A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101,COMPLETED,Healthy,BIOLOGICAL: AL101|OTHER: Placebo,Alector Inc.,,INTERVENTIONAL,"December 14, 2019","December 14, 2019","June 9, 2022"
NCT04513548,Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria,TERMINATED,Chronic Spontaneous Urticaria|Cholinergic Urticaria|Cold Urticaria,DRUG: Ligelizumab|DRUG: Placebo,Novartis Pharmaceuticals,,INTERVENTIONAL,"August 5, 2020","August 5, 2020","July 19, 2022"
NCT05001451,Study of GDX012 in Patients With MRD Positive AML,TERMINATED,Acute Myeloid Leukemia,BIOLOGICAL: GDX012 Suspension for IV Infusion,GammaDelta Therapeutics Limited,,INTERVENTIONAL,"August 13, 2021","August 13, 2021","June 3, 2022"
NCT02768766,Intermittent Selumetinib for Uveal Melanoma,ACTIVE_NOT_RECRUITING,Uveal Melanoma,DRUG: Selumetinib,Richard D. Carvajal,AstraZeneca|Melanoma Research Alliance,INTERVENTIONAL,"February 28, 2017","February 28, 2017",September 2022
NCT05050448,Comparative Usability Evaluation of Sustained Acoustic Medicine (SAM) Devices and Topical Gel for OA Knee Pain,RECRUITING,Knee Osteoarthritis,DEVICE: Sustained Acoustic Device with 2.5% Diclofenac Patch|DRUG: 1% Diclofenac Topical Gel,"ZetrOZ, Inc.",,INTERVENTIONAL,"August 1, 2021","August 1, 2021","September 1, 2022"
NCT05439148,OPC-61815 in Healthy Chinese Male Subjects,RECRUITING,Healthy Adult Male,DRUG: OPC-61815 injection,Otsuka Beijing Research Institute,,INTERVENTIONAL,"June 30, 2022","June 30, 2022",September 2022
NCT04850222,Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma,RECRUITING,Musculoskeletal Injury,DRUG: Fluoxetine|DRUG: Calcium,University of Florida,,INTERVENTIONAL,"September 2, 2021","September 2, 2021","June 16, 2022"
NCT03424122,"INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",COMPLETED,B-cell Lymphoma,DRUG: Parsaclisib|DRUG: Rituximab|DRUG: Bendamustine|DRUG: Ibrutinib,Incyte Corporation,,INTERVENTIONAL,"July 2, 2018","July 2, 2018","June 27, 2022"
NCT02490800,Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma,ACTIVE_NOT_RECRUITING,Neoplasms,DRUG: Oral daily administration of BAL101553,Basilea Pharmaceutica,,INTERVENTIONAL,June 2015,June 2015,September 2022
NCT04985500,ESP/PIF for Sternotomy,RECRUITING,Cardiac Surgery|Sternotomy,PROCEDURE: ESP block|PROCEDURE: PIF block|PROCEDURE: Ultrasound|DRUG: Bupivacain,Icahn School of Medicine at Mount Sinai,,INTERVENTIONAL,"July 8, 2021","July 8, 2021",August 2022
NCT04500548,"Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study",WITHDRAWN,Constitutional Mismatch Repair Deficiency Syndrome|Hematopoietic and Lymphoid Cell Neoplasm|Lynch Syndrome|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Neuroblastoma|Recurrent Primary Central Nervous System Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Neuroblastoma|Refractory Primary Central Nervous System Neoplasm|Xeroderma Pigmentosum,PROCEDURE: Biospecimen Collection|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab,National Cancer Institute (NCI),,INTERVENTIONAL,"January 28, 2021","January 28, 2021","June 21, 2022"
NCT05391048,An BE Study to Compare 10mg & 20mg of IMP4297 Capsules in Healthy Chinese Subjects Under Fed Condition,NOT_YET_RECRUITING,Solid Tumor,DRUG: IMP4297(20mg)|DRUG: IMP4297(10mg),"Impact Therapeutics, Inc.",,INTERVENTIONAL,"June 6, 2022","June 6, 2022","June 25, 2022"
NCT04289948,Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes,WITHDRAWN,Diabetes|Diabetic Foot|Diabetic Foot Infection,DRUG: Phage,University Hospitals of Derby and Burton NHS Foundation Trust,Wellcome Trust|BioPhage Theraputics Limited|Nottingham University Hospitals NHS Trust,INTERVENTIONAL,"March 1, 2019","March 1, 2019","June 1, 2022"
NCT04964622,the Effect of Preoperative Sodium Ibuprofen on Postoperative Endodontic Pain,RECRUITING,Irreversible Pulpitis,DRUG: nurofen,Cairo University,,INTERVENTIONAL,"December 1, 2021","December 1, 2021","July 1, 2022"
NCT05162222,A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-dose of Danicamtiv in Healthy Participants,COMPLETED,Healthy Participants,DRUG: Danicamtiv|DRUG: Itraconazole|DRUG: Diltiazem,Bristol-Myers Squibb,,INTERVENTIONAL,"December 15, 2021","December 15, 2021","July 8, 2022"
NCT05335447,Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667,COMPLETED,Healthy,DRUG: GLPG3667 capsule|DRUG: [14C]-GLPG3667 solution for infusion|DRUG: [14C]-GLPG3667 capsule,Galapagos NV,,INTERVENTIONAL,"April 19, 2022","April 19, 2022","June 3, 2022"
NCT04665154,"A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers",COMPLETED,Healthy Volunteers,DRUG: MAS825|DRUG: Placebo,Novartis Pharmaceuticals,,INTERVENTIONAL,"June 7, 2019","June 7, 2019","August 3, 2022"
NCT04581954,Inflammatory Signal Inhibitors for COVID-19 (MATIS),RECRUITING,Coronavirus|Covid19|Pneumonia,DRUG: Ruxolitinib|DRUG: Fostamatinib|OTHER: Standard of care,Imperial College London,Imperial College Healthcare NHS Trust|Rigel Pharmaceuticals|Novartis,INTERVENTIONAL,"October 2, 2020","October 2, 2020","June 30, 2022"
NCT04238754,Oral Cannabidiol for Opioid Withdrawal,COMPLETED,Opioid Withdrawal|Opioid Craving|Opioid Use Disorder,DRUG: Epidiolex 100 mg/mL Oral Solution|OTHER: Cherry Syrup Oral Solution,Johns Hopkins University,Dalio Foundation,INTERVENTIONAL,"November 1, 2020","November 1, 2020","June 30, 2022"
NCT03479203,Acute Effects of E-Cigarette Aerosol Inhalation,RECRUITING,Endothelial Dysfunction|Biochemical Markers,DRUG: Electronic Cigarette Aerosol,University of Pennsylvania,"National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)",INTERVENTIONAL,"May 22, 2018","May 22, 2018","August 31, 2022"
NCT05150756,Intraoperative Lidocaine Infusion as a Sole Analgesic Versus Morphine in Laparoscopic Gastric Bypass Surgery,RECRUITING,"Pain, Postoperative",DRUG: Lidocaine Hydrochloride 2% Intravenous Solution [XYLOCAINE]|DRUG: morphine sulphate (10mg/ ml ampoule),Ain Shams University,,INTERVENTIONAL,"January 1, 2022","January 1, 2022",July 2022
NCT04537403,PET Detection of CCR2 in Human Atherosclerosis,RECRUITING,Carotid Atherosclerosis,DRUG: Group 1-64CU-DOTA-ECL1i (radioactive imaging medicine)|DRUG: Group 2 64CU-DOTA-ECL1i (radioactive imaging medicine),Washington University School of Medicine,,INTERVENTIONAL,"October 1, 2020","October 1, 2020","September 1, 2022"
NCT05163522,"First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants",RECRUITING,HIV Infections,DRUG: VH4004280|DRUG: Placebo,ViiV Healthcare,,INTERVENTIONAL,"December 13, 2021","December 13, 2021","August 26, 2022"
NCT04031547,fMRI Study of tES in Major Depression,ACTIVE_NOT_RECRUITING,Depression,DEVICE: Transcranial Electrical Stimulation (tES),Northwestern University,Brain & Behavior Research Foundation,INTERVENTIONAL,"February 1, 2019","February 1, 2019",July 2022
NCT05183347,A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are Tolerated,COMPLETED,Healthy,DRUG: BI 1291583|DRUG: Placebo,Boehringer Ingelheim,,INTERVENTIONAL,"February 4, 2022","February 4, 2022","July 27, 2022"
NCT05172622,"Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Characteristics of JP-2266 in Healthy Subjects",RECRUITING,Diabetes Mellitus,DRUG: JP-2266|DRUG: JP-2266 Placebo,"Jeil Pharmaceutical Co., Ltd.",,INTERVENTIONAL,"November 24, 2020","November 24, 2020","August 31, 2022"
NCT05373147,αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors,RECRUITING,Solid Tumor,BIOLOGICAL: αPD1-MSLN-CAR T cells,Shanghai Mengchao Cancer Hospital,"Shanghai Cell Therapy Group Co.,Ltd",INTERVENTIONAL,"October 30, 2020","October 30, 2020",June 2022
NCT04976959,High Fiber in Parkinson's Disease,RECRUITING,Parkinson Disease,DRUG: High Fiber supplement,"Rutgers, The State University of New Jersey",,INTERVENTIONAL,"July 8, 2021","July 8, 2021","June 30, 2022"
NCT04220775,Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer,RECRUITING,Recurrent Head and Neck Squamous Cell Carcinoma|Second Primary Squamous Cell Carcinoma of the Head and Neck,DRUG: Bintrafusp Alfa|OTHER: Quality-of-Life Assessment|OTHER: Questionnaire Administration|RADIATION: Stereotactic Body Radiation Therapy,M.D. Anderson Cancer Center,National Cancer Institute (NCI),INTERVENTIONAL,"March 18, 2020","March 18, 2020","August 31, 2022"
NCT04081350,A Study of LY3471851 in Participants With Eczema,ACTIVE_NOT_RECRUITING,"Dermatitis, Atopic",DRUG: LY3471851|DRUG: Placebo,Eli Lilly and Company,Nektar Therapeutics,INTERVENTIONAL,"December 4, 2019","December 4, 2019","June 17, 2022"
NCT05005247,Study to Assess a Booster Dose of GBS-NN/NN2 Vaccine,COMPLETED,Group B Streptococcus Infection,BIOLOGICAL: GBS-NN/NN2,Minervax ApS,,INTERVENTIONAL,"August 17, 2021","August 17, 2021","August 5, 2022"
NCT05322447,High-dose L-Carnitine and Diaphragmatic Function Assessed by Ultrasonography in Patients With Respiratory Failure.,RECRUITING,Respiratory Failure,DRUG: L Carnitine ( low dose)|DRUG: L-Carnitine ( high dose),Ain Shams University,,INTERVENTIONAL,"May 24, 2022","May 24, 2022",July 2022
NCT04325503,Neurobiological Drivers of Mobility Resilience: The Dopaminergic System,COMPLETED,Parkinsonian Signs in Older Persons,DRUG: carbidopa,University of Michigan,,INTERVENTIONAL,"October 18, 2019","October 18, 2019","June 30, 2022"
NCT04247256,A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI,RECRUITING,Metastatic Colorectal Cancer,DRUG: FOLFIRI Protocol|DRUG: SCO-101,Scandion Oncology A/S,TFS Trial Form Support,INTERVENTIONAL,"May 14, 2020","May 14, 2020","June 30, 2022"
NCT04272203,"A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers",TERMINATED,Acute Myeloid Leukemia (AML)|Non Small Cell Lung Cancer|Cancer,DRUG: ABBV-184,AbbVie,,INTERVENTIONAL,"May 5, 2020","May 5, 2020","June 27, 2022"
NCT05341856,Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL,NOT_YET_RECRUITING,Recurrent Pregnancy Loss,DRUG: isosorbide mononitrate|DRUG: Placebo,Al-Azhar University,,INTERVENTIONAL,"May 1, 2022","May 1, 2022",August 2022
NCT04385056,Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of Bradykinesia,RECRUITING,Bradykinesia,BIOLOGICAL: MSCTC-0010,"IMAC Holdings, Inc.",,INTERVENTIONAL,"December 15, 2020","December 15, 2020","July 1, 2022"
NCT05499156,Safety of Injection of Placental Mesenchymal Stem Cell Derived Exosomes for Treatment of Resistant Perianal Fistula in Crohn's Patients,ACTIVE_NOT_RECRUITING,Perianal Fistula in Patients With Crohn's Disease,OTHER: placenal MSC derived exosomes,Tehran University of Medical Sciences,,INTERVENTIONAL,"January 20, 2022","January 20, 2022",August 2022
NCT03575403,"Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)",RECRUITING,Alcohol Use Disorder,DRUG: Alcohol|DRUG: Placebos|DRUG: Duloxetine|DRUG: Methylphenidate,Craig Rush,National Institute on Alcohol Abuse and Alcoholism (NIAAA),INTERVENTIONAL,"September 1, 2018","September 1, 2018",June 2022
NCT05137275,Study of Anti-5T4 CAR-raNK Cell Therapy in Locally Advanced or Metastatic Solid Tumors,RECRUITING,Locally Advanced or Metastatic Solid Tumors,BIOLOGICAL: Anti-5T4 CAR-raNK Cells,Shanghai East Hospital,"Imbioray (Hangzhou) Biomedicine Co., Ltd.",INTERVENTIONAL,"November 24, 2021","November 24, 2021",August 2022
NCT05331859,Topical Insulin Versus Autologous Serum After Corneal Surgeries,NOT_YET_RECRUITING,Corneal Epithelial Wound,DRUG: Insulin|DRUG: autologous serum (AS)|DRUG: conventional,Benha University,,INTERVENTIONAL,May 2022,May 2022,August 2022
NCT05316259,A Food-Effect Study of BPI-16350 in Healthy Subjects,ACTIVE_NOT_RECRUITING,Healthy,DRUG: BPI-16350,"Betta Pharmaceuticals Co., Ltd.",,INTERVENTIONAL,"April 22, 2022","April 22, 2022","June 30, 2022"
NCT04278859,"Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced Malignancies",UNKNOWN,Advanced Solid Tumor,"BIOLOGICAL: Drug: JS004, Recombinant humanized IgG4κ monoclonal antibody specific to BTLA for injection Intravenous infusion","Shanghai Junshi Bioscience Co., Ltd.",,INTERVENTIONAL,"April 28, 2020","April 28, 2020","July 1, 2022"
NCT05074459,A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines,COMPLETED,Healthy Participants,DRUG: Eptinezumab Mammalian Cell Line|DRUG: Eptinezumab Yeast Cell Line,H. Lundbeck A/S,,INTERVENTIONAL,"September 27, 2021","September 27, 2021","July 18, 2022"
NCT04033159,Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies,TERMINATED,Centronuclear Myopathy,DRUG: DYN101,Dynacure,,INTERVENTIONAL,"January 9, 2020","January 9, 2020","June 22, 2022"
NCT04261075,IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.,COMPLETED,Advanced Solid Tumors,BIOLOGICAL: IPH5201|BIOLOGICAL: durvalumab|BIOLOGICAL: oleclumab,MedImmune LLC,,INTERVENTIONAL,"March 3, 2020","March 3, 2020","June 16, 2022"
NCT03613259,Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma,WITHDRAWN,Stage II Adult Soft Tissue Sarcoma|Stage IIA Adult Soft Tissue Sarcoma|Stage IIB Adult Soft Tissue Sarcoma|Stage IIC Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma,DRUG: Fluorothymidine F-18|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Positron Emission Tomography,OHSU Knight Cancer Institute,National Cancer Institute (NCI),INTERVENTIONAL,"June 1, 2020","June 1, 2020","June 1, 2022"
NCT05029856,Evaluation of the Safety and Immunogenicity of SII Vaccine Constructs Based on the SARS-CoV-2 (COVID-19) Variant in Adults,WITHDRAWN,Covid19,BIOLOGICAL: SII B.1.351|BIOLOGICAL: SII B.1.351|BIOLOGICAL: SII Bivalent|BIOLOGICAL: SII Bivalent|BIOLOGICAL: SII B.1.617.2,Novavax,,INTERVENTIONAL,"February 4, 2022","February 4, 2022",August 2022
NCT04283656,Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women,RECRUITING,Transgender Health|Gender Dysphoria|Transgender Women|Human Immunodeficiency Virus,DRUG: Doravirine/Lamivudine/Tenofovir|DRUG: Spironolactone 100mg|DRUG: Estradiol 2mg|OTHER: Placebo,Thomas Jefferson University,,INTERVENTIONAL,"February 14, 2022","February 14, 2022","June 1, 2022"
NCT05378997,"Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds",RECRUITING,Blister|Wound of Skin,DRUG: TCP-25 gel 0.86 mg/ml or placebo gel|DRUG: TCP-25 gel 2.9 mg/ml or placebo gel|DRUG: TCP-25 gel 8.6 mg/ml or placebo gel,Xinnate AB,Region Skane,INTERVENTIONAL,"April 7, 2022","April 7, 2022","June 20, 2022"
NCT03664297,Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor,ACTIVE_NOT_RECRUITING,Mature B Cell Neoplasms,DRUG: SHR1459,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"February 6, 2018","February 6, 2018","June 30, 2022"
NCT03844997,Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia,RECRUITING,Acute Myeloid Leukemia|AML,DRUG: Palcociclib|DRUG: CPX-351,Sudipto Mukherjee,,INTERVENTIONAL,"June 6, 2019","June 6, 2019",July 2022
NCT04418297,"A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy",RECRUITING,"Cardiomyopathy, Hypertrophic Obstructive",DRUG: CT-G20|DRUG: Placebo,Celltrion,,INTERVENTIONAL,"October 23, 2020","October 23, 2020",September 2022
NCT05236543,A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole,COMPLETED,Healthy Volunteers,DRUG: AZD4831|DRUG: Itraconazole,AstraZeneca,Parexel,INTERVENTIONAL,"February 18, 2022","February 18, 2022","August 12, 2022"
NCT04774107,The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection,COMPLETED,"Hepatitis C, Chronic",DRUG: P1101 + Ribavirin,PharmaEssentia,,INTERVENTIONAL,"November 26, 2020","November 26, 2020","July 18, 2022"
NCT04314856,Novel Clinical Target in Fragile X Syndrome,WITHDRAWN,Fragile X Syndrome (FXS),DRUG: 18F-FTC-146,"Guido A. Davidzon, MD, SM",,INTERVENTIONAL,"January 12, 2021","January 12, 2021",June 2022
NCT03954990,Treatment of Bacterial Vaginosis Prior to Active Labor and Infectious Morbidity,RECRUITING,Bacterial Vaginoses,DRUG: Metronidazole Oral|DRUG: Placebo Oral Tablet,"The University of Texas Medical Branch, Galveston",,INTERVENTIONAL,"October 11, 2019","October 11, 2019","August 31, 2022"
NCT02152956,Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML),TERMINATED,AML,BIOLOGICAL: Flotetuzumab dose escalation|BIOLOGICAL: Flotetuzumab dose expansion|DRUG: Ruxolitinib,MacroGenics,,INTERVENTIONAL,"June 9, 2014","June 9, 2014","July 5, 2022"
NCT05032690,Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule,COMPLETED,Healthy Participants,DRUG: Bosutinib capsule|DRUG: Bosutinib capsule|DRUG: Bosutinib|DRUG: Bosutinib capsule,Pfizer,,INTERVENTIONAL,"January 19, 2022","January 19, 2022","June 25, 2022"
NCT04348890,Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis,WITHDRAWN,Pediatric Ulcerative Colitis,DRUG: Vamorolone 4% suspension for oral dosing,"ReveraGen BioPharma, Inc.",,INTERVENTIONAL,"September 1, 2020","September 1, 2020","September 1, 2022"
NCT04126590,Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors,RECRUITING,Advanced Solid Tumors,BIOLOGICAL: KN044,Changchun Intellicrown Pharmaceutical Co. LTD,,INTERVENTIONAL,"January 9, 2020","January 9, 2020","June 1, 2022"
NCT03829254,"A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma",RECRUITING,Advanced Cancer|Lymphoma|Solid Tumor,DRUG: NUC-7738,NuCana plc,,INTERVENTIONAL,"June 17, 2019","June 17, 2019",July 2022
NCT05098054,A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function,COMPLETED,Hepatic Impairment|Healthy Volunteers,DRUG: Soticlestat,Takeda,,INTERVENTIONAL,"October 28, 2021","October 28, 2021","June 1, 2022"
NCT04620954,"Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin",RECRUITING,Epithelial Ovarian Cancer,DRUG: Oregovomab|DRUG: Nivolumab|DRUG: Chemotherapy,"National Cancer Centre, Singapore",OncoQuest Pharma USA Inc.|Bristol-Myers Squibb,INTERVENTIONAL,"October 7, 2020","October 7, 2020",July 2022
NCT04898543,QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors,RECRUITING,Metastatic Solid Tumor,"BIOLOGICAL: M-CENK, Suspension for Infusion, Cryopreserved (M-CENK)|BIOLOGICAL: N803|OTHER: Apheresis collection of lymphocytes (part A)","ImmunityBio, Inc.",,INTERVENTIONAL,"June 21, 2021","June 21, 2021",June 2022
NCT04554667,Heavy Lifting Strength Training in Head and Neck Cancer Survivors,COMPLETED,Cancer of Head and Neck,BEHAVIORAL: Exercise Intervention,University of Alberta,,INTERVENTIONAL,"November 24, 2020","November 24, 2020","July 31, 2022"
NCT05362045,A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants,RECRUITING,Healthy Participants,DRUG: Mavacamten,Bristol-Myers Squibb,,INTERVENTIONAL,"May 16, 2022","May 16, 2022","July 21, 2022"
NCT05248945,DDI Study of Evobrutinib and Carbamazepine,COMPLETED,Healthy,DRUG: Evobrutinib|DRUG: Carbamazepine,"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany",,INTERVENTIONAL,"January 13, 2022","January 13, 2022","July 18, 2022"
NCT05468645,In Vivo Mass Balance Study of [14C]Hemay005,NOT_YET_RECRUITING,Health Volunteer,DRUG: [14C]Hemay005,"Ganzhou Hemay Pharmaceutical Co., Ltd",,INTERVENTIONAL,"July 25, 2022","July 25, 2022","August 17, 2022"
NCT03509545,Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide,UNKNOWN,Body Weight Changes,DRUG: CHF Patients: ER Torsemide 40 mg|DRUG: CHF Patients: Furosemide 40 mg,"Sarfez Pharmaceuticals, Inc.",,INTERVENTIONAL,"June 30, 2021","June 30, 2021","June 30, 2022"
NCT04608045,"Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors",RECRUITING,Advanced Solid Tumor,DRUG: CPX-POM,CicloMed LLC,,INTERVENTIONAL,"May 19, 2019","May 19, 2019","September 1, 2022"
NCT02608268,Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,ACTIVE_NOT_RECRUITING,Advanced Malignancies,DRUG: MBG453|DRUG: PDR001|DRUG: Decitabine,Novartis Pharmaceuticals,,INTERVENTIONAL,"November 23, 2015","November 23, 2015","August 29, 2022"
NCT05141097,Integrative Medicine Quality of Life Study,NOT_YET_RECRUITING,Integrative Medicine,OTHER: Integrative medicine approach,University of Arizona,,INTERVENTIONAL,"December 1, 2021","December 1, 2021","June 30, 2022"
NCT05437783,Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers,RECRUITING,Comparative Bioavailability Study,DRUG: Azithromycin Dihydrate,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",,INTERVENTIONAL,"January 1, 2020","January 1, 2020","July 1, 2022"
NCT05081583,Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients,RECRUITING,"Interaction, Adverse Herb-Drug|Diabetes Mellitus, Type 2",DRUG: Midazolam Hcl 1Mg/Ml Inj|DIETARY_SUPPLEMENT: Goldenseal (Hydrastis canadensis),Washington State University,National Center for Complementary and Integrative Health (NCCIH),INTERVENTIONAL,"September 16, 2021","September 16, 2021","August 31, 2022"
NCT05150795,Effect of Preoperative Oral Pregabalin Versus Intraoperative Fentanyl on Postoperative Analgesia,RECRUITING,"Post Operative Pain, Acute",DRUG: Pregabalin 150mg|DRUG: Fentanyl 100 micrograms ampoule,Ain Shams University,,INTERVENTIONAL,"January 1, 2022","January 1, 2022",July 2022
NCT03233633,Marijuana in Combination With Opioids in Palliative and Hospice Patients,COMPLETED,Pain,DRUG: Medical Marijuana,The Connecticut Hospice Inc.,,INTERVENTIONAL,"May 10, 2017","May 10, 2017","August 5, 2022"
NCT05386433,Paxlovid in the Treatment of COVID-19 Patients With Uremia,NOT_YET_RECRUITING,COVID-19|Uremia,DRUG: Paxlovid|DRUG: standard-of-care,Ruijin Hospital,,INTERVENTIONAL,June 2022,June 2022,July 2022
NCT03515733,PF-04995274 and Emotional Processing in Treatment Resistant Depression,RECRUITING,"Depression, Unipolar|Treatment Resistant Depression",DRUG: PF-04995274|DRUG: Placebo Oral Tablet,University of Oxford,,INTERVENTIONAL,"May 31, 2018","May 31, 2018","July 26, 2022"
NCT05099133,"A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects",COMPLETED,Atopic Dermatitis,DRUG: LEO 138559|DRUG: LEO 138559 Placebo,LEO Pharma,,INTERVENTIONAL,"November 3, 2021","November 3, 2021","June 28, 2022"
NCT04203433,A Study of DLX105-DMP in Subjects With Plaque Psoriasis,RECRUITING,Plaque Psoriasis,DRUG: DLX105-DMP,"DelArrivo, Inc.",,INTERVENTIONAL,"March 21, 2022","March 21, 2022","July 31, 2022"
NCT04105283,Tc99m-MAA Bronchial Artery Injection During Bronchial Embolization for Pulmonary Mass Induced Hemoptysis for Dosimetry Planning,RECRUITING,Lung Cancer,BIOLOGICAL: Tc99m-MAA,Massachusetts General Hospital,BTG International Inc.,INTERVENTIONAL,"August 1, 2020","August 1, 2020","June 1, 2022"
NCT04941183,"Phase 1 Study to Assess Safety, Tolerability, PD, PK, Immunogenicity of IV NTR-441 Solution in Healthy Volunteers and COVID-19 Patients",RECRUITING,Covid19,DRUG: NTR-441|DRUG: Placebo,Neutrolis,,INTERVENTIONAL,"April 14, 2021","April 14, 2021",June 2022
NCT05366283,"Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation",RECRUITING,Drug Kinetics|Drug Effects on Physiology,BIOLOGICAL: sargramostim,"Partner Therapeutics, Inc.",,INTERVENTIONAL,"April 13, 2022","April 13, 2022",June 2022
NCT03454295,Easing Psychosocial Burden for Informal Caregivers,ACTIVE_NOT_RECRUITING,Glioblastoma,BEHAVIORAL: Focus Group|BEHAVIORAL: Meaning-Centered Psychotherapy for Cancer Caregivers / MCP-C|BEHAVIORAL: Enhanced Usual Care / EUC,Memorial Sloan Kettering Cancer Center,,INTERVENTIONAL,"February 12, 2018","February 12, 2018",August 2022
NCT04702516,The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture,RECRUITING,Osteopenia,DRUG: Ozempic|DRUG: Placebo,Morten Frost,Hospital of South West Jutland,INTERVENTIONAL,"March 24, 2021","March 24, 2021","August 31, 2022"
NCT04940845,"Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults",RECRUITING,Postmenopausal Osteoporosis,DRUG: HS-20090-2|DRUG: Prolia,"Shanghai Hansoh Biomedical Co., Ltd",,INTERVENTIONAL,"July 26, 2021","July 26, 2021",June 2022
NCT05065645,"Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19",RECRUITING,Covid19,DRUG: Angiotensin Converting Enzyme 2|DRUG: Sodium chloride,Apeiron Biologics,Apeiron Respiratory Therapies GmbH,INTERVENTIONAL,"October 19, 2021","October 19, 2021",June 2022
NCT05470868,Safety and Tolerability of PRO-185,NOT_YET_RECRUITING,Hyperemia Eye,DRUG: Naphazoline / Hypromellose Ophthalmic,Laboratorios Sophia S.A de C.V.,,INTERVENTIONAL,"August 1, 2022","August 1, 2022","August 31, 2022"
NCT05064345,A Study to Evaluate HB0034 in Healthy Adult Participants,COMPLETED,Healthy,DRUG: HB0034|DRUG: Placebo,"Shanghai Huaota Biopharmaceutical Co., Ltd.",,INTERVENTIONAL,"December 3, 2021","December 3, 2021","September 1, 2022"
NCT05369468,Dexmetomidine With Erector Spinae Plane Block in Cholecystectomy,RECRUITING,Dexmedtomidine in Erector Spinae Block for Laparscopic Cholecystectomy,DRUG: dexmedetomidine as adjuvant with bupivacaine|DRUG: Bupivacain only,Tanta University,,INTERVENTIONAL,"January 22, 2020","January 22, 2020","June 30, 2022"
NCT03929068,Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis,COMPLETED,Amyotrophic Lateral Sclerosis|Motor Neuron Disease,DRUG: carbidopa-levodopa|DRUG: Placebo Oral Tablet,Washington University School of Medicine,,INTERVENTIONAL,"May 13, 2019","May 13, 2019","July 8, 2022"
NCT03466216,Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET,RECRUITING,Neuroendocrine Tumor,DRUG: AlphaMedix,"Radiomedix, Inc.",Orano Med LLC,INTERVENTIONAL,"February 5, 2018","February 5, 2018","July 1, 2022"
NCT05278845,Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects,COMPLETED,Food-drug Interaction,DRUG: SLC-391,SignalChem Lifesciences Corporation,Syneos Health,INTERVENTIONAL,"February 12, 2022","February 12, 2022","June 14, 2022"
NCT03883945,A Safety and Efficacy Study to Evaluate Rosacea,WITHDRAWN,Papulopustular Rosacea,DRUG: AIV001|DRUG: Vehicle,"AiViva BioPharma, Inc.",,INTERVENTIONAL,July 2021,July 2021,July 2022
NCT05473468,"Single Dose Study To Study The Absorption, Metabolism And Excretion Of Famitinib",RECRUITING,Healthy Subjects,DRUG: Famitinib,"Jiangsu HengRui Medicine Co., Ltd.",,INTERVENTIONAL,"August 26, 2022","August 26, 2022",September 2022
NCT03960645,"Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters",COMPLETED,HIV-1-infection,DRUG: B/F/TAF,Gilead Sciences,,INTERVENTIONAL,"June 28, 2019","June 28, 2019","July 20, 2022"
NCT03604445,This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours),COMPLETED,Neoplasms,DRUG: BI 905677,Boehringer Ingelheim,,INTERVENTIONAL,"August 8, 2018","August 8, 2018","July 27, 2022"
NCT04862416,Safety and Efficacy of R0.6C Vaccine,COMPLETED,"Malaria|Malaria,Falciparum",BIOLOGICAL: R0.6C transmission blocking vaccine,Radboud University Medical Center,Statens Serum Institut|Novavax,INTERVENTIONAL,"May 17, 2021","May 17, 2021","June 29, 2022"
NCT05126316,A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen,RECRUITING,Allergic Rhinitis,DRUG: Lu AG09222|DRUG: Placebo,H. Lundbeck A/S,,INTERVENTIONAL,"November 1, 2021","November 1, 2021","September 1, 2022"
NCT05011916,The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization,RECRUITING,Corneal Neovascularization,DRUG: KDR2-2 suspension eye drops,"Zhongshan Ophthalmic Center, Sun Yat-sen University",,INTERVENTIONAL,"August 10, 2021","August 10, 2021","August 9, 2022"
NCT01682616,A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma,COMPLETED,Small Lymphocytic Lymphoma|Chronic Lymphocytic Leukemia,DRUG: ABT-199|DRUG: Rituximab,AbbVie,"Genentech, Inc.",INTERVENTIONAL,"July 25, 2012","July 25, 2012","June 23, 2022"
NCT03956017,"Anti-oxidant Therapy and Postoperative Cardiac Events (ACE) Trial, Preoperative Intervention in Vascular Surgery",ACTIVE_NOT_RECRUITING,Myocardial Injury,DRUG: Ubiquinone|DRUG: Placebo,Minneapolis Veterans Affairs Medical Center,,INTERVENTIONAL,"August 5, 2013","August 5, 2013","August 4, 2022"
NCT03516604,PF-04995274 and Emotional Processing in Un-medicated Depression,RECRUITING,"Depression, Unipolar",DRUG: PF-04995274|DRUG: Citalopram|DRUG: Placebo Oral Tablet|DRUG: Placebo oral capsule,University of Oxford,Medical Research Council|Pfizer,INTERVENTIONAL,"May 16, 2018","May 16, 2018","July 29, 2022"
NCT05406752,Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML),NOT_YET_RECRUITING,Acute Pain,DRUG: paracetamol Uniflash (125 mg/ 1.25 mL),"Unither Pharmaceuticals, France",Raptim Research,INTERVENTIONAL,"July 1, 2022","July 1, 2022","July 21, 2022"
NCT05019105,Phase 1 ALKS 1140 in Healthy Adults,TERMINATED,Central Nervous System Diseases,DRUG: Placebo|DRUG: ALKS 1140,"Alkermes, Inc.",,INTERVENTIONAL,"October 13, 2021","October 13, 2021","August 23, 2022"
NCT04637815,A Social Network AOD Intervention for Homeless Youth Transitioning to Housing,RECRUITING,Substance Use,BEHAVIORAL: Motivational Network Intervention|OTHER: Usual Care,RAND,National Institute on Drug Abuse (NIDA),INTERVENTIONAL,"February 9, 2021","February 9, 2021","June 30, 2022"
NCT04831996,"To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.",COMPLETED,Advanced Malignancies,DRUG: parsaclisib,Incyte Corporation,,INTERVENTIONAL,"May 4, 2021","May 4, 2021","July 8, 2022"
